



HAL
open science

Fat-soluble vitamin and phytochemical metabolites: Production, gastrointestinal absorption, and health effects

Patrick Borel, Olivier Dangles, Rachel Kopec

► **To cite this version:**

Patrick Borel, Olivier Dangles, Rachel Kopec. Fat-soluble vitamin and phytochemical metabolites: Production, gastrointestinal absorption, and health effects. *Progress in Lipid Research*, 2023, 90, pp.1-93. 10.1016/j.plipres.2023.101220 . hal-04001264

HAL Id: hal-04001264

<https://hal.inrae.fr/hal-04001264>

Submitted on 11 Sep 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Fat-soluble vitamin and phytochemical metabolites: production, gastrointestinal**
2 **absorption, and health effects.**

3

4 Patrick BOREL^{a*}, Olivier DANGLES^b and Rachel E. KOPEC^c

5

6 ^aC2VN, INRAE, INSERM, Aix-Marseille Univ, Marseille, France.

7 ^bAvignon Univ, UMR408, INRAE, F-84000 Avignon, France.

8 ^cHuman Nutrition Program, Department of Human Sciences; Foods for Health Discovery Theme,
9 The Ohio State University, Columbus, OH 43210, USA.

10

11 Full postal addresses:

12 ^asee the one mentioned for the corresponding author.

13 ^bUMR408 SQPOV. Centre INRAE PACA. Domaine St Paul - Site Agroparc - CS 40509, 228 route
14 de l'aérodrome, 84914 Avignon Cedex 9, France. olivier.dangles@univ-avignon.fr

15 ^cCampbell Hall, 1787 Neil Ave, Columbus, OH 43210, USA. kopec.4@osu.edu

16

17 *Corresponding author:

18 Patrick.Borel@univ-amu.fr

19 UMR INRAE/INSERM/AMU "Center for CardioVascular and Nutrition Research of Marseille"

20 Faculté de Médecine

21 27, boulevard Jean Moulin

22 13005 Marseille, France

23 Phone: +33 (0)4 91 32 42 77

24 **Abstract**

25

26 Consumption of diets rich in fruits and vegetables, which provide some fat-soluble vitamins
27 and many phytochemicals, is associated with a lower risk of developing certain degenerative
28 diseases. It is well accepted that not only the parent compounds, but also their derivatives formed
29 upon enzymatic or nonenzymatic transformations, can produce protective biological effects. These
30 derivatives can be formed during food storage, processing, or cooking. They can also be formed in
31 the lumen of the upper digestive tract during digestion, or via metabolism by microbiota in the colon.
32 This review compiles the known metabolites of fat-soluble vitamins and fat-soluble phytochemicals
33 (FSV and FSP) that have been identified in food and in the human digestive tract, or could
34 potentially be present based on the known reactivity of the parent compounds in normal or
35 pathological conditions, or following surgical interventions of the digestive tract or consumption of
36 xenobiotics known to impair lipid absorption. It also covers the very limited data available on the
37 bioavailability (absorption, intestinal mucosa metabolism) and summarizes their effects on health.
38 Notably, despite great interest in identifying bioactive derivatives of FSV and FSP, studying their
39 absorption, and probing their putative health effects, much research remains to be conducted to
40 understand and capitalize on the potential of these molecules to preserve health.

41

42 **Keywords:** carotenoids, cholecalciferol, phylloquinone, phytosterols, retinol, tocopherol.

43 **Introduction**

44 Of the thousands of different molecules consumed through plant foods in our diet, the best
45 known are macronutrients (proteins, fats, carbohydrates) and micronutrients (vitamins and trace
46 elements). However, we also ingest a multitude of compounds called “phytochemicals”, plant
47 secondary metabolites with great chemical diversity. Phytochemicals are classified into large
48 families, e.g. terpenoids and phenolics, which are thought to be at least partially involved in the
49 prevention of numerous pathologies [1-4]. Until now, research on fat-soluble phytochemicals (FSP)
50 has primarily focused on the parent molecules originally found in plant foods [5-8]. This review will
51 focus on metabolites of fat-soluble vitamins (FSV) and FSP, i.e. metabolites of food components that
52 are insoluble in water and typically associated with lipids in oils, emulsions or cell membranes.
53 These metabolites may be derived from the chemical degradation of these molecules during culinary
54 preparation or food processing [9-11], or phase I and phase II metabolism in the intestinal mucosa or
55 within the liver (from previously absorbed FSV and FSP whose metabolites can be secreted into the
56 intestinal lumen via bile). It is also now appreciated that these metabolites could be produced by
57 microbiota [12, 13], elicit effects on the intestinal microbiota [14, 15], or even be absorbed [16],
58 although research in this area is nascent.

59 The biological roles of FSV metabolites, e.g. retinoic acid and 1,25-dihydroxycholecalciferol
60 on maintaining health are well established. In contrast, the biological roles of FSP metabolites are
61 much less well known, although their potential beneficial health effects are supported by the fact that
62 some are antioxidants [17, 18], have anti-inflammatory effects [19-22], modulate gene expression
63 [23, 24] or affect the epigenome [25-27]. It is also likely that some of these compounds exert several
64 effects simultaneously, e.g. lycopene which acts with different molecular and cellular mechanisms
65 [28].

66 Likewise, certain carotenoid metabolites with a structure analogous, but not identical to, retinoic
67 acid have effects on gene expression, while their parent precursors do not [29]. Thus, this review

68 focuses on chemical transformations of FSV and FSP during the technological and culinary
69 transformation of food, as well as molecules resulting from the chemical degradation and metabolism
70 of these compounds in all compartments of the human digestive tract. Known, or hypothesized
71 absorption and health effects will also be discussed. This review also highlights gaps in knowledge
72 regarding microbial metabolism of FSV & FSP. Indeed, it is plausible that the very limited
73 understanding of FSV & FSP microbial transformations have limited appreciation for the full range of
74 biological effects elicited by these compounds, analogous to the field of polyphenols, for which the
75 critical role of microbial transformation is now appreciated [30-32].

76 Out of the 13 vitamins essential to humans, vitamins A, D, E and K are fat-soluble. The
77 basics of their digestion, absorption and metabolism have been widely discussed in previous books
78 and review papers: vitamin A [33-35]; vitamin D [36], vitamin E [37, 38], vitamin K [39, 40].
79 Unlike FSV, FSP are nonessential compounds and there is no pathology associated with a
80 deficiency. However, they can elicit significant biological effects and their long-term consumption
81 has been associated with beneficial effects on pathologies linked to aging. Terpenoids are the main
82 class of FSP. They are biosynthesized through the assembly of a variable number (N) of a 5-carbon
83 (isoprene) unit, and subdivided accordingly: monoterpenes ($N = 2$, e.g. limonene, menthol and
84 vanillin), diterpenes ($N = 4$), tetraterpenes ($N = 8$), including the carotenoid pigments. In plants,
85 carotenoids play an essential role in photosynthesis, and in mammals some serve as provitamin A
86 (i.e. α - and β -carotenes, β -cryptoxanthin, γ -carotene). Some xanthophyll carotenoids (i.e. lutein and
87 zeaxanthin) appear to play a role in visual function and in the prevention of age-related macular
88 degeneration. The carotenoid lycopene (i.e., the red pigment of tomato) has anti-inflammatory
89 effects [20], which may explain partly its association with a reduced risk of cardiometabolic disease
90 [41-43]. Triterpenes ($N = 6$) have also aroused much scientific interest, in particular their sterol
91 derivatives, e.g. β -sitosterol, stigmasterol, sitostanol. These so-called phytosterols have a structure
92 analogous to cholesterol and serve a similar biological function in plants. They have been observed

93 to decrease the capacity and the rate of cholesterol absorption in humans [44]. Thus, they have
94 garnered interest in reducing hypercholesterolemia [45], and ultimately the risk of cardiovascular
95 disease. In addition to carotenoids and phytosterols, a selection of FSP having interesting *in vitro*
96 properties, for example antioxidant or antimicrobial, will be mentioned.

97

98 **1. Commonalities and differences between FSV vs. FSP metabolism and biological effects**

99 Because FSV and FSP are closely related to lipids, there is some overlap in the process of
100 absorption and metabolism and the that of triacylglycerols, phospholipids and sterols. At dietary
101 doses of FSV, it is well established that apical membrane proteins of the enterocyte, e.g. SR-BI and
102 NPC1L1, facilitate the absorption of some FSV, e.g., vitamins D and E, and that of some FSP, e.g.
103 some carotenoids [46]. However, at supplemental/pharmacological doses, both FSV and FSP are
104 assumed to enter the enterocyte via passive diffusion. Once taken up, some FSV and FSP can be
105 phase I metabolized within the enterocyte. It has been shown that some FSV can also be effluxed
106 back into the intestinal lumen via specific transporters [47-49]. Following uptake, lipophilic
107 compounds, e.g. parent molecules of FSV & FSP, are packaged into the chylomicron particle, while
108 amphipathic and polar metabolites, e.g. some derivatives of FSV and FSP, are released directly into
109 the blood, and travel from the portal vein to the liver for “first pass” metabolism. This often includes
110 oxidation by cytochrome P450 enzymes, regardless of the compound in question. Routes of
111 excretion, including release of the parent FSV and FSP, as well as their phase I and phase II
112 metabolites, occur in the liver and the kidney, respectively.

113 Despite these shared pathways, there are many fundamental points of difference in the handling
114 of FSV absorption and metabolism, as compared to FSP. Once shuttled into the enterocyte, the FSV
115 are often chaperoned around via specific binding proteins, which again recognize particular
116 structures or functional groups. For vitamins A and D, this shuttling begins in the enterocyte of the
117 small intestine, while for vitamin E (and potentially vitamin K₁) this occurs in the liver, thanks to α -

118 tocopherol transfer protein [50]. In contrast, it is assumed that most FSP are non-specifically bound
119 to unknown proteins, in order to remain soluble in the cytosol. Another important distinction is the
120 regulation of active vitamin concentrations in the blood stream following a meal. Vitamins A, D,
121 and K are primarily found in foods as non-active “provitamin” forms, which require additional
122 transformation via metabolism to produce the active forms. Recent evidence suggests that dietary
123 forms of vitamin E may also serve as provitamins for some functions [51]. This additional step
124 permits great fluctuations in circulating concentrations of the provitamin forms following a meal,
125 without disrupting the highly regulated steady-state concentrations of the active forms. In contrast,
126 many FSP are rapidly and non-specifically metabolized for excretion. Thus, they require repeated
127 dosing over a given window of time to reach and maintain a concentration within the biological
128 window of effect [52]. An additional point of difference between FSV and FSP is high specificity
129 in mechanisms of action. Vitamins A and D metabolites, i.e. retinoic acid and 1,25-
130 dihydrocholecalciferol, are nuclear receptor agonists with high specificity in binding to the retinoic
131 acid receptors (RAR) and to the vitamin D receptors (VDR), respectively. Vitamin E can act as a
132 direct antioxidant to inhibit lipid peroxidation, and some of its metabolites may also directly bind
133 nuclear receptors [53, 54]. Vitamin K has a clear role in converting glutamate into γ -
134 carboxyglutamate – a required step in the blood coagulation cascade, which may also be important
135 in bone mineralization [55]. Furthermore, a total of 17 vitamin K-dependent proteins have been
136 identified to date and involved in bone and cardiovascular health [56]. In contrast, diverse
137 mechanism(s) of action are proposed for many FSP metabolites, e.g. direct antioxidant effects,
138 regulation of gene expression, effect on inflammation.

139

140 **2. Derivatives of FSV and FSP found in foods**

141 Upon storage food is subject to various physical and chemical agents, e.g. UV radiation or
142 dioxygen, which can start altering the most labile molecules. Microorganisms growth can also

143 begin to metabolize many molecules including FSV and FSP. Transformation of foods via cooking
144 or industrial processing may enzymatically or nonenzymatically, i.e. physically or chemically,
145 produce derivatives of FSV and FSP. Chopping or grinding food for preparation can cleave cell
146 walls and allow enzymes to come into contact with substrates previously located in different cells
147 or sub-cellular compartments. Mixing or blending can accelerate this process and also introduce
148 dioxygen, which can serve as an essential cofactor for many enzymes, as well as a chemical
149 oxidant. Heat can also rupture cell tissue and increase the reaction rate for most chemical
150 transformations in foods. Additionally, consumption of products transformed by yeasts, bacteria,
151 and fungi (e.g. cheese, yogurt, kimchi, sauerkraut), or mammals (e.g. dairy products, meat), can
152 result in intakes of FSV and FSP metabolites produced by microbial species, the animal, or the
153 microbiome within the animal. These metabolites are likely present at trace levels in all
154 transformed products, but can be especially rich in organs known to concentrate metabolites (e.g.
155 mammalian liver, kidney), or in animal byproducts consumed by humans.

156 Mechanisms of production of FSV metabolites by the main animal species that we consume,
157 i.e. cattle, poultry and pigs, are similar to those in humans. Concerning vitamin A, it is accepted
158 that the same metabolites that play a biological role in visual function and in gene expression in
159 humans, namely 11-*cis*-retinal and retinoic acid respectively, are synthesized from the pro-vitamin
160 A carotenoids by the main animals that we eat, i.e. beef, pork and chicken. These metabolites are
161 therefore theoretically present in the meat produced from these animals. Nevertheless, 11-*cis*-retinal
162 is present in the eyes, which are generally not consumed, and retinoic acid is present in very low
163 concentrations in tissues. The main form of vitamin A present in food from farm animals is
164 primarily retinyl palmitate, which can be present in very high, even toxic, concentrations in the
165 liver of certain animals (e.g. polar bears) [57]. To our knowledge, there is no data on the human
166 consumption of endogenously synthesized vitamin E metabolites present in tissues from livestock.
167 Vitamin E is intentionally supplemented to livestock to reduce lipid peroxidation in meat products

168 post-slaughter [58]. The resulting metabolites are presumed to be regenerated via intracellular
169 reducing reagents [58], although to the best of our knowledge this has not been studied directly.
170 Vitamin D, as either vitamin D₂ or D₃ isoforms in foods, undergoes hydroxylation in the
171 mammalian and avian liver to produce 25-hydroxyvitamin D₂ and D₃, respectively [59, 60]. These
172 25-hydroxy metabolites are found in beef, pork, chicken, and eggs, [61, 62], as well as in milk,
173 cream, and butter [63], in concentrations on the same order of magnitude as the vitamin D₂ and D₃
174 precursors. Trace quantities of 25-hydroxyvitamin D₃ have also been reported in salmon, tilapia,
175 and mahi-mahi [61]. Like most sterols, 25-hydroxyvitamin D is robust to various methods of
176 cooking [64]. Although not systematically measured in the food supply, the most potent vitamin D
177 metabolite, 1,25-dihydroxyvitamin D, is especially rich in beef kidney and liver, with
178 concentrations ~5-10 times lower in beef muscle tissue [65]. Data suggests that it can be
179 significantly isomerized and degraded by food processing, notably heat [66][67](**Fig. 1**). Vitamin K
180 is present in food either as vitamin K₁ (phylloquinone) or as vitamin K₂ (menaquinones).
181 Menaquinones are actually a cluster of K₂ isoforms produced either by mammalian metabolism of
182 vitamin K₁ or by bacteria such as the lactic acid bacteria (the most common form of bacteria in
183 fermented foods). Menaquinones can have 5-10 isoprenyl units and are found in the human colon
184 (see section 7), as well as in food sources (e.g. buttermilk, whole-fat milk, various cheeses,
185 sauerkraut) [68]. The most common menaquinone, menaquinone-4 (MK-4), is a mammalian
186 metabolite of phylloquinone (vitamin K₁), and is found in whole-fat milk, cheeses, salami, beef,
187 pork, and chicken [68, 69]. Small quantities of MK-4 have also been reported in fermented foods,
188 like sauerkraut and natto [70, 71]. Vitamin K₁ in plant oils is robust to high heat processing
189 conditions, but sensitive to degradation by daylight [72]. Chemically, it has no clear structural
190 vulnerabilities to autoxidation or hydrolysis.

191 Provitamin A carotenoids (i.e. mainly β -carotene, α -carotene, and β -cryptoxanthin) as well as
192 xanthophyll carotenoids (e.g. lutein and zeaxanthin) are consumed by grazing beef, dairy cattle and

193 sheep, and are thus found in tissues and milk [73]. Ruminants cleave a significant fraction of
194 provitamin A into vitamin A (retinal) in the intestine, which is stored primarily in the liver as
195 retinol esters. Thus, vitamin A, as a metabolite of provitamin A carotenoids, is found in dairy and
196 cuts of beef, goats, lamb, and especially liver tissue [74]. Although lutein metabolites have been
197 previously reported in human breastmilk [75], their presence in meat or dairy has not been
198 investigated.

199 There is apparently little degradation of carotenoids in foods. Lycopene, one of the most
200 chemically labile carotenoids, only undergoes mild (*Z*)-(*E*) isomerization following traditional
201 thermal processing of tomato products [76]. Likewise, β -carotene and lutein have also been
202 reported to be quite stable in a variety of foods following domestic or industrial thermal processing
203 [77-79]. Shorter-chain metabolites of β -carotene and lycopene, respectively termed “ β -apo-
204 carotenoids” and “apo-lycopenoids”, have also been reported in both raw and processed fruits and
205 vegetables [80-83]. However, their origins are unknown. Carotenoid cleavage enzymes within the
206 plant can produce these apo-carotenoids [84]. It is also likely that at least a portion of these apo-
207 carotenoids are enzymatically or chemically produced during food storage, food processing and
208 food preparation/cooking, although studies are lacking. In supplements, high carotenoid
209 concentrations and presence of oil (for which co-oxidation can occur) would be expected to
210 produce higher concentrations of apo-carotenoids. Lutein extract from marigold following was
211 found to degrade following 10 days of exposure to mid-day heat (31°C) + sunlight (5.89 kW h m⁻²)
212 to produce derivatives with shorter carbon chains which elicit PPAR- γ activity [85]. The presence
213 of these products in lutein containing foods or supplements has not been reported, but may merit
214 further investigation due to the pronounced biological effects.

215 Phytosterols in foods are susceptible to oxidation of the B ring, via free radical or UV-exposure,
216 with oxidation product concentrations positively increasing with storage time [86]. Their diversity
217 in structures and occurrence in a wide array of foods has been nicely summarized previously [87,

218 88]. Following oxidation, an epoxide, keto, mono- or di-hydroxyl group is added to the B-ring.
219 These phytosterol oxidation products primarily occur in plant oils exposed to heat (during the
220 extraction or cooking process), or UV-light, and in fried products (i.e. potato chips, French fries)
221 [87, 89]. They are also found in coffee silverskin, a roasting byproduct [90]. Food products
222 “enriched” with phytosterols, including heat-treated milk products [86, 91] and dark chocolate [92],
223 have also been reported to contain oxidized metabolites. Although it has been shown that thermal
224 treatment of foods containing phytosterols acylated by a PUFA chain leads to phytosterol oxidation
225 [93] (**Fig. 2**), co-heating of phytosterols with a saturated lipid induced a greater concentration of
226 oxidized metabolites than with unsaturated lipid [94]. Phytostanols, another type of plant sterols,
227 are largely protected from oxidation, likely due to the absence of a double bond on the B-ring [89,
228 94].

229 Finally, there are a few studies on the degradation of chlorophyll during food processing.
230 Thermal processing and acids added to some foods (e.g. pickling cucumbers) cause the magnesium
231 ion to be released from the porphyrin ring, thus producing olive-green pheophytin [95]. Further
232 heating converts the pheophytin into pyropheophytin, with loss of the carboxymethyl group but
233 retention of the lipophilic phytol tail. Alternatively, rapid blanching causes enzymatic cleavage of
234 the phytol tail to produce water-soluble metabolites (i.e. chlorophyllides) and their breakdown
235 products (i.e. pheophorbides).

236

237 **3. Possible transformations of FSV and FSP in the oral cavity**

238 The metabolism of FSV and FSP likely starts in the mouth as chewing produces mechanical
239 grinding and partial breakdown of food matrices. Indeed, this process disrupts a fraction of the plant
240 cell walls, and disrupts intracellular organelles in which the FSV and FSP are located. This puts FSV
241 and FSP into contact with enzymes and other molecules located in other organelles and tissues for
242 the first time, and can completely change the fate of these molecules. For example, carotenoids may

243 be exposed to known oxidants or prooxidants within the plant tissue itself or from the atmosphere
244 (e.g. ferrous iron, dioxygen). Saliva also comes into contact with food in the oral cavity, and
245 provides food lubrication, antimicrobial defense, assistance with taste and early digestion [96].
246 Indeed, the oral cavity has been considered a “bioreactor” [97, 98] in which multiple interactions
247 occur between salivary components (e.g. ions, proteins, including digestive enzymes, such as alpha-
248 amylase) and macro- and micronutrients and phytochemicals. Salivary lactoperoxidase and
249 myeloperoxidase catalyze the reaction of hydrogen peroxide with thiocyanate to produce the highly
250 reactive hypothiocyanous acid, which has antimicrobial activity and can also react with FSV and
251 FSP. Activated phagocytes in saliva can also release a series of toxic oxidants [99, 100] which could
252 oxidize redox-sensitive molecules. Theoretically, the hydrophobic parent molecules of FSV and FSP
253 remain within lipid phases through the oral cavity, which can confer protection (if the lipids are not
254 oxidized). In contrast, we hypothesize that some of their less apolar derivatives might bind to
255 salivary proteins, analogous to what occurs with polyphenols [101, 102]. The risk of oxidation of
256 FSV and FSP and their derivatives will depend on the proportion of prooxidants (e.g. ferrous iron,
257 hydrogen peroxide, hypothiocyanous acid) and oxidation-sensitive nutrients (e.g. polyunsaturated
258 fatty acids) to antioxidants (e.g. polyphenols, carotenoids, vitamin C), simultaneously present in the
259 mouth. The risk of oxidation also depends on the location of the molecules of interest in the different
260 phases, which depends both on hydrophobicity and on their physical state. For example, it is
261 probable that crystallized carotenoids (like those found in carrots or tomatoes) are less sensitive to
262 oxidation. Finally, the oral microbiome, comprised of different bacterial and yeast species, also
263 produces enzymes that likely metabolize certain FSV and FSP.

264 Surprisingly, no data exists on the metabolites of FSV and FSP that are potentially produced
265 in the oral cavity. Nevertheless, based on data obtained on the role of saliva in oxidation processes
266 possibly taking place in the stomach [103] and inhibited by dietary antioxidants, we can imagine
267 certain scenarios resulting in metabolite production. For example, we know that the oral microbiota

268 reduces nitrate secreted by saliva to nitrite, a precursor of nitric oxide. We also know that apple
269 polyphenols, by inhibiting nitrosation/nitration [104], form nitrated and oxidized polyphenols. Such
270 pathway could also apply to some oxidizable or nucleophilic FSV and FSP (e.g. carotenoids), thus
271 generating nitrated or oxidized metabolites as end-products.

272

273 **4. Metabolism of FSV and FSP in the stomach**

274 The stomach of mono-gastric animals could have two main roles on the digestion of FSV and
275 FSP. The first, for which we have the most data is to amplify the digestion of food [105]. This
276 process leads to the release of FSV and FSP from their matrices, transfer to the lipid phase of the
277 digestate, and possible chemical transformations dependent upon physicochemical structures and
278 gastric enzymes. The typical gastric conditions are: 37 °C, pH from weakly to fairly acidic [106],
279 the presence of a significant partial pressure of O₂ [107] and of digestive enzymes, e.g. pepsin and
280 gastric lipase, and the presence of potentially prooxidant agents (e.g. ferrous iron) [108, 109]. These
281 conditions can promote varied chemical reactions ranging from association, e.g. binding of the
282 water-soluble carotenoid crocin to starch [110], to chemical modifications, e.g. autoxidation of
283 carotenoids [108, 109, 111, 112].

284 The second hypothetical role of the stomach could be to secrete proteins that facilitate FSV and
285 FSP and/or their derivatives, parallel to intrinsic factor released in the stomach to facilitate vitamin
286 B₁₂ intestinal absorption, This hypothesis is supported by the observation that the glandular
287 stomach secretes 2-3 glycoproteins which are able to bind retinol [113], and could influence uptake
288 in the lower intestine.

289

290 ***4.1 Distribution of FSV and FSP between the different matrices coexisting in the stomach***

291 The formation of FSV and FSP derivatives of in the stomach depends on the ability to
292 interact with agents (i.e. physical, chemical or enzymatic) which are likely to transform them. It is

293 therefore important to determine in which phase(s) or interface(s) these molecules are distributed.
294 Initially, these molecules are located in the food matrices in which they are ingested, but during
295 digestion they are gradually released and distribute themselves between the different phases present
296 in the digestive tract. For FSV and FSP to be freed from the structural barriers which impede
297 release from the food matrices, [114, 115], the biochemical action of gastric juice and the peristaltic
298 movements are required. The importance of the peristaltic movements in freeing FSP was
299 confirmed by a study showing that β -carotene was better released from sweet potatoes when
300 mechanical forces were applied [105, 116]. A small number of studies have also been devoted to
301 measuring the transfer of FSV and FSP between the different phases present in the stomach during
302 digestion (**Fig. 3**). Tyssandier et al. [106] fed human volunteers with test meals that contained
303 vegetable purees and sunflower oil, then separated the gastric contents into 3 phases: a lipid phase,
304 an aqueous phase, and a pellet of insoluble plant debris. A significant fraction of carotenoids was
305 recovered in the lipid phase, showing that they were transferred from the vegetable purees to this
306 phase during the oral and/or gastric phase(s). Interestingly, the percentage of carotenoid transferred
307 was very different depending on the food matrix and carotenoid subclasses. This result suggests
308 that the percentage of carotenoid transferred depends on the carotenoids' physicochemical
309 properties, as well as on their location in, and interactions with, the plant matrix. *In vitro* studies
310 have further deciphered the factors involved. Rich et al. suggested that carotenoids incorporated
311 into cell membranes are more difficult to transfer than carotenoids in crystalline form [117]. Then,
312 Goupy et al. conducted a study to specify the respective roles of the carotenoid structure, the
313 presence and nature of emulsifiers covering lipid droplets, and the effect of the food matrix on the
314 transfer efficiency of carotenoids from vegetable matrices to lipid droplets [118]. The results
315 confirmed what was deduced from the clinical study [106], i.e. that the transfer of carotenoids
316 between plant foods and lipid emulsions depends on all of these factors. Additionally, Yuan et al.
317 reported that carotenoid transfer was greater when the lipid droplets were emulsified with caseinate

318 than with Tween 20 or modified starch [119]. They hypothesized that this was because caseinate
319 was partially hydrolysed by pepsin to facilitate carotenoid transfer. This hypothesis was reinforced
320 by the results of another study in which Tween 20-stabilized emulsions had a lower rate and extent
321 of lipid digestion than those of protein-stabilized emulsions [120]. Furthermore, β -carotene was
322 more easily released from emulsions when they were coated with β -lactoglobulin, as compared to
323 other milk proteins [121]. Thus, the type of proteins that cover the interface also has an influence
324 on the transfer. In summary, the presence and nature of emulsifiers is a key factor that governs the
325 transfer of carotenoids from the food matrix to lipid emulsions in the stomach during digestion.
326 With regard to the transfer of other FSV and FSP or their derivatives between the different phases
327 present in the stomach, there is, to our knowledge, no data available. It can nevertheless be assumed
328 that transfer also depends on the parameters mentioned above.

329 330 **4.2 Formation of FSV and FSP derivatives in the stomach lumen**

331 The physicochemical conditions that exist in the stomach, e.g. acidic pH, presence of
332 dioxygen, prooxidants and digestive enzymes, can lead to chemical and/or enzymatic changes of
333 FSV and FSP, especially those sensitive to oxidation. However, because these modifications first
334 require FSV and FSP to be accessible to factors likely to modify them, they are very difficult to
335 predict. Likewise, pathologies, including microbial infection (e.g. by *Helicobacter pylori*), aging,
336 and alcohol ingestion can also affect FSV and FSP concentrations [122]. The rest of this chapter
337 discusses the state-of-the-art knowledge regarding these factors.

338 The first factor of influence in the stomach is the acidic pH. To our knowledge, its effect on
339 the potential degradation of FSV and FSP has only been studied on a vitamin D and vitamin D
340 analogues in simplified chemical models [66, 67] (**Fig. 1**), suggesting possible isomerization in the
341 stomach. It would therefore be interesting to systematically study the effect of pH on the potential
342 degradation of other FSV & FSP, considering the fact that they are not absorbed in pure forms but

343 incorporated in food matrices or in excipients (case of nutritional supplements), which will
344 probably protect them significantly from this acidity.

345 Concerning carotenoids, there is no data on the effect of pH on the molecules themselves, but
346 only a clinical study on the effect of pH on the bioavailability of β -carotene. Tang and her
347 colleagues [123] questioned the role of gastric acidity on the bioavailability of a pharmacological
348 dose of *all-trans* β -carotene incorporated in a gelatine capsule. Using omeprazole to inhibit gastric
349 secretions (HCl and digestive enzymes), they observed that the bioavailability of β -carotene was
350 approximately halved, as compared to control without omeprazole (low gastric pH). They
351 hypothesized that the relatively high pH produced more negatively charged β -carotene-containing
352 micelles, which reduced their absorption. We put forth an alternative hypothesis: the higher pH,
353 together with the absence of gastric enzymes, e.g. gastric lipase [124, 125] and pepsin, could cause
354 a large fraction of β -carotene to remain trapped within the undigested lipids of the meal.
355 Consequently, the decreased gastric secretion, which can occur with ageing or disease [126], could
356 affect the bioavailability of β -carotene, and by extension, that of other FSV and FSP. Nevertheless,
357 this likely happens in subjects with clinical signs of decreased gastric secretion, since studies in
358 apparently healthy elderly people did not show a significant effect of age on carotenoid
359 bioavailability [127, 128] or on vitamin E response to supplementation [129].

360 Another factor important for metabolism of FSV and FSP in the gastric lumen is the presence
361 of salivary or gastric enzymes that could hydrolyse some of these compounds. Gastric lipase is one
362 of the two main digestive enzymes secreted by the stomach. Rabbit gastric lipase, which has been
363 used as a model for the human version [125, 130], is able to hydrolyse a fraction of cryptoxanthin
364 esters with concomitant release of free cryptoxanthin [130]. We hypothesize that this lipase is also
365 capable of hydrolysing other xanthophyll esters and perhaps other FSV and FSP esters, e.g.
366 phytosterol esters. As the bioaccessibility of free cryptoxanthin is superior to that of esterified
367 cryptoxanthin [130], and assuming that it is the same for other FSV and FSP, we also hypothesize

368 that the hydrolysis of any FSV or FSP ester by gastric lipase could enhance its overall
369 bioavailability.

370 The second main digestive enzyme secreted by the stomach is the protease pepsin, which is
371 not assumed to directly interact with FSV and FSP. However, by hydrolysing proteins located at
372 the interface of lipid droplets [131], pepsin might facilitate the release of FSV and FSP solubilized
373 into the triglyceride core of lipid droplets, which in turn could enhance their bioavailability.

374 Derivatives resulting from the degradation or modification of certain FSV and FSP in the
375 stomach have been detected, for example, carotenoid (*Z*)-isomers were observed following
376 exposure to cation or dication radicals, or to triplet oxygen [132]. *In vitro* incubation of lycopene
377 from tomato puree in gastric juice resulted in $\leq 10\%$ (*Z*)-(*E*) isomerization, and pure encapsulated
378 lycopene $\leq 20\%$ over 3h, as compared to controls [133]. Surprisingly, the isomerization percentage
379 was not different between 1 min and 3 h of incubation [133], suggesting that gastric isomerization
380 is a rapid and primarily chemical process. Additionally, no unidentified products (which could be
381 shorter-chain metabolites) were reported [133, 134]. In contrast, incubating different (*Z*)-isomers of
382 lycopene emulsified with tributyrin for up to 3 h led to significant lycopene breakdown [134]. It's
383 not clear if the artificial tributyrin micelle or the artificially low gastric pH ~ 2 (only observed on an
384 empty stomach) [126, 135] drove these differences. Interestingly, the acidic conditions appeared to
385 drive 13-(*Z*)-lycopene to convert back to the all-(*E*) form during digestion, which was unexpected
386 [134]. *In vivo* studies, in which the concentrations of carotenoid derivatives were measured in
387 gastric samples collected at different time points during digestion, do not show a significant
388 increase in the concentration of (*Z*)-isomers [106, 108, 111] nor apo-carotenoids, previously
389 predicted to be major *in vitro* metabolites [108, 111]. Kopec et al. [111] found that in healthy men,
390 [^{13}C]- β -apo-carotenal levels remained ~ 3 orders of magnitude lower than that of [^{13}C]- β -carotene
391 throughout digestion, and neither [^{13}C]- β -apo-carotenols, nor [^{13}C]- β -apo-carotenoic acids were
392 observed in the gastric digesta. In an *in vitro* study using gastric human juices adjusted to pH 2.5

393 (rather low, compared to *in vivo* conditions), the stability of lycopene, the carotenoid most sensitive
394 to oxidation, was extremely high in tomato (~ 92% recovery) [136]. This stability was probably due
395 to the fact that lycopene was protected within the food matrix. Indeed, another study showed that β -
396 carotene and retinyl-palmitate standards, i.e. pure molecules, were strongly degraded at the end of
397 the gastric phase, while β -carotene was largely spared when provided by carrot juice [137]. In
398 addition, β -carotene and violaxanthin provided by raw spinach were highly degraded, suggesting
399 that not all food matrices provide the same level of carotenoid protection. By contrast, lutein was
400 largely spared, when provided by the same matrix [137], suggesting that the different carotenoids
401 do not have the same sensitivity to degradation. Another study, using a dynamic gastrointestinal
402 model (TIM-1, assumed to better mimic *in vivo* conditions than static *in vitro* models) showed that
403 egg xanthophylls were stable (average recovery of about 90%) and that no (*Z*)-(*E*) isomerization
404 occurred during *in vitro* digestion [138]. A lack of significant (*Z*)-(*E*) isomerization of lycopene
405 was also observed in another study using the same model [139]. Collectively, the majority of *in*
406 *vitro* and *in vivo* evidence suggests that limited isomerization and loss occurs for most carotenoids
407 when embedded in a food matrix, or when provided in a form that is highly insoluble in the digesta.
408 Furthermore, these results highlight the importance of accurately reproducing gastric
409 physicochemical conditions and their evolution during digestion.

410 Iron, both heme or non-heme, is abundant in animal muscle tissue, with 1 g of beef
411 containing 20 - 30 μg of total iron [140]. Dietary iron is a potential initiator of oxidative processes
412 called autoxidation (non-enzymatic oxidation by O_2). Oxidizable (electron-rich) FSV and FSP,
413 such as vitamin E and carotenoids, are intrinsically vulnerable to autoxidation in the stomach
414 following an iron-rich meal. Sy et al. [109] studied the autoxidation of pure β -carotene at pH 4.0,
415 corresponding to the mid-digestion of meals rich in fruits and vegetables [106]. Under these
416 conditions, Fe^{2+} and metmyoglobin induced the isomerization and oxidation of β -carotene to
417 epoxides and cleavage products of various chain lengths [109] (**Fig. 4**). *In vitro* work by Kopec et

418 al. [112] with the inclusion of gastric enzymes found more attenuated effects of gastric digestion on
419 β -carotene, with a ~20% drop from the initial dose observed when β -carotene was digested alone,
420 and a ~50-60% drop when digested with metmyoglobin or Fe^{2+} . In the same study, no statistically
421 significant drop in concentrations of lutein or lycopene during the gastric phase when digested
422 alone, or with the addition of metmyoglobin or Fe^{2+} . *In vivo*, both increased time of sampling and
423 the presence of FeSO_4 consumed with a lycopene-rich beverage resulted in less lycopene in the
424 stomach than the lycopene-rich beverage alone [108]. Free retinol itself is also known to be highly
425 susceptible to autoxidation [141]. Collectively, these results highlight that contrasting results can be
426 obtained depending on meal composition, pH, the presence of digestive enzymes, and the presence
427 of prooxidant agents.

428 In addition to iron, all lipid-rich foods contain traces of lipid hydroperoxides (LOOH) with
429 peroxide values typically in the range of 1 – 5 $\mu\text{mol/g}$ [142, 143]. The Fenton reaction between Fe^{II}
430 and LOOH is a source of highly reactive oxyl radicals (LO^\bullet), while heme- Fe^{III} reacting with
431 hydroperoxides also leads to hypervalent iron forms (heme- Fe^{IV}) that are efficient initiators of lipid
432 peroxidation through the propagating lipid peroxy radicals (LOO^\bullet) [144] (**Fig. 5**). The prooxidant
433 character of a meal rich in iron and oxidizable (polyunsaturated) lipids may be mitigated by plant
434 antioxidants. Hydrophilic antioxidants, such as phenolic compounds, either bind non-heme iron
435 under inert complexes or reduce hypervalent heme iron, while lipophilic antioxidants, such as
436 vitamin E and carotenoids, reduce the lipid oxyl and peroxy radicals, or trap them as stabilized
437 radical adducts. Under model gastric conditions using micelles and emulsions, this chemistry is
438 well-established [145-150], and shows that the co-oxidation of electron-rich FSV and FSP with
439 polyunsaturated lipids is much faster than their direct autoxidation. For instance, both α -tocopherol
440 and β -carotene are rapidly consumed via co-oxidation when incubated with heated turkey muscle in
441 a simulated gastric fluid at pH 3, 37°C., but protected upon addition of red wine polyphenols [107,
442 151]. It is also noteworthy that apo-carotenoids (possibly present in plant food or formed in the

443 course of carotenoid – polyunsaturated fatty acids co-oxidation during food processing or in the
444 gastric phase of digestion) are themselves antioxidants [147]. In a simple model using micelles of
445 linoleic acid, apo-6'-lycopenal and apo-8'-lycopenal were even better inhibitors of metmyoglobin-
446 induced lipid peroxidation than (all-*E*)-lycopene itself [147]. In general, a long unsaturated chain
447 and a terminal carboxylic acid group both favor the antioxidant activity of apo-lycopenoids. The
448 short-chain apo-14'-lycopenoic acid was also shown to directly reduce the hypervalent iron form of
449 metmyoglobin, thus behaving as a hydrophilic antioxidant [147]. Of course, the *in vivo* relevance of
450 this chemistry is much more difficult to demonstrate. As an example, in minipigs equipped with a
451 canula for uptake of gastrointestinal fluids, end-markers of lipid peroxidation (TBARs) following a
452 meal combining sunflower oil and beef meat were found in lower concentrations when the meal
453 also included fruit and vegetable purées [152].

454 Other electron-rich FSP that could also undergo autoxidation and co-oxidation with
455 polyunsaturated fatty acids along the gastric digestion are the fat-soluble catechols of rosemary and
456 olives. Indeed, the catechol ring (1,2-dihydroxybenzene) is a critical moiety conferring electro-
457 donating capacity on phenolic compounds. It can be involved in one- and two-electron transfers
458 with concomitant formation of a semiquinone and an *ortho*-quinone, respectively. For instance, the
459 rosemary diterpene carnosic acid is a potent antioxidant and its oxidized derivatives retain the
460 catechol ring [153] (**Fig. 6**). These antioxidant diterpenes, as well as a decarboxylated derivative,
461 were also detected in the meat of lambs fed diets supplemented with rosemary extracts. They confer
462 higher oxidative stability to the meat [154]. Hydroxytyrosol and its derivatives are present in
463 substantial concentration in virgin olive oil (up to ca. one gram / kg, **Fig. 7A**) [155, 156].
464 Hydroxytyrosol inhibits lipid peroxidation in synergy with α -tocopherol under model gastric
465 conditions [157]. While acting as an antioxidant, it is converted into dimers and higher oligomers,
466 which undergo further oxidation, thus prolonging the antioxidant activity [158](**Fig. 7B**).

467 Regeneration of the amphiphilic antioxidant α -tocopherol (TocOH) from its oxidized forms is
468 key to prolonging its lipid-protecting activity while avoiding the prooxidant activity of the
469 corresponding aryloxy radical (TocO[•]) (**Fig. 8**). The reduced forms of coenzyme Q and vitamin K,
470 as well as vitamin C and a variety of polyphenols may play this role. This regeneration may occur
471 from TocO[•] upon one-electron reduction, but also from some non-radical two-electron oxidized
472 forms of TocOH (e.g., *o*-methylenequinones, the *p*-quinone form and its hemiketal tautomer, **Fig.**
473 **8**). Similarly, oxidation and metabolism of vitamin K is shown in **Fig. 9**.

474 Many other factors may lead to chemical modifications of certain FSV and FSP. For instance,
475 alcohol seems to lower the stability of some FSV and FSP in the gastric lumen, as it was observed
476 that alcohol consumers had significantly lower antral mucosal and gastric juice concentrations of β -
477 carotene, compared to non-consumers [122]. The physicochemical and enzymatic conditions in the
478 gastric compartment can also be altered under certain pathological states or during aging, which is
479 associated with a higher prevalence of atrophic gastritis [126], or during infection by *Helicobacter*
480 *pylori*. For example, it has been shown that infection with *H. pylori* decreases the concentration of β -
481 carotene in gastric juice [122], suggesting that a fraction of this provitamin A carotenoid was
482 converted to metabolites. No significant effects of age on β -carotene concentration in gastric juice
483 [122] or on the (*E*)-(*Z*) isomerization of β -carotene during absorption were observed.

484 Gastric metabolism of carotenoids has largely been focused on the lumen because it is
485 presumed that the absorption of these compounds by the mucosa (as well as that of the other FSV /
486 FSP, and their metabolites) is low or negligible. However, when β -carotene was incubated with
487 gastric mucosal homogenates or with soy lipoxygenase, the production of known β -carotene
488 metabolites, i.e. apo-carotenals, β -apo-13-carotenone, retinoic acid and retinal, were successfully
489 detected [159]. The authors suggested that a mucosa lipoxygenase is responsible for the metabolism
490 of β -carotene. However, it is not known whether metabolites produced in the mucosa can be re-
491 secreted in the gastric lumen or directly enter the systemic circulation. Further work is required.

492

493 ***4.3 Potential uptake of FSV and FSP and their derivatives by the gastric mucosa***

494 Some FSV and FSP, i.e. α -tocopherol and β -carotene [122], as well as other carotenoids
495 (lutein, zeaxanthin and β -cryptoxanthin) [160], have been found in the gastric mucosa. Moreover,
496 in the same study it was reported that the concentration of certain carotenoids was lower in
497 cancerous gastric mucosal tissues than in non-cancerous ones. Although it is likely that a
498 significant fraction of the compounds present in the gastric mucosa are derived from the blood
499 circulation, it is possible that a fraction was absorbed from the gastric lumen.

500

501 ***4.4 Potential health effects of FSV and FSP in the gastric lumen and mucosa***

502 Several FSV and FSP, e.g. vitamin E and carotenoids, are known to be important antioxidants
503 in cell membranes and plasma lipoproteins. Others (e.g., the lipophilic phenols from olives and
504 rosemary, and generally all dietary phenolic compounds) are more likely to exert their antioxidant
505 effects in the lumen of the digestive tract, where they can reach millimolar concentrations under
506 postprandial conditions as compared to the nano-micromolar concentrations in certain cells.
507 Polyunsaturated fatty acids (PUFA) are the main class of oxidizable essential fatty acids. PUFA
508 oxidation lowers the nutritional quality of the meal, not only through loss of essential lipids but also
509 by the alteration of dietary proteins [161], which are vulnerable to electrophilic and/or oxidizing
510 lipid peroxidation products (e.g. lipid hydroperoxides, malondialdehyde, 4-hydroxy-2-alkenals).
511 Moreover, the delivery of these potentially toxic products to intestinal cells or their incorporation
512 into the circulating lipoproteins may be risk factors in atherosclerosis [98] and colon cancer [162].

513 Some FSV and FSP and/or their metabolites could also have beneficial effects on the gastric
514 mucosa, not only through their antioxidant activity, but also by scavenging nitrite, as some
515 polyphenols do [163, 164], thus participating in the prevention of stomach cancer [165]. This
516 hypothesis is supported by a study showing that lycopene was capable of inhibiting nitrite-induced

517 gastric carcinogenesis in rats [166]. A fraction of FSV and FSP and/or their metabolites could also
518 be absorbed by the gastric mucosa where they could modulate inflammation. Indeed, it has been
519 shown that retinoic acid, which is present in some foods of animal origin, can inhibit mucosal
520 inflammation [167], possibly by an NF-kappa B-driving mechanism, as has been shown in adipose
521 tissue [168].

522 Furthermore, it has been shown that apo-carotenals, possibly produced by carotenoid – PUFA
523 co-oxidation in the stomach, have anti-inflammatory and antioxidant properties in cells through the
524 respective down- and up-regulation of the NF-κB and nrf2 (antioxidant/electrophile response
525 element) pathways, while the corresponding apo-carotenoic acids are inactive [169, 170]. This is
526 explained by the fact that apo-carotenals are electrophilic unsaturated aldehydes capable of reacting
527 with key nucleophilic thiols (Cys residues) of proteins controlling the activity of these transcription
528 factors.

529

530 **5. Metabolism of FSV and FSP in the upper intestine, i.e. duodenum, jejunum and ileum.**

531 After being pre-digested in the stomach, the food, mixed with the digestive juices secreted in
532 the mouth and in the stomach, is poured into the duodenum via the pylorus. The physicochemical
533 and enzymatic conditions then radically change. The partial pressure of oxygen decreases [171], the
534 pH increases to about 6.5 [172, 173], and bile and pancreatic secretions arrive bringing new
535 molecules and enzymes, e.g. bile salts, pancreatic lipase, that can induce chemical and biochemical
536 modifications of FSV and FSP and their derivatives.

537

538 ***5.1 Distribution of FSV and FSP between the different matrices coexisting in the upper intestine***

539 After exiting the stomach, the FSV and FSP and their derivatives potentially have the ability
540 to be transferred in two new phases resulting from bile secretion: mixed micelles, which results from
541 the interaction of bile micelles with the lipolysis products of dietary triglycerides, and lipid vesicles,

542 which consist mainly of uni- and multilamellar liposomes [174, 175]. Note that bile micelles can
543 contain FSV and FSP [176-178], as well as some of their derivatives, because enterohepatic
544 recycling of some of these molecules may occur [177]. Thus, there are several phases in the upper
545 intestine between which the FSV and FSP and their derivatives can theoretically be distributed: the
546 food matrix being digested, the lipid phase, which is transformed during digestion into emulsified
547 lipid droplets, the micellar phase, which contains both mixed micelles and lipid vesicles, i.e.
548 liposome-like structures, and the aqueous phase, which can contain food-borne or salivary proteins
549 (**Fig. 10**). However, there is little data on the distribution or transfer of FSV and FSP or their
550 derivatives between these different phases during digestion. Thus, only hypotheses can be
551 formulated.

552 When entering the duodenum, a fraction of the parent FSV and FSP and derivatives are still
553 in the partially digested food matrix and a fraction transferred into lipid emulsions following gastric
554 processing (**see section 4.1**). At least a portion of the more hydrophilic derivatives may have
555 associated with aqueous soluble proteins or peptides of partially digested dietary proteins. Some
556 derivatives may also be water-soluble. Of course, this distribution is dynamic and evolves during
557 digestion, with FSV and FSP and their derivatives transferred to the other phases as lipolysis
558 continues. It has been shown *in vitro* that parent FSV and FSP are transferred partly to lipid
559 emulsions and partly to micelles [117, 179, 180], but it is likely that a fraction is also transferred to
560 vesicles and another binds to soluble proteins [181]. Some limited *in vivo* data are available for
561 retinyl palmitate, α -tocopherol and the major carotenoids [106, 179, 182]. However, the distribution
562 of these molecules between all the phases mentioned above has not been assessed, and nothing is
563 known about the derivatives.

564 The distribution of these molecules between the different phases is governed by two key
565 parameters, i.e. their intrinsic solubility in the different phases, and their capacity to transfer between
566 the different phases. Indeed, when a liquid/liquid extraction is performed, the distribution between

567 the two phases occurs based upon relative solubility alone. In contrast, in the lumen of the digestive
568 tract, the transfer is prevented by the very weak mixing of the different phases and by the presence of
569 many molecules, located within the phases or at the interface, and acting as barriers against free
570 transfer [114].

571 To date, only data on the intrinsic solubility of the parent molecules in emulsified lipid
572 droplets and micelles is available. Data on carotenoids show differential distribution between the
573 triglyceride core and the phospholipid interface of emulsified lipid droplets. β -Carotene is
574 preferentially localized in the core, whereas zeaxanthin, which has two polar hydroxyl groups, is
575 preferentially localized at the lipid droplet surface [183]. Scattered data exists concerning the
576 solubility of FSV and FSP and their derivatives in mixed micelles [184]. A comparative study of the
577 intrinsic solubility of FSV and FSP in micelles whose composition mimics those formed *in vivo* is
578 lacking, but this is probably a key parameter to explain the very different absorption rates of these
579 molecules.

580 **Fig. 10** details what is known regarding the factors that drive interphase transfer of FSV and
581 FSP and their derivatives. The first step, the transfer between food matrices and emulsified lipid
582 droplets, was recently been studied for carotenoids [118]. This transfer is basically governed by van
583 der Waals interactions occurring between carotenoids and triglycerides. It has also been shown that
584 amphiphilic molecules that coat triglyceride droplets in the gut, e.g. phospholipids and proteins,
585 strongly impair the transfer of pure carotenoids to triglyceride droplets [118], suggesting that they act
586 as a barrier that impair the transfer. However, carotenoids incorporated in plant matrices were better
587 transferred to triglyceride droplets coated with emulsifiers than to uncoated ones [118].

588 The second and arguably best-studied step is the FSV + FSP transfer between lipid emulsions
589 and micelles [185]. For example, the transfer of carotenoids is inversely related to carotenoid
590 hydrophobicity with maximal transfer occurring: between pH 6 and 7, with ≥ 2 mmol/L bile salts.
591 Carotene transfer, but not xanthophyll transfer, was impaired by the presence of other carotenoids.

592 In the absence of pathologies of the digestive tract during digestion, the pH in the duodenum
593 is very stable at ~ 6.5 [185], and the concentration of bile salts is ~10 mmol/L (with bile salt
594 concentrations falling to ≥ 5 mmol/L in a fasted state) [173]. Therefore, as the pH is very stable in the
595 pH zone in which the transfer is maximal, and the concentration of bile salts is always much higher
596 than the concentration which allows a maximal transfer, we hypothesize that, in vivo, pH and bile
597 salt concentration do not influence transfer efficiency.

598 Finally, no data exist regarding the possible presence of FSV / FSP derivatives in the aqueous
599 phase, nor on the potential association of FSV / FSP and their derivatives with proteins or vesicles.

600 In summary, much remains to be discovered about the distribution of FSV / FSP and their
601 derivatives between the different intestinal phases, and on the underlying mechanisms that govern
602 phase transfer. This information would be very useful to better understand the distribution, and
603 therefore the absorption efficiency, of these molecules, especially if we plan to improve their
604 bioavailability.

605

606 ***5.2 Metabolism of FSV and FSP in the upper intestinal lumen and identified metabolites.***

607 The most easily identified duodenal products of FSV / FSP metabolism are those arising from
608 the hydrolysis of fatty acid esters, e.g. retinyl esters and xanthophyll esters. Three pancreatic
609 enzymes are able to hydrolyse these esters. Carboxyl ester lipase, also called bile salt-stimulated
610 lipase, which is able to hydrolyse the esters of xanthophylls [186] and α -tocopherol [179], but also
611 pancreatic lipase and pancreatic lipase-related protein 2, which are able to hydrolyse retinyl esters
612 [187, 188]. It is likely that these enzymes, given their low substrate specificity, are also capable of
613 hydrolysing other FSV and FSP esters (e.g. phytosterol esters), but this remains to be demonstrated.
614 This hydrolysis is important for the bioavailability of these compounds, assumed to be effectively
615 absorbed only in their non-esterified form.

616 It is very likely that derivatives of FSV and FSP are produced in the upper intestine following
617 the combined influence of lipases and other enzymes present in pancreatic secretions, as well as
618 interactions with other co-consumed species (e.g. iron). Regardless of the absence or presence of
619 digestive enzymes (i.e. mimicking chemical and biochemical degradation, respectively), *in vitro*
620 digestion experiments revealed no significant change in lutein or β -carotene as digestion progressed
621 from the gastric to the duodenal phase [112]. However, in the absence of enzymes, a ~13% loss was
622 observed for lycopene, the carotenoid most sensitive to oxidation (no change in the presence of
623 enzymes).

624 The addition of myoglobin (heme iron) most dramatically influenced β -carotene
625 concentrations, causing a ~25% loss between the gastric and duodenal compartments in the absence
626 of enzymes, and a ~35% loss in the presence of enzymes [112]. Follow-up studies in healthy males
627 with isotopically labelled β -carotene demonstrated the presence of labelled β -apo-carotenals
628 (aldehyde catabolites) in the oral dose provided [111]. Increased concentrations of most β -apo-
629 carotenals were observed over time in the duodenal digesta, with duodenal concentrations of the
630 shorter chain products increasing relative to the longer chain ones. However, β -apo-carotenals
631 remained ~1000 times less abundant than β -carotene in the same samples, and were not detected in
632 the newly-absorbed lyophilic fraction of blood (nor the plasma itself) afterward. Thus, the data does
633 not support β -carotene conversion to apo-products in the enterocyte. However, β -apo-13-carotenone
634 and β -apo-14'-carotenal were shown to act as antagonists of the retinoic acid receptor *in vitro* [189].
635 Based on the lack of uptake of labelled β -apo-carotenals in the blood stream, this activity most
636 plausibly could occur in enterocytes.

637 The effect of iron (as ferrous sulfate) on lycopene metabolism in the lumen of the digestive
638 tract was tested in a clinically. The orally administered dose was relatively rich in apo-lycopenals
639 (although ~200 times less abundant than lycopene). When the dose was given in the absence of iron,
640 the apo-lycopenal concentrations in the digesta increased over 4 h. By contrast, in the presence of

641 iron, the concentrations of most apo-lycopenals decreased, probably because of autoxidation to
642 shorter-chain products [108]. Moreover, apo-lycopenals were detected in the newly-absorbed lipid
643 fraction of blood, suggesting that at least a portion was absorbed from the diet [108]. In contrast to
644 these results, the feeding of isotopically labelled lycopene (with undetectable apo-lycopenals in the
645 dose) to healthy subjects resulted in no labelled apo-lycopenals in the plasma (the digesta was not
646 tested). However, the appearance of labelled lycopene 1,2-epoxide in the plasma, fairly rapidly after
647 administration (~2 h after dosing), suggests oxygenation in the gastrointestinal tract during digestion
648 or shortly after absorption [190].

649 In conclusion, these data clearly show that there is production of β -carotene and lycopene
650 metabolites in the lumen of the upper intestine and that this production is modulated by iron.
651 Additionally, the proportions of β -carotene and lycopene transformed into metabolites are relatively
652 low. Nevertheless, it is important to remember that some FSV / FSP metabolites can be very active at
653 very low concentrations (e.g. retinoic acid and 1,25-dihydroxyvitamin D) and it is not known in what
654 proportions are metabolized the other FSV and FSP, and what are their derivatives produced
655 upstream, i.e. in food or in the stomach. Thus, many studies remain to be conducted.

656

657 *5.3 Uptake of FSV and FSP and their derivatives by enterocytes*

658 The understanding of the molecular mechanisms of uptake of several FSV and FSP by the
659 intestinal cell has considerably advanced over the past decade. Indeed, while it was thought that all
660 these molecules were absorbed by passive diffusion, Borel and co-workers, as well as other teams,
661 have identified enterocyte proteins that are involved in both apical uptake and efflux back to the
662 intestinal lumen, as well as through the basolateral membrane. For further details, we refer the reader
663 to a review published in the same journal [46]. Since this previous publication, new proteins involved
664 in uptake and basolateral efflux of FSV and FSP have been identified. The ABCG5/G8 complex,
665 well known for its key role in the efflux of phytosterols back to the intestinal lumen, has also been

666 involved in the absorption and efflux of vitamin D [47]. ABCB1 has also been shown to participate
667 in the efflux of vitamins D and K [48, 191]; SR-BI in the uptake of phytoene, phytofluene [192] and
668 vitamin K₁ [193]; CD36 in the uptake of vitamin E [194] and vitamin K₁ [193]; ABCG1 in the efflux
669 of vitamin E [195]. Overall, these proteins are able to interact with the uptake of FSV and FSP
670 having very different structures. This observation suggests that it is the more homogenous lipid
671 components of mixed micelles that are recognized by these transporter proteins. Thus, FSV and FSP
672 incorporated into these micelles are inadvertently driven to areas of the enterocyte membrane, e.g.
673 lipid rafts, in which they are more easily solubilized. To our knowledge, there is no data on specific
674 proteins that would facilitate the capture, or efflux, of FSV / FSP derivatives, but it is possible that
675 the same transporter proteins are involved.

676

677 *5.4 Bile secretion and enterohepatic circulation of FSV and FSP derivatives*

678 Unlike the enterohepatic cycle of bile salts, the enterohepatic circulation of FSV and FSP
679 derivatives is poorly documented. Regarding vitamin A, injection of ¹⁴C-retinol and ¹⁴C-retinoic acid
680 directly into the duodenum of rats led to release of ~40% of the dose in the bile within 24 h. This bile
681 fraction was placed into the intestinal loop of another rat, and ~30% of the radioactivity re-excreted
682 over a 24 h period, confirming enterohepatic circulation [196, 197]. Retinoic acid esters and retinoyl-
683 β-glucuronic acid were identified as the primary bile components [198, 199]. Studies of ³H-retinoic
684 acid in rats confirmed the previous metabolites, as well as the presence of retinotaurine [200].

685 Concerning vitamin D, 24 h after intravenous administration of the metabolite 25-
686 hydroxyvitamin D₃ in humans, ~30% of the radioactivity could be measured in the duodenum, thus
687 demonstrating biliary secretion. Moreover, ~85% of this secreted dose was reabsorbed [201, 202]
688 [203, 204]. A series of experiments by Avioli et al. [205], supported by follow-up studies [206, 207],
689 shows that the inactive phase II metabolites comprise the bulk of the radioactivity recovered in bile
690 following an intravenous injection. These products were recently confirmed to be sulfates and

691 glucuronides of 25-hydroxyvitamin D₃ [208]. However, it is unexpected that phase II metabolites
692 would be released in bile instead of urine. The authors speculated that once released back into the
693 gastrointestinal lumen, deconjugation of these metabolites into free 25-hydroxyvitamin D₃ may
694 provide a source of vitamin D for intestinal cells.

695 Data in rodents suggests that vitamin E undergoes enterohepatic recycling following
696 metabolism. Indeed, rodents release ~20% of labeled α -tocopherol into bile in the first 24 h post-
697 consumption, with only ~3% as α -tocopherol, and the remaining portion as biliary metabolites
698 [202][203, 204]. In humans, intravenous injection of labeled α -tocopherol (bypassing first-pass
699 metabolism in the liver), results in only ~6% of the label in the bile [209, 210], suggesting that
700 enterohepatic recycling is low. Furthermore, biliary metabolites of γ - and δ -tocopherol were
701 observed at greater concentrations relative to α -tocopherol, following mixed tocopherol consumption
702 in humans and mice [204]. This effect is due to the high relative affinity of hepatic α -tocopherol
703 transfer protein for RRR α -tocopherol relative to other vitamin E isoforms [211]. To date, the
704 intestinal absorption of long-chain metabolites of tocopherols and tocotrienols, either following
705 secretion from the bile or from direct feeding with the metabolites, has not been studied.

706 Intravenous administration of either ¹⁴C-labeled vitamin K₁, K₂, or K₃, to rodents resulted in
707 8.5, 74 and 37% of the isotope in bile after 12 h of collection, respectively [212], demonstrating a
708 high propensity for biliary elimination. An elegant series of cannulation experiments in rodents by
709 Hirota et al. [213] reported no secretion of labeled phylloquinone or its menaquinone-4 metabolite in
710 bile following controlled dosing, implying that the excreted biliary dose is exclusively comprised of
711 metabolites. Finally, humans intravenously injected with isotopically labeled vitamin K₁ secreted
712 slightly more polar labeled metabolites (relative to the parent compound) into the bile duct [214].
713 However, the structures were not identified and the possibility for these metabolites to be taken up
714 from the small intestine is unknown.

715 In summary, secretions of metabolites of the four essential FSV have been observed, but it has
716 not been elucidated if these metabolites are reabsorbed by the intestinal cell and further metabolized
717 back to parent structures (to exert biological effects), or whether additional metabolism into other
718 species occurs. A better understanding of this process could demonstrate whether true enterohepatic
719 cycling occurs (analogous to bile salts), and whether this contributes to whole-body FSV intakes.

720 Very little data is available regarding the potential enterohepatic cycling of FSP. Regarding
721 phytosterols, we hypothesize that since their initial absorption is very low ($\leq 2\%$ for sterols, $\leq 0.2\%$
722 for stanols) [215], it is unlikely that there is a significant enterohepatic cycle. Furthermore, an
723 increase in serum oxyphytosterol concentrations (i.e. 7- β -OH-campesterol, 7- β -OH-sitosterol) has
724 been reported following a second meal (after initial phytosterol dosing). However, it's not clear if
725 these oxyphytosterol metabolites were produced in intestinal cells, so that their presence in serum
726 reflects delayed absorption, or whether true enterohepatic recycling occurred [216]. Two studies in
727 humans and rabbits suggest that the chlorophyll metabolites pheophytin and pheophorbide can
728 undergo enterohepatic recycling [217]. Finally, to the best of our knowledge, the enterohepatic
729 recycling of non-provitamin A metabolites of carotenoids, e.g. lycopene and lutein, has not been
730 explored.

731

732 **6. Metabolism of FSV and FSP in the mucosa of the upper intestine and biological effects** 733 **of metabolites in this tissue.**

734 Metabolic pathways, based upon localized expression of enzymes active in the jejunum and
735 ileum, and whose specific activity toward FSV and FSP has been studied in other tissues, are detailed
736 below. While much is understood about vitamin A, limited work on vitamins D, E, and especially K
737 has been conducted so far to determine the role of these enzymes in influencing local or whole-body
738 FSV and FSP metabolite concentrations, maintaining FSV homeostasis, and in eliciting local
739 bioactivity.

740 Provitamin A is absorbed and converted to the vitamin A metabolite retinal via BCO1 in the
741 small intestine [218] (**Fig. 1**). Preformed vitamin A (as retinol alone or produced from the cleavage
742 of retinyl esters) is also absorbed throughout the jejunum, with less uptake in the ileum [219]. It can
743 be transported within the cells via cellular retinol binding protein [220], and reduced to retinal via
744 aldehyde dehydrogenases like retinol dehydrogenase 11 (RDH11) [220]. Retinal is further converted
745 to the bioactive vitamin A metabolite all-*trans*-retinoic acid by retinaldehyde dehydrogenase I
746 (RALDH1), for local utilization both by enterocytes and by mucosal dendritic cells involved in
747 immune homeostasis [221, 222]. Indeed, retinoic acid synthesized by gut-associated lymphoid
748 tissues imprints gut tropism, ultimately providing regional immunity and preventing autoimmune
749 attack [223, 224]. It also stimulates gap junction growth and tight junction formation between
750 epithelial cells to keep pathogens out, and stimulates cell repair following damage [225, 226].
751 Intestinal deactivation of retinoic acid occurs via conversion to oxo- and hydroxy-metabolites by
752 cytochromes CYP1A1 and CYP3A, CYP26 [221], which might be transported directly into the
753 blood, followed by phase II metabolized for urinary excretion, or directly effluxed back into the
754 intestinal lumen for fecal excretion.

755 Vitamin D metabolism within the jejunum and ileum is largely driven by cytochrome P450
756 enzymes (CYPs), of which many have shown activity, as extensively reviewed elsewhere [227, 228].
757 Hydroxylation of the 25th carbon occurs primarily by CYP27A1 and CYP2R1 expressed throughout
758 the small intestine [228]. The resulting 25-OH vitamin D metabolite could be released into the blood
759 stream, or metabolized further by CYP27B1, which performs 1 α -hydroxylation to produce bioactive
760 1,25-dihydroxyvitamin D. CYP27B1 is expressed in the fetal small intestine at highly regulated
761 levels, which are measurable but considerably lower than in the colon [229]. CYP24 is believed to be
762 the primary enzyme responsible for inactivation of 1,25-dihydroxyvitamin D via hydroxylation of
763 the 23rd or 24th carbon, producing metabolites with ~10 times less bioactivity [228]. CYP3A4, an
764 enzyme catalyzing the hydroxylation of the 4 β -position of 25-hydroxyvitamin D or 1,25-

765 dihydroxyvitamin D for clearance, is also expressed in the small intestine [230]. Collectively, the
766 presence of each of these enzymes in the small intestine supports a role for locally controlled
767 production, and subsequent inactivation, of bioactive vitamin D.

768 Vitamin E metabolism is largely driven by cytochrome P450s, whose upregulation may be at
769 least partially driven following binding of tocotrienols to the steroid and xenobiotic (SXR) nuclear
770 receptor [231], also known as the pregnane X receptor (PXR). Cytochrome P450 4F2 (CYP4F2),
771 responsible for the ω -hydroxylation of multiple vitamin E isoforms (**Fig. 8**) and vitamin K₁ (the
772 initial step required for β -oxidation of the phytyl tail), is more highly expressed in the human
773 jejunum and ileum relative to the duodenum [232, 233]. Rodent studies suggest that the jejunum is
774 particularly important for metabolism of isoforms of vitamin E distinct from α -tocopherol. Selective
775 knockdown of murine hepatic equivalent of CYP4F2 (i.e. CYP4F14) only reduced γ - and δ -
776 tocopherol metabolism by 70% [203]. Similarly, oral feeding of γ -tocopherol or a mixture of
777 tocotrienols (including γ -tocotrienol) to rats resulted in γ -CEHC in the jejunum 3 h afterward [234].
778 Importantly, jejunal γ -CEHC concentration was significantly diminished when the CYP4F inhibitor
779 ketoconazole was co-administered [234]. Co-administration of α -tocopherol with ketoconazole did
780 not significantly alter jejunal concentrations relative to administration α -tocopherol alone, echoing
781 previous reports of limited CYP4F2 activity toward α -tocopherol [235]. CYP4F11, expressed in the
782 same location, can also catalyze ω -hydroxylation of vitamin K [236]. β -Oxidation may continue in
783 the intestine or in other tissues as long as the aliphatic chain contains at least 5 carbons. The jejunum
784 and ileum likely resorb α -tocopherol metabolites produced in the liver and released into bile (e.g. α -
785 13'-hydroxytocopherol, α -13'-carboxytocopherol, etc.), although this hasn't been tested. The anti-
786 inflammatory bioactivity of these vitamin E metabolites has recently been reviewed in great detail
787 [54]. In summary, they inhibit 5-lipoxygenase, cyclooxygenases 1 and 2, and reduce nitric oxide
788 production in *in vitro* models. It has also been speculated that the dietary isoforms of vitamin E may

789 be provitamins with metabolism conferring binding activity toward nuclear receptors like PXR
790 and/or PPAR- γ [51], although this has not been proven.

791 Following enterocyte uptake of vitamin K₁, a portion of the administered dose can have the
792 phytol tail cleaved to produce vitamin K₃, followed by prenylation catalyzed by the enzyme UbiA
793 prenyltransferase domain-containing 1 (UBIAD1/TERE1) to produce bioactive vitamin K₂ [213,
794 237] (**Fig. 9**). Insufficient evidence is available to determine if UBIAD1/TERE1 is the only enzyme
795 involved in this two-step conversion to K₂, and the relative proportion of conversion occurring in the
796 intestine vs. other tissues [55, 238]. However, it is known that a murine knockout of UBIAD1 is
797 embryonically lethal [239], highlighting the potent bioactivity conferred by the vitamin K₂
798 metabolite, which is the primary isoform of vitamin K found in extra-hepatic tissues. For vitamin K₁,
799 the metabolites remaining after β -oxidation in the enterocyte (as discussed above) can be
800 glucuronidated for urinary excretion [40]. The γ -carboxylation activity (the primary role of vitamin
801 K in blood clotting) of these phase I and II metabolites has not been completely characterized,
802 although anecdotal evidence suggests it is highly diminished [40].

803 Data suggests that at least some cholesterol-like FSP, including phytosterols and triterpenoids
804 (e.g. stigmasterol, enoxolone), influence CYP3A activity [240, 241]. This cytochrome is also heavily
805 involved in the metabolism of vitamins A & D and drugs, setting up the possibility of competition
806 for metabolism of these compounds. Human data also suggests that solanidine (a steroidal
807 glycoalkaloid) is preferentially metabolized via CYP2D6, a CYP which metabolizes ~25% of all
808 drugs currently in use [242], and likewise solanadine metabolism may further limit metabolism and
809 excretion of other compounds. Phytosterols have also been shown to be effluxed via ABC
810 transporters back into the intestinal lumen, and to facilitate trans-intestinal cholesterol excretion via
811 another as-yet unidentified mechanism [243].

812

813 **7. Metabolism and health effects of FSV and FSP and their metabolites in the colon.**

814 Because only a portion of the dietary FSV and FSP (and likely their derivatives), are absorbed
815 in the small intestine, and because enterohepatic circulation occurs, a substantial percentage of the
816 ingested dose is available for colonic or microbial metabolism. While certainly the bulk of FSV
817 transport occurs in the small intestine, the colon also expresses (lower levels) of the apical
818 transporters NPC1L1, CD-36, and SR-BI [244, 245]. These transporters could permit localized FSV
819 uptake to this tissue (and subsequent metabolism), analogous to the mechanisms detailed in the
820 previous section. This hypothesis is supported by numerous *in vitro* studies, which directly apply
821 FSV to cultured colon tissues and assess uptake. *Ex vivo* evidence from the murine intestinal tract
822 has also demonstrated that incubation of the tissue with at least one isoform of each FSV resulted in
823 small, but measurable, quantities taken up by the colon [219].

824 Both vitamins A and D play key roles in colon health, largely mediated by the immune
825 system, as extensively reviewed [246]. The bioactive vitamin A metabolite retinoic acid is critical for
826 the adaptive and innate immune functions of the intestinal mucosa [247], and these biological
827 activities are equally relevant in the colon. Vitamin D appears to play a more active role in the health
828 of colonocytes and other colon cell types relative to the small intestine. Elimination of the receptor
829 for 1,25-dihydroxyvitamin D increases susceptibility to colitis via increased tight junction membrane
830 permeability [225]. 1,25-Dihydroxyvitamin D has also been shown to induce regulatory T-cells of
831 the intestinal mucosa, which in turn suppress production of cytokines associated with autoimmune
832 responses [248, 249]. The influence of FSV on immune function also has relevance to colorectal
833 cancer, as discussed in the following section.

834 Beyond maintenance of the host gastrointestinal barrier, recent research has revealed that the
835 colon microbiome composition and abundance of specific species are correlated with, or directly
836 influenced by, the intake of each of the FSV [246, 250-252]. These observations reflect the
837 importance of FSV for the microbiota itself, and likely highlight an inability of many species to
838 synthesize them. In most instances, it is not clear if the parent FSV, bioactive FSV derivatives, or

839 both, drive taxa changes. Regardless, the ability to modulate the relative abundance of pathogenic
840 species, or to elicit a pathogenic phenotype from otherwise innocuous species based upon dietary
841 intake alone, highlights the importance of better understanding the relation between host dietary
842 behavior and microflora growth. As an example, some microbial species have lost the ability to
843 produce menaquinones, but data suggests they rely on neighboring species or dietary intakes to
844 obtain vitamin K necessary for respiration [252]. This reliance was proposed to be the cause of lower
845 cecal abundance of vitamin K-requiring species on a vitamin K-deficient diet, simultaneously
846 permitting increased abundance of other non-vitamin K-dependent species in the same animals
847 [252].

848 Unique to vitamin K, some menaquinone isoforms are synthesized by the colonic microflora.
849 However, very little is known about their subsequent metabolism. *In vitro* culturing of human feces
850 with labeled vitamins K₁, K₂, and K₃ demonstrated that the gut microflora was able to metabolize
851 vitamin K₃ to produce bioactive vitamin K₂ (i.e. menaquinone 4), as well as menaquinones with
852 longer chain lengths [252]. These results suggest the possibility that mammalian cleavage of vitamin
853 K₁ in the small intestine provides a source of vitamin K₃ to be further metabolized to K₂ via the
854 colonic microbiota. This K₂ could be used by colonic species directly and/or absorbed by the host.

855 Several FSP have been shown to influence colon health via host-derived mechanisms, as well
856 as through enhanced or diminished growth of specific microbial species in the colon, as recently
857 reviewed in detail [253]. Importantly, some microbial species contain enzymes having the ability to
858 hydrolyze glycosides, permitting FSP aglycones to be absorbed. The aglycone form is generally
859 thought to be more potent. For example, the microbiota of the colon is hypothesized to be the
860 primary driver behind the conversion of saponins to sapogenins, and recent research suggests that
861 sapogenins behave like prebiotics [254]. Likewise, murine studies have shown that phytosterols
862 appear to rescue colon metabolism under conditions of colitis, alleviating symptoms and colon
863 damage [255], which may be at least partially driven by changes in bile acid metabolism [256]. In

864 rodents, the growth of some microbial species also appears to be driven by phytosterol
865 concentrations, and evidence suggests some microbial species produce phytosterol metabolites [253].

866

867 **8. Effect of diseases of the gastrointestinal tract on FSV and FSP metabolism**

868 Looking at the effect of different diseases of the digestive tract on the concentrations of FSV
869 and FSP and their derivatives in the digestive tract can be very interesting. Indeed, variations in
870 concentrations compared to normal, i.e. healthy subjects, or the appearance or disappearance of
871 certain derivatives, can give us information on the normal transformations that take place in the
872 healthy subject and on the factors responsible for these transformations.

873

874 ***8.1 Oesophageal cancer***

875 Limited metabolism of FSV and FSP is expected in the oral cavity and the oesophagus (see
876 **section 3**), thus the effects of oesophageal cancer are also expected to be limited. Some studies have
877 reported that individuals with some types of oesophageal cancer have lower circulating
878 concentrations of α -tocopherol [257] and retinol [258], compared to controls. Likewise, upper
879 gastrointestinal cancer (including both oesophageal and gastric cancer) subjects of East Asian
880 ancestry, but not those of European ancestry, had lower circulating 25-hydroxy-vitamin D
881 concentrations [259]. Although these differences could be due to altered metabolism of these FSV in
882 the oesophagus area, it is likely that they are mostly due to lower FSV intakes, as the disease can
883 make swallowing (and thus eating) difficult.

884

885 ***8.2 Gastric cancer***

886 Because some FSV have been suggested to be protective against different types of cancer, a
887 number of historical studies have correlated gastric cancer risk with FSV intakes and/or circulating
888 FSV or FSV metabolite concentrations [260, 261]. For example, lower blood concentrations of both

889 retinol [258] and 25-hydroxyvitamin D [259] have been associated with increased incidence of
890 gastric cancer in individuals of East Asian ancestry. Although these correlations are generally
891 interpreted by assuming that these FSV reduce the risk of developing gastric cancer, it can also be
892 hypothesized that this cancer leads to a lower absorption and/or a higher use of these vitamins by the
893 body. Another contributing factor is the bacterium *H. Pylori*, which is well known to increase the
894 risk of gastric cancer [262]. Since this microbe causes the loss of acid-producing parietal cells, we
895 would expect a higher susceptibility of some FSV and FSP (e.g. vitamin E) to autoxidation because
896 of the higher pH. In contrast, the increased pH may favor the growth of additional gastric microbial
897 species, which would also be expected to influence the production of FSV and FSP metabolites. In
898 summary, it is likely that infection with this bacterium is responsible for changes in the absorption
899 and metabolism of FSV and FSP, which would explain altered blood concentrations of the
900 corresponding metabolites in patients with gastric cancer.

901

902 ***8.3 Biliary atresia/cholangitis, cholestasis***

903 Blockage of the bile duct, due either to congenital defects (i.e. atresia) or to autoimmune-
904 induced damage (i.e. cholangitis/cirrhosis) limits enterohepatic circulation of compounds commonly
905 found in this digestive fluid, including bile salts and some FSV metabolites [263] (**see section 5.4**).
906 Recycling of FSP metabolites, if it occurs, would also be predicted to be limited. In more severe
907 and/or untreated cases when liver disease accompanies biliary cholangitis, active FSV metabolite
908 production (in the case of vitamins A and D) and retention (in the case of vitamin E) by the liver are
909 even more pronounced, with patients often presenting with symptoms of deficiency [263]. Under
910 these conditions, it would be expected that localized metabolism of these vitamins would be
911 upregulated in target tissues (including the GI tract itself) that do not receive sufficient quantities of
912 metabolites from the liver. Furthermore, due to limited bile release, production of micelles is greatly
913 diminished (as evidenced by steatorrhea) and thus limited FSV and FSP uptake is expected, further

914 exacerbating the problem. Indeed, plasma concentrations of retinol, α -tocopherol, and commonly
915 consumed carotenoids are reduced in subjects with even early stages of cholestasis, relative to
916 healthy controls [264]. Fortunately, treatment with the bile salt ursodeoxycholic acid proves to be
917 highly effective at earlier stages of the disease, and limits the severity of FSV deficiency in this
918 population [265].

919

920 *8.4 Alcoholic fatty Liver, non-alcoholic fatty Liver, non-alcoholic steatohepatitis, and hepatic* 921 *cirrhosis*

922 Both alcoholic fatty liver (driven by excess alcohol consumption) and non-alcoholic fatty
923 liver (driven primarily by obesity) are characterized by hepatic steatosis, which impairs liver
924 functioning [266]. Data suggests that the bioactive metabolites of FSV and carotenoids themselves
925 may both be influenced by, and may directly influence, fatty liver disease progression, especially in
926 younger individuals and/or earlier stages of condition development [266-269]. Fatty liver disease
927 upregulates utilization of FSV vitamin stores found there, increases synthesis of bioactive FSV
928 isoforms, and increases phase I metabolism for excretion. Impaired functioning of the “classical” bile
929 acid synthesis pathway leads to increased metabolism by a secondary pathway involving CYP27A1,
930 the same enzyme that produces 25-hydroxyvitamin D [270]. Likewise, in a murine model of alcohol-
931 induced hepatic steatosis, increased expression of hepatic CYP26A1 and CYP26B1, which convert
932 retinoic acid to phase I metabolites for excretion, as well as broad-spectrum phase I CYPs, i.e.
933 CYP2C29, CYP2C39 and CYP3A11, were observed [271]. In the same study, liver vitamin A stores
934 were also simultaneously depleted. Thus, we would expect increased enterohepatic recycling of
935 vitamin A and D metabolites, and increased concentrations in the intestinal lumen of these
936 metabolites in patients with fatty liver. The change in the composition of bile acids released may also
937 influence microbiota composition/abundance, and thus FSV and FSP metabolism in the distal small
938 intestine and colon [270]. Increased plasma concentrations of the oxidized vitamin E metabolite α -

939 tocopheryl quinone have also been reported in human subjects with non-alcoholic fatty liver disease
940 [272], with a fraction likely released into the bile.

941 Over time, non-alcoholic fatty liver disease can progress to non-alcoholic steatohepatitis,
942 with up to ~20% evolving into cirrhosis [273]. Liver cirrhosis is a severe form of liver disease
943 characterized by accumulated fibrous scar tissue that greatly hinders cell functioning. Multiple
944 studies have demonstrated that the majority (~70%) of adults with liver cirrhosis undergoing
945 evaluation for organ transplant present with deficient concentrations of circulating vitamin A and D
946 metabolites, while ~40% have vitamin E deficiency [274-276]. There is no clear link between
947 cirrhosis etiology and the severity of FSV deficiency, but there is correlation with albumin
948 concentrations, as a surrogate biomarker reflective of liver function [274].

949

950 ***8.5 Cholestatic liver diseases, cholestasis, chronic liver disease***

951 Cholestatic liver diseases produce the same phenotype as biliary cholangitis. However, the
952 changes are driven by insufficient bile production by the liver itself (as opposed to impaired bile and
953 FSV metabolite release into the intestinal lumen). Thus, these patients experience lipid
954 malabsorption, leaving more FSV and FSP in the gastrointestinal lumen (and likely their derivatives)
955 available for interactions with the colonic microbiota. Like liver cirrhosis, other forms of chronic
956 liver disease in both children and adults reduce liver functioning (and thus metabolism) and produce
957 FSV deficiencies [277].

958

959 ***8.6 Chronic pancreatitis, pancreatic insufficiency, Shwachman-Diamond syndrome (SDS)***

960 Because the pancreas is responsible for lipase production and release necessary for FSV and
961 FSP absorption, it is no surprise that chronic pancreatitis is associated with an increased prevalence
962 in FSV deficiencies relative to healthy controls [278]. Similarly, studies have demonstrated that

963 chronic pancreatitis patients have significantly lower blood carotenoid concentrations, relative to
964 healthy controls [279][280].

965 Shwachman-Diamond syndrome, a rare inherited disorder diagnosed in childhood and
966 characterized by pancreatic insufficiency, severely limits lipid and FSV / FSP absorption [281].
967 Treatment commonly includes pancreatic enzyme replacement therapy and micronutrient
968 supplementation. However, data in children shows that this treatment still leaves half of them
969 deficient in vitamins A and E [282].

970 Collectively, data suggests that chronic pancreatitis, pancreatic insufficiency, and
971 Shwachman-Diamond syndrome cause increased FSV / FSP concentrations to remain in the
972 intestinal lumen, and provide higher concentrations for metabolism by the colonic microbiota.

973

974 ***8.7 Celiac disease***

975 The dramatically reduced small intestinal luminal surface area typical of celiac subjects
976 would be expected to reduce FSV and FSP absorption and localized metabolism, again leaving
977 higher concentrations in the intestinal lumen for microbial metabolism. Surprisingly, only a few FSV
978 and FSP studies have been performed in this population. A case-control study in children reported
979 reduced circulating concentrations of the metabolite status markers of vitamin A and D in a majority
980 of those newly diagnosed with celiac disease [283]. Nevertheless, mixed results have been reported
981 in relation to deficiencies in vitamins E and K, with some studies showing little prevalence [284],
982 and others showing high prevalence [283, 285, 286].

983

984 ***8.8 Cystic fibrosis***

985 Patients with cystic fibrosis display malfunction in the transporter responsible for sodium and
986 chloride exchange (i.e. the cystic fibrosis transmembrane conductance regulator, CFTR), leading to
987 excess mucus secretion throughout the gastrointestinal tract [287]. CFTR also influences the ability

988 to secrete pancreatic digestive enzymes, and limits the ability of the liver to produce bile salts,
989 leading to lipid (and FSV) malabsorption. Indeed, FSV deficiency is common at diagnosis, with FSV
990 supplementation included with treatment [288]. Reduced circulating concentrations of FSP have also
991 been reported in patients with cystic fibrosis, including carotenoids and phytosterols, relative to
992 healthy controls [289, 290]. For these reasons, one would expect cystic fibrosis patients to have
993 reduced enterohepatic circulation of FSV and FSP metabolites.

994 Increased nutrient retention in the small intestinal lumen, as well as reduced gut motility,
995 provide a rich environment for small intestinal bacterial overgrowth and colonic dysbiosis [288].
996 Changes in microbiota would certainly be expected to influence microbial FSV / FSP metabolism,
997 thus producing metabolites and/or metabolite concentrations not typically observed in healthy
998 subjects, although to date this point remains undocumented.

999

1000 ***8.9 Intestinal failure***

1001 Intestinal failure presents a host of digestive challenges, especially when the disease is
1002 diagnosed in growing children, whose bodies demand adequate macro- and micronutrient absorption
1003 to thrive. Treatment typically involves re-sectioning of the damaged tissue, producing short-bowel
1004 syndrome and accompanying side-effects (e.g. bile acid malabsorption, steatorrhea, reduced number
1005 of transporters for uptake, etc.) [291]. Besides obvious challenges in absorption, re-sectioning
1006 increases the risk of luminal contents leaking through the intestinal barrier. Tissue transplantation is
1007 an alternative option in very severe cases [292].

1008 Previous studies have reported limited re-sectioning success under conditions of vitamin A
1009 deficiency [291]. Intestinal failure also causes deficiencies in vitamins D and E [292, 293], while
1010 vitamin K remains unstudied in this population. Historical oils used to produce the intravenous lipid
1011 emulsions provided to this population (e.g. Intralipid®) primarily containing soybean oil naturally
1012 rich in γ -tocopherol and phytosterols (as well as omega-6 long chain polyunsaturated fatty acids),

1013 which would be expected to be metabolized by the liver and excreted back into the intestinal lumen.
1014 In contrast, more contemporary formulations contain fish oil (rich in omega-3 long chain
1015 polyunsaturated fatty acids), α -tocopherol and less phytosterols [294]. Like the other diseases
1016 mentioned above, a higher percentage of FSV and FSP remaining in the gastrointestinal tract would
1017 permit greater colonic metabolism.

1018

1019 ***8.10 Familial Hypobetalipoproteinemia***

1020 Familial hypobetalipoproteinemia is a genetic disease that may be due to 1) a defect in the
1021 assembly of lipoproteins in the intestine, 2) in the secretion of these lipoproteins by the intestine
1022 (classified as class I), 3) an accelerated catabolism of these lipoproteins in the blood (classified as
1023 class II) [295]. We focus here on class I because this category would be expected to modify the
1024 production of FSV and FSP metabolites in the intestine. It is known that individuals with this disease
1025 absorb FSV poorly and are thus treated with high doses of these vitamins, but no data exists on FSP
1026 supplementation (likely because they are not considered essential). There are also no data on the FSV
1027 metabolites present in the enterocyte of subjects with this pathology, but due to increased FSV
1028 retention, increased FSV metabolites would be anticipated. From here, it is not clear whether these
1029 metabolites would be secreted in the portal vein, returned to the intestinal lumen, or released into the
1030 lymphatic system. While not yet known, such subjects could potentially serve as excellent models to
1031 further study enterocyte FSV and FSP metabolism.

1032

1033 ***8.11 Inflammatory bowel disease***

1034 Overall, subjects with Crohn's disease and ulcerative colitis have reduced circulating
1035 concentrations of vitamins A, D, and E, relative to healthy controls [296, 297]. Results on vitamin K
1036 are mixed, with some studies demonstrating higher concentrations in inflammatory bowel disease
1037 subjects, and others demonstrating a deficiency [296, 297]. Oral supplementation in this population

1038 has been rather disappointing, but is still often prescribed [297]. Changes in the mucosal membrane
1039 of the colon, which exacerbates the symptoms of inflammatory bowel disease, should stimulate
1040 bacterial growth. This might cause unique production of FSV / FSP metabolites in this cohort.

1041 In summary, we can conclude that most of the digestive tract diseases probably reduce, to a
1042 greater or lesser extent, the absorption and metabolism of FSV and FSP. However, nothing is known
1043 about the consequences this may have on the biliary re-secretion of the FSV / FSP metabolites, on
1044 the microbiota, and on the FSV / FSP metabolism by the microbiota.

1045

1046 **9. Effects of surgery of the gastrointestinal tract on FSV and FSP metabolism in this organ**

1047 Surgeons may have to operate on certain parts of the digestive tract following various
1048 diseases, e.g. stomach or colon cancer, but also to treat obesity and the diseases associated with it,
1049 e.g. bariatric surgery. These surgical procedures can result in the removal of certain parts of the
1050 digestive tract and/or changes in the normal course of food, e.g. after gastric bypass. This can lead to
1051 lower FSV and FSP intake due to the lower amount of food consumed/day. This can also decrease
1052 absorptive surface areas and thus the number of proteins involved in FSV and FSP uptake by
1053 intestinal cell (**section 5.3**). It is also likely that some of these surgeries alter the intraluminal
1054 metabolism of certain FSV / FSP and consequently the production of metabolites. Surgical
1055 interventions might require correcting the FSV [298-301] or carotenoid [302-304] status of patients.
1056 It is also interesting for the physiologist to better understand the key factors that modulate the
1057 bioavailability of these compounds [305]. Very little is known about the effects of different surgical
1058 procedures on the production and uptake of FSV / FSP metabolites, thus we postulate the
1059 consequences of these interventions based on our knowledge of metabolism in the healthy digestive
1060 tract.

1061

1062 ***9.1 Gastrectomy / gastric resection***

1063 The first part of the digestive tract that may be partially or totally removed is the stomach, as
1064 frequently observed with stomach cancer. Malabsorption of lipids, and therefore of FSV / FSP and
1065 their fat-soluble metabolites, can occur after total gastrectomy [306, 307]. For example, following
1066 surgical treatment, gastric cancer patients are at risk of vitamin A and E deficiencies [308]. The
1067 cause is apparently either excessively rapid intestinal transit or bacterial overgrowth [309].
1068 Malabsorption also depends on the portion of the intestine that has been resected together with the
1069 stomach, e.g. duodenum vs. jejunum [310].

1070 Patients who undergo bariatric surgery are assumed to be at greater risk of developing FSV
1071 deficiencies, as well as lower blood and tissue concentrations of FSP and their metabolites. This is
1072 supported by a recent review showing that these subjects are at higher risk of vitamin E deficiency
1073 [301]. Nevertheless, it is difficult to conclude that this is due to a lower absorption efficiency of the
1074 FSV of interest for two main reasons. First, most subjects who have undergone bariatric surgery are
1075 supplemented with vitamins and minerals following the operation to compensate for anticipated
1076 deficiencies [311]. Thus, blood concentrations of vitamin E can be higher after Roux-en-Y gastric
1077 bypass than prior to the surgery [312]. Second, most studies that have claimed to assess the
1078 consequences of bariatric surgery on vitamin absorption have measured the concentrations of
1079 vitamins in the blood of fasting subjects several weeks or months after surgery. Although this does
1080 not make it possible to conclude the effect of surgery on absorption, it gives an indication of the
1081 vitamin status after surgery, which is modulated by absorption but also by the vitamin intake and
1082 use/elimination by the body. To our knowledge, only two studies have reported the effect of bariatric
1083 surgery, specifically Roux-en-Y gastric bypass surgery, on absorption efficiency of the FSV. In the
1084 first study, [313] cholecalciferol absorption was decreased by 25% after the surgery. In the second
1085 study, despite the fact that vitamin A intakes remained unchanged pre- vs. post-surgery, and despite
1086 post-surgical supplementation of retinol palmitate, serum vitamin A concentrations were lower
1087 following surgery [314]. Thus, bariatric surgery appears to decrease FSV / FSP absorption, but a

1088 comparison remains to be made between the effects of different bariatric surgery techniques on the
1089 absorption efficiency of FSV / FSP. Nothing is known about the consequences of bariatric surgery on
1090 the production of metabolites in the digestive lumen.

1091

1092 ***9.2 Intestinal failure***

1093 Vitamin D deficiency is highly prevalent in children with a history of intestinal failure, who
1094 have achieved enteral autonomy despite enteral supplementation with higher than standard doses of
1095 vitamin D. Shorter remnant small-bowel length and longer duration of parenteral nutrition were the
1096 main parameters associated with vitamin D deficiency [315]. This suggests that this pathology has
1097 more consequences on the absorption of FSV and FSP than stomach diseases. This result is logical
1098 since these compounds are absorbed in the intestine, but it does not provide information on the
1099 production of degradation compounds or metabolites in the intestine vs. stomach.

1100

1101 ***9.3 Pancreatic resection***

1102 The key role of pancreatic secretions on the absorption of vitamins A and D, and most likely
1103 also on the absorption of other FSV / FSP and their derivatives, is supported by the observation of a
1104 severe deficiency of these vitamins in a 12-year-old girl, who had undergone pancreatic resection for
1105 chronic calcific pancreatitis [305].

1106 Nevertheless, two studies suggest that the digestive tract can, in the long term, adapt to
1107 compensate for the loss of absorption capacities. In the first one, shortening of rat jejunum by an
1108 end-to-end anastomosis (jejunum-bypass operation) [316] increased the ileal concentration of
1109 CRBP(II) by a factor 2, which would be an adaptation of the body to compensate for the loss of
1110 vitamin A absorption capacity. In the second one, a rat model of short bowel syndrome [317] pointed
1111 to an increase in the expression of genes involved in the intestinal metabolism of vitamin A, in that

1112 case *Rbp2* and *Apoa4*. It remains to be seen whether the intestine is also able to adapt for lower
1113 absorption of other FSV and FSP after GI tract surgery.

1114

1115 **10. Effect of xenobiotics that impair lipid absorption**

1116 Many strategies have been developed to combat obesity. Among these are administrations of
1117 compounds and drugs that decrease lipid absorption. An obvious question is the impact on FSV
1118 absorption and numerous studies have been carried out to address it. Concerning olestra, a zero-
1119 calorie fat replacement manufactured by Proctor & Gamble under the name olean, it has been shown
1120 that, as expected, it reduces the absorption of FSV and FSP with a logP (P: water-octanol partition
1121 coefficient) > 7.5 [318]. Thus, this additive has been banned in Canada and Europe, although it
1122 remains approved for use in snack foods in the USA. Interestingly, olestra has recently been shown
1123 to decrease plasma concentrations of lipid-soluble persistent organic pollutants, following 6 months
1124 of randomized, controlled administration, highlighting both the risks and benefits of consuming
1125 compounds that interfere with the absorption of very hydrophobic molecules [319].

1126 Mineral oil, an indigestible lipid, has been used for many decades as a remedy to treat
1127 constipation, and as a placebo in some randomized, controlled trials. As long as the mineral oil is
1128 administered between meals, the impact on FSV / FSP status is limited [320, 321]. In the best
1129 controlled study to date, children treated for up to 4 months with mineral oil had a drop in serum β -
1130 carotene, but an increase in retinol (and no change in α -tocopherol) during the study period [322]. It
1131 is not clear whether the mineral oil has a direct effect on the provitamin-to-vitamin A conversion
1132 [322]. With more sophisticated methods of FSV / FSP delivery in new foods and supplements (e.g.
1133 encapsulation and nanoemulsion), *in vitro* evidence suggests that mineral oil negatively impacts
1134 vitamin D bioaccessibility [323]. Thus, further evaluation is warranted.

1135 Finally, the anti-obesity drug orlistat, a lipase inhibitor, has been shown to reduce both
1136 postprandial absorption and circulating plasma concentrations of FSV and provitamin A, following

1137 prospective dosing [324]. The favourable effects of orlistat on carbohydrate metabolism and non-
1138 alcoholic fatty liver disease will probably override concerns on FSV / FSP uptake in the short-term in
1139 adults, but these effects have also been reported in children, for whom ensuring sufficient FSV status
1140 is critical for growth and development [324]. Additionally, some evidence suggests that a greater
1141 percentage of provitamin A is metabolized to vitamin A in the intestine when the meal is consumed
1142 with digestible lipid. Thus, reducing digestible lipid may also influence FSV metabolism [325].

1143 In summary, xenobiotics aiming to decrease the absorption of lipids also decrease the
1144 absorption of some FSV and carotenoids. However, the effects on the absorption of other FSP / FSV
1145 and their metabolites are unknown, as well as the consequences of these xenobiotics on the biliary
1146 secretion of FSV / FSP metabolites, and on the metabolism of FSV / FSP by the microbiota.

1147

1148 **Conclusions**

1149 Overall, we have highlighted several recent developments in the understanding of FSV / FSP
1150 metabolite production, absorption, and potential bioactivity in digestive tract. We have also
1151 identified many areas where FSV / FSP metabolism remains unknown or poorly documented. In
1152 these instances, we have relied upon what is known about the parent FSV / FSP. Technological
1153 developments in analytical chemistry (e.g. metabolomics) have increased the capacity to identify and
1154 quantify a larger number of FSV and FSP metabolites in biological samples simultaneously. When
1155 paired with multi-omic integration (e.g. considering genetic, epigenetic, proteomic, exposomic, and
1156 microbiome factors) and the current knowledge on the gastrointestinal physiology and
1157 physiopathology, many more FSV / FSP metabolites are likely to be identified and correlated with
1158 various bioactivities.

1159

1160 **Funding:** This work was partially supported by the USDA National Institute of Food and
1161 Agriculture [Hatch project W4122].

1162

1163 **Declarations of interest:** none.

1164 **Table 1.** Vitamins and phytochemicals with computed octanol-water partition coefficients ($\log_{10} P >$
 1165 5).

Compound	Compound Class	Computed $\log_{10} P^1$
menaquinone 8-14 (vitamin K ₂ isoforms)	vitamin	16.4-27.5
lycopene	carotenoid	15.6
neurosporene	carotenoid	15.5
phytofluene	carotenoid	15.4
phytoene	carotenoid	15.3
menaquinone-7 (vitamin K ₂ isoform)	vitamin	14.5
chlorophyll b	tetrapyrrole	13.9
α -carotene (provitamin A)	carotenoid	13.6
β -carotene (provitamin A)	carotenoid	13.3
chlorophyll a	tetrapyrrole	12.9
menaquinone-6 (vitamin K ₂ isoform)	vitamin	12.6
β -cryptoxanthin (provitamin A)	carotenoid	12.3
pheophytin a	tetrapyrrole	11.7
cafestol palmitate	diterpene ester	11.2
kahweol palmitate	diterpene ester	11.2
pheophytin b	tetrapyrrole	11.0
lutein	carotenoid	11.0
zeaxanthin	carotenoid	10.9
phylloquinone (vitamin K ₁)	vitamin	10.9
menaquinone-5 (vitamin K ₂ isoform)	vitamin	10.9
α -tocopherol (vitamin E)	vitamin	10.7

β -tocopherol (vitamin E isoform)	vitamin	10.3
γ -tocopherol (vitamin E isoform)	vitamin	10.3
astaxanthin	carotenoid	10.3
24-methylenecycloartanol	phytosterol	10.3
δ -tocopherol (vitamin E isoform)	vitamin	10.0
cycloartenol	phytosterol	9.8
α -tocotrienol (vitamin E isoform)	vitamin	9.3
β -sitosterol	phytosterol	9.3
β -tocotrienol (vitamin E isoform)	vitamin	8.9
γ -tocotrienol (vitamin E isoform)	vitamin	8.9
menaquinone-4 (vitamin K ₂)	vitamin	8.9
campesterol	phytosterol	8.8
stigmasterol	phytosterol	8.6
δ -tocotrienol (vitamin E isoform)	vitamin	8.6
brassicasterol	phytosterol	8.0
cholecalciferol (vitamin D ₃)	vitamin	7.9
ergocalciferol (vitamin D ₂)	vitamin	7.4
ergosterol	phytosterol	7.4
soyasapogenol B	phytosterol	7.0
calcifediol (25-hydroxyvitamin D ₃)	vitamin	6.2
solanidine	steroidal alkaloid	6.1
tomatidine	steroidal alkaloid	6.0
falcarinone	polyacetylene	6.0
ercalcidiol (25-hydroxyvitamin D ₂)	vitamin	6.0
rosmaridiphenol	other	5.9

falcarinol

polyacetylene

5.5

1166

1167

¹Value computed by XLOGP3 version 3.0 [326].

1168

1169 **Figure legends**

1170

1171 **Figure 1: Vitamin D derivatives and possible mechanisms of formation.** Left panel,
1172 physicochemical mechanisms for the degradation of $1\alpha,25$ -dihydroxycholecalciferol [66]. **A)**
1173 Thermal degradation in DMSO, possibly occurring during thermal processing. **B)** Acid-catalyzed
1174 degradation in a 1:1 pH 3 phosphate buffer – MeCN mixture, possibly occurring in stomach. Middle
1175 panel, biochemical mechanisms for metabolism in the liver and intestine. Right panel, hypothesized
1176 deconjugation by the microbiota.

1177

1178 **Figure 2: Phytosterol derivatives and possible mechanisms of formation.** Left panel,
1179 physicochemical mechanisms for the formation of phytosterol oxidation products upon thermal
1180 treatment of fat-rich food containing phytosterols acylated by polyunsaturated fatty acids [93]. Upon
1181 thermal treatment of lipid food (e.g. phytosterol-enriched margarine), phytosterols acylated by fatty
1182 acids are more vulnerable to oxidation when the unsaturation degree of the acyl chain increases.
1183 Autoxidation of a PUFA chain leads to highly reactive peroxy radicals that efficiently oxidize the
1184 nearby phytosterol moiety. Middle panel, biochemical mechanisms that can happen in the stomach
1185 and intestine. Right panel, no data available on the metabolism of phytosterols by the microbiota.

1186

1187 **Figure 3: Gastric phases / structures in which parent FSV / FSP and their derivatives can be**
1188 **distributed during digestion.** Derivatives (**D**) mean compounds formed upon either
1189 physicochemical or enzymatic modification of the parent molecule (**P**); *filled arrow*: known transfer
1190 route; *dotted arrows*: some hypothesized transfer routes.

1191

1192 **Figure 4: Vitamin A derivatives and possible mechanisms of formation.** Left panel,
1193 physicochemical mechanisms for the iron-induced autoxidation of carotenoids [109, 327]. Dioxygen

1194 activation involves non-heme Fe^{II} traces. The reaction with Fe^{III} is slower as it requires a first rate-
1195 limiting step of Fe^{III} reduction by carotenoids. Such mechanisms may occur during food processing
1196 and digestion, especially when dietary carotenoids are transferred from emulsions to mixed micelles
1197 along lipid digestion. Middle panel, metabolism of the main dietary source of preformed vitamin A
1198 by human gastrointestinal enzymes. Right panel, hypothesized deconjugation by the microbiota.

1199

1200 **Figure 5: Prooxidant effect of polyunsaturated fatty acids on FSV and FSP.** Upper panel: Co-
1201 oxidation of polyunsaturated fatty acids (LH) and antioxidants during iron-induced lipid peroxidation
1202 [145-148]. LH = polyunsaturated fatty acids; AO1 = water-soluble antioxidant, e.g. phenolic
1203 compounds, vitamin C, short-chain apocarotenoids; AO2 = fat-soluble antioxidant, e.g. vitamin E,
1204 carotenoids, long-chain apocarotenoids; LOOH = lipid hydroperoxides. A) Initiation by heme iron
1205 (Fe^{III}). Lower panel: initiation by non-heme iron (Fe^{II}). Such mechanisms may occur in the gastric
1206 compartment where dietary iron and traces of hydroperoxides from lipid food can initiate PUFA
1207 peroxidation under vigorous mixing, favorable acidic conditions and non-limiting O₂ concentrations.

1208

1209 **Figure 6: Derivatives of the fat-soluble phenols of rosemary.** Upon autoxidation (during food
1210 processing or in the GI tract) or in the course of its antioxidant activity, carnosic acid (**1**), one of the
1211 main antioxidant diterpenes of rosemary, is converted into carnosol (**2**), then into rosmanol (**3**) [154].
1212 Through its electron-rich catechol ring, rosmanol itself can undergo additional two-electron
1213 oxidation. These electron transfer sequences sustain the strong antioxidant activity of rosemary
1214 extracts

1215

1216 **Figure 7: Derivatives of the fat-soluble phenols of olive oil.** A) Some olive phenols (except parent
1217 glucosides, which are only present in the non-oily part of the olive fruit) are present in substantial
1218 concentration in virgin olive oil (up to ca. one gram / kg) [155, 156]. They are known to contribute to

1219 the nutritional benefits of olive oil consumption, which is emphasized by a EFSA health claim [328].
1220 **B)** Hydroxytyrosol (HT), the typical phenolic antioxidant of olive oil, inhibits lipid peroxidation in
1221 synergy with α -tocopherol [157]. While acting as an antioxidant, HT is converted in dimers and
1222 higher oligomers that undergo further oxidation. Some incorporate water molecules [158].

1223

1224 **Figure 8: Vitamin E derivatives and possible mechanisms of formation.** Left panel,
1225 physicochemical mechanisms with the example of interplay between α -tocopherol and other dietary
1226 antioxidants [329-334]. α -Tocopherol regeneration by other antioxidants is important to prolong
1227 tocopherol activity and avoid tocopherol-mediated lipid peroxidation within lipid-rich phases. This
1228 interplay between tocopherol and other dietary antioxidants may also apply with vitamin K. Vitamin
1229 K itself (through its reduced form) inhibits lipid peroxidation. Middle panel, biochemical
1230 mechanisms for the metabolism of vitamin E in the liver. Right panel, no data available on the
1231 metabolism of vitamin E by the microbiota.

1232

1233 **Figure 9: Vitamin K derivatives and possible mechanisms of formation.** Left panel,
1234 physicochemical mechanisms with the example of the possible interplay between menaquinone MQ-
1235 7 (R = hepta-isoprenyl chain) and carotenoids in the presence of heme or non-heme iron [335].
1236 Carotenoids are spared in the process. MQ-7, naturally present in cocktails of bacterial carotenoids,
1237 is insensitive to iron-induced autoxidation and a poor antioxidant in the inhibition of iron-induced
1238 lipid peroxidation. However, in the presence of heme or non-heme iron, MQ-7 efficiently protects
1239 carotenoids against autoxidation and potentiates their antioxidant activity. Middle panel, biochemical
1240 mechanisms for the metabolism of phylloquinone in the small intestine. Right panel, vitamin K
1241 metabolite produced by the microbiota.

1242

1243 **Figure 10: Upper intestinal phases / structures in which parent molecules and their derivatives**
1244 **can be distributed during digestion.** In the upper intestine FSV and FSP and their derivatives are
1245 assumed to distribute between the phases / structures present in the gastric lumen (see **Fig. 3**) and
1246 secreted into the duodenum through the pylorus plus additional phases / structures coming from
1247 biliary secretion and the digestion of dietary lipids, i.e. mainly triglycerides and phospholipids. **P**:
1248 parent molecule; **D**: derivative; **P***: parent molecule previously absorbed, then secreted in the bile;
1249 **D***: derivative previously absorbed, or resulting from metabolism of **P**, then secreted in the bile;
1250 **filled arrows**: known transfer routes; **doted arrows**: some hypothesized transfer routes.

1251 **References**

- 1252 [1] Waladkhani AR, Clemens MR. Effect of dietary phytochemicals on cancer development (Review). *Int J Mol*
1253 *Med* 1998; 1: 747-53.
- 1254 [2] Manach C, Hubert J, Llorach R, Scalbert A. The complex links between dietary phytochemicals and human
1255 health deciphered by metabolomics. *Mol Nutr Food Res* 2009; 53: 1303-15.
- 1256 [3] Kim J, Fann DYW, Seet RCS, Jo DG, Mattson MP, Arumugam TV. Phytochemicals in Ischemic Stroke.
1257 *Neuromolecular Med* 2016; 18: 283-305. <https://doi.org/10.1007/s12017-016-8403-0>.
- 1258 [4] Velmurugan BK, Rathinasamy B, Lohanathan BP, Thiyagarajan V, Weng CF. Neuroprotective Role of
1259 Phytochemicals. *Molecules* 2018; 23: 2485. <https://doi.org/10.3390/molecules23102485>.
- 1260 [5] Bujor A, Miron A, Trifan A, Luca SV, Gille E, Miron SD, et al. Phytochemicals and endothelial dysfunction:
1261 recent advances and perspectives. *Phytochem Rev* 2021; 20: 653-91. [https://doi.org/10.1007/s11101-](https://doi.org/10.1007/s11101-020-09728-y)
1262 [020-09728-y](https://doi.org/10.1007/s11101-020-09728-y).
- 1263 [6] Orhan IE, Nabavi SF, Daglia M, Tenore GC, Mansouri K, Nabavi SM. Naringenin and Atherosclerosis: A
1264 Review of Literature. *Curr Pharm Biotechnol* 2015; 16: 245-51.
1265 <https://doi.org/10.2174/1389201015666141202110216>.
- 1266 [7] Fenni S, Hammou H, Astier J, Bonnet L, Karkeni E, Couturier C, et al. Lycopene and tomato powder
1267 supplementation similarly inhibit high-fat diet induced obesity, inflammatory response and associated
1268 metabolic disorders. *Mol Nutr Food Res* 2017; 61. <https://doi.org/10.1002/mnfr.201601083>.
- 1269 [8] Moeller SM, Jacques PF, Blumberg JB. The potential role of dietary xanthophylls in cataract and age-
1270 related macular degeneration. *J Am Coll Nutr* 2000; 19: 522S-7S.
- 1271 [9] Chandler LA, Schwartz SJ. HPLC separation of cis-trans carotene isomers in fresh and processed fruits and
1272 vegetables. *J Food Sci* 1987; 52: 669-72.
- 1273 [10] Chandler LA, Schwartz SJ. Isomerization and losses of trans-.beta.-carotene in sweet potatoes as
1274 affected by processing treatments. *J. Agri. Food Chem.* 1988; 36: 129-33.
1275 <https://doi.org/10.1021/jf00079a033>.

- 1276 [11] Ogunlesi AT, Lee CY. Effect of thermal-processing on the stereo-isomerization of major carotenoids and
1277 vitamin-A value of carrots. *Food Chem* 1979; 4: 311-8. [https://doi.org/10.1016/0308-8146\(79\)90019-](https://doi.org/10.1016/0308-8146(79)90019-0)
1278 [0](https://doi.org/10.1016/0308-8146(79)90019-0).
- 1279 [12] Laparra JM, Sanz Y. Interactions of gut microbiota with functional food components and nutraceuticals.
1280 *Pharmacol Res* 2010; 61: 219-25. <https://doi.org/10.1016/j.phrs.2009.11.001>.
- 1281 [13] Hanhineva K, Aura AM, Rogachev I, Matero S, Skov T, Aharoni A, et al. In Vitro Microbiotic Fermentation
1282 Causes an Extensive Metabolite Turnover of Rye Bran Phytochemicals. *PLoS ONE* 2012; 7: e39322.
1283 <https://doi.org/10.1371/journal.pone.0039322>.
- 1284 [14] Carrera-Quintanar L, Roa RIL, Quintero-Fabian S, Sanchez-Sanchez MA, Vizmanos B, Ortuno-Sahagun D.
1285 Phytochemicals That Influence Gut Microbiota as Prophyllactics and for the Treatment of Obesity and
1286 Inflammatory Diseases. *Mediators Inflamm* 2018; 2018: 9734845.
1287 <https://doi.org/10.1155/2018/9734845>.
- 1288 [15] Wang Y, Lim YY, He ZD, Wong WT, Lai WF. Dietary phytochemicals that influence gut microbiota: Roles
1289 and actions as anti-Alzheimer agents. *Crit. Rev. Food Sci. Nutr.* 2021; 9: 1-27.
1290 <https://doi.org/10.1080/10408398.2021.1882381>.
- 1291 [16] Bohn T, McDougall GJ, Alegria A, Alminger M, Arrigoni E, Aura AM, et al. Mind the gap-deficits in our
1292 knowledge of aspects impacting the bioavailability of phytochemicals and their metabolites--a position
1293 paper focusing on carotenoids and polyphenols. *Mol Nutr Food Res* 2015; 59: 1307-23.
1294 <https://doi.org/10.1002/mnfr.201400745>.
- 1295 [17] Chen X, Li HY, Zhang B, Deng ZY. The synergistic and antagonistic antioxidant interactions of dietary
1296 phytochemical combinations. *Crit. Rev. Food Sci. Nutr.* 2021; 22: 1-20.
1297 <https://doi.org/10.1080/10408398.2021.1888693>.
- 1298 [18] Franco R, Navarro G, Martinez-Pinilla E. Hormetic and Mitochondria-Related Mechanisms of Antioxidant
1299 Action of Phytochemicals. *Antioxidants (Basel)* 2019; 8: 373. <https://doi.org/10.3390/antiox8090373>.
- 1300 [19] Marcotorchino J, Romier B, Gouranton E, Riollot C, Gleize B, Malezet-Desmoulin C, et al. Lycopene
1301 attenuates LPS-induced TNF-alpha secretion in macrophages and inflammatory markers in adipocytes

1302 exposed to macrophage-conditioned media. Mol Nutr Food Res 2012; 56: 725-32.
1303 <https://doi.org/10.1002/mnfr.201100623>.

1304 [20] Landrier JF, Tourniaire F, Fenni S, Desmarchelier C, Borel P. Tomatoes and lycopene: inflammatory
1305 modulator effects. Tomatoes and lycopene in human nutrition and health, preventing chronic
1306 diseases. 2017; Rao, A.V. (ed).

1307 [21] Zhang LJ, Virgous C, Si HW. Synergistic anti-inflammatory effects and mechanisms of combined
1308 phytochemicals. J Nutr Biochem 2019; 69: 19-30. <https://doi.org/10.1016/j.jnutbio.2019.03.009>.

1309 [22] Shin SA, Joo BJ, Lee JS, Ryu G, Han M, Kim WY, et al. Phytochemicals as Anti-Inflammatory Agents in
1310 Animal Models of Prevalent Inflammatory Diseases. Molecules 2020; 25: 5932.
1311 <https://doi.org/10.3390/molecules25245932>.

1312 [23] Anuradha CV. Phytochemicals targeting genes relevant for type 2 diabetes. Can. J. Physiol. Pharmacol.
1313 2013; 91: 397-411. <https://doi.org/10.1139/cjpp-2012-0350>.

1314 [24] Fenni S, Astier J, Bonnet L, Karkeni E, Gouranton E, Mounien L, et al. (all-E)- and (5Z)-Lycopene Display
1315 Similar Biological Effects on Adipocytes. Mol Nutr Food Res 2019; 63: e1800788.
1316 <https://doi.org/10.1002/mnfr.201800788>.

1317 [25] Debnath T, Nath NCD, Kim EK, Lee KG. Role of phytochemicals in the modulation of miRNA expression in
1318 cancer. Food Funct 2017; 8: 3432-42. <https://doi.org/10.1039/c7fo00739f>.

1319 [26] Dincer Y, Yuksel S. Antiobesity effects of phytochemicals from an epigenetic perspective. Nutrition 2021;
1320 84: 111119. <https://doi.org/10.1016/j.nut.2020.111119>.

1321 [27] Bhattacharjee S, Dashwood RH. Epigenetic Regulation of NRF2/KEAP1 by Phytochemicals. Antioxidants
1322 2020; 9: 865. <https://doi.org/10.3390/antiox9090865>.

1323 [28] Marzocco S, Singla RK, Capasso A. Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-
1324 Based Treatment for Cancer. Molecules 2021; 26: 5333. <https://doi.org/10.3390/molecules26175333>.

1325 [29] Gouranton E, Aydemir G, Reynaud E, Marcotorchino J, Malezet C, Caris-Veyrat C, et al. Apo-10'-
1326 lycopenoic acid impacts adipose tissue biology via the retinoic acid receptors. Biochim Biophys Acta
1327 2012; 1811: 1105-14.

- 1328 [30] Williamson G, Clifford MN. Colonic metabolites of berry polyphenols: the missing link to biological
1329 activity? *Br J Nutr* 2010; 104 Suppl 3: S48-66. 10.1017/S0007114510003946.
- 1330 [31] Williamson G, Kay CD, Crozier A. The Bioavailability, Transport, and Bioactivity of Dietary Flavonoids: A
1331 Review from a Historical Perspective. *Compr Rev Food Sci Food Saf* 2018; 17: 1054-112. 10.1111/1541-
1332 4337.12351.
- 1333 [32] Gui H, Sun L, Liu R, Si X, Li D, Wang Y, et al. Current knowledge of anthocyanin metabolism in the
1334 digestive tract: absorption, distribution, degradation, and interconversion. *Crit Rev Food Sci Nutr*
1335 2022; 1-14. 10.1080/10408398.2022.2026291.
- 1336 [33] Carazo A, Macáková K, Matoušová K, Krčmová LK, Protti M, Mladěnka P. Vitamin A Update: Forms,
1337 Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity. *Nutrients* 2021; 13:
1338 1703. <https://doi.org/10.3390/nu13051703>.
- 1339 [34] Blaner WS, Li Y, Brun PJ, Yuen JJ, Lee SA, Clugston RD. Vitamin A Absorption, Storage and Mobilization.
1340 *Subcell Biochem* 2016; 81: 95-125. https://doi.org/10.1007/978-94-024-0945-1_4.
- 1341 [35] Harrison EH, Kopec RE, Chapter 50 - Digestion and Intestinal Absorption of Dietary Carotenoids and
1342 Vitamin A☆, in: HM Said (Ed.), *Physiology of the Gastrointestinal Tract (Sixth Edition)*, Academic
1343 Press2018, pp. 1133-51.
- 1344 [36] Dominguez LJ, Farruggia M, Veronese N, Barbagallo M. Vitamin D Sources, Metabolism, and Deficiency:
1345 Available Compounds and Guidelines for Its Treatment. *Metabolites* 2021; 11: 255.
1346 <https://doi.org/10.3390/metabo11040255>.
- 1347 [37] Desmarchelier C, Borel P, Chapter 52 - Bioavailability of Vitamin E, in: HM Said (Ed.), *Physiology of the*
1348 *Gastrointestinal Tract (Sixth Edition)*, Academic Press2018, pp. 1181-96.
- 1349 [38] Wu JH, Croft KD. Vitamin E metabolism. *Mol Aspects Med* 2007; 28: 437-52.
1350 10.1016/j.mam.2006.12.007.
- 1351 [39] Shearer MJ, Fu X, Booth SL. Vitamin K nutrition, metabolism, and requirements: current concepts and
1352 future research. *Adv Nutr* 2012; 3: 182-95. <https://doi.org/10.3945/an.111.001800>.

- 1353 [40] Card DJ, Gorska R, Cutler J, Harrington DJ. Vitamin K metabolism: current knowledge and future
1354 research. *Mol Nutr Food Res* 2014; 58: 1590-600. <https://doi.org/10.1002/mnfr.201300683>.
- 1355 [41] Cheng HM, Koutsidis G, Lodge JK, Ashor A, Siervo M, Lara J. Tomato and lycopene supplementation and
1356 cardiovascular risk factors: A systematic review and meta-analysis. *Atherosclerosis* 2017; 257: 100-8.
1357 [10.1016/j.atherosclerosis.2017.01.009](https://doi.org/10.1016/j.atherosclerosis.2017.01.009).
- 1358 [42] Song B, Liu K, Gao Y, Zhao L, Fang H, Li Y, et al. Lycopene and risk of cardiovascular diseases: A meta-
1359 analysis of observational studies. *Mol Nutr Food Res* 2017; 61: doi: 10.1002/mnfr.201601009.
1360 [10.1002/mnfr.201601009](https://doi.org/10.1002/mnfr.201601009).
- 1361 [43] Hsieh MJ, Huang CY, Kiefer R, Lee SD, Maurya N, Velmurugan BK. Cardiovascular Disease and Possible
1362 Ways in Which Lycopene Acts as an Efficient Cardio-Protectant against Different Cardiovascular Risk
1363 Factors. *Molecules* 2022; 27. [10.3390/molecules27103235](https://doi.org/10.3390/molecules27103235).
- 1364 [44] Mel'nikov SM, Seijen ten Hoorn JW, Eijkelenboom AP. Effect of phytosterols and phytostanols on the
1365 solubilization of cholesterol by dietary mixed micelles: an in vitro study. *Chem. Phys. Lipids* 2004; 127:
1366 121-41.
- 1367 [45] Ostlund REJ. Phytosterols in human nutrition. *Annu Rev Nutr* 2002; 22: 533-49.
- 1368 [46] Reboul E, Borel P. Proteins involved in uptake, intracellular transport and basolateral secretion of fat-
1369 soluble vitamins and carotenoids by mammalian enterocytes. *Prog Lipid Res* 2011; 50: 388-402.
- 1370 [47] Antoine T, May CL, Margier M, Halimi C, Nowicki M, Defoort C, et al. The complex ABCG5/ABCG8
1371 Regulates Vitamin D Absorption Rate and Contributes to its Efflux from the Intestine. *Mol Nutr Food*
1372 *Res* 2021; e2100617. <https://doi.org/10.1002/mnfr.202100617>.
- 1373 [48] Margier M, Collet X, le May C, Desmarchelier C, Andre F, Lebrun C, et al. ABCB1 (P-glycoprotein)
1374 regulates vitamin D absorption and contributes to its transintestinal efflux. *FASEB J* 2019; 33: 2084-94.
1375 <https://doi.org/10.1096/fj.201800956R>.
- 1376 [49] Reboul E, Klein A, Bietrix F, Gleize B, Malezet-Desmoulins C, Schneider M, et al. Scavenger receptor class
1377 B type I (SR-BI) is involved in vitamin E transport across the enterocyte. *J Biol Chem* 2006; 281: 4739-
1378 45.

- 1379 [50] Hentati A, Deng HX, Hung WY, Nayer M, Ahmed MS, He XX, et al. Human alpha-tocopherol transfer
1380 protein: Gene structure and mutations in familial vitamin E deficiency. *Ann Neurol* 1996; 39: 295-300.
- 1381 [51] Brigelius-Flohé R. Vitamin E research: Past, now and future. *Free Radic Biol Med* 2021; 177: 381-90.
1382 <https://doi.org/10.1016/j.freeradbiomed.2021.10.029>.
- 1383 [52] Golan DE, Tashjian AH, Armstrong EH, Armstrong AW, Principles of pharmacology : the pathophysiologic
1384 basis of drug therapy, Third Edition., 2011.
- 1385 [53] Zingg JM. Vitamin E: Regulatory Role on Signal Transduction. *IUBMB Life* 2019; 71: 456-78.
1386 <https://doi.org/10.1002/iub.1986>.
- 1387 [54] Birringer M, Lorkowski S. Vitamin E: Regulatory role of metabolites. *IUBMB Life* 2019; 71: 479-86.
1388 <https://doi.org/10.1002/iub.1988>.
- 1389 [55] Shearer MJ, Okano T. Key Pathways and Regulators of Vitamin K Function and Intermediary Metabolism.
1390 *Annu Rev Nutr* 2018; 38: 127-51. <https://doi.org/10.1146/annurev-nutr-082117-051741>.
- 1391 [56] Wen L, Chen J, Duan L, Li S. Vitamin K-dependent proteins involved in bone and cardiovascular health.
1392 *Mol Med Rep* 2018; 18: 3-15. 10.3892/mmr.2018.8940.
- 1393 [57] Rodahl K, Moore T. The vitamin A content and toxicity of bear and seal liver. *Biochem J* 1943; 37: 166-8.
1394 10.1042/bj0370166.
- 1395 [58] Morrissey PA, Sheehy PJ, Galvin K, Kerry JP, Buckley DJ. Lipid stability in meat and meat products. *Meat*
1396 *Sci* 1998; 49S1: S73-86.
- 1397 [59] Lund J, DeLuca HF. Biologically active metabolite of vitamin D3 from bone, liver, and blood serum. *J Lipid*
1398 *Res* 1966; 7: 739-44.
- 1399 [60] Soares JH, Jr., Kerr JM, Gray RW. 25-hydroxycholecalciferol in poultry nutrition. *Poult Sci* 1995; 74: 1919-
1400 34. <https://doi.org/10.3382/ps.0741919>.
- 1401 [61] Bilodeau L, Dufresne G, Deeks J, Clément G, Bertrand J, Turcotte S, et al. Determination of vitamin D3
1402 and 25-hydroxyvitamin D3 in foodstuffs by HPLC UV-DAD and LC-MS/MS. *Journal of Food*
1403 *Composition and Analysis* 2011; 24: 441-8. <https://doi.org/10.1016/j.jfca.2010.08.002>.

- 1404 [62] Cashman KD, O'Sullivan SM, Galvin K, Ryan M. Contribution of Vitamin D(2) and D(3) and Their
1405 Respective 25-Hydroxy Metabolites to the Total Vitamin D Content of Beef and Lamb. *Curr. Dev. Nutr.*
1406 2020; 4: nzaa112. <https://doi.org/10.1093/cdn/nzaa112>.
- 1407 [63] Jakobsen J, Clausen I, Leth T, Ovesen L. A new method for the determination of vitamin D3 and 25-
1408 hydroxyvitamin D3 in meat. *Journal of Food Composition and Analysis* 2004; 17: 777-87.
1409 <https://doi.org/10.1016/j.jfca.2003.10.012>.
- 1410 [64] Ložnjak P, Jakobsen J. Stability of vitamin D(3) and vitamin D(2) in oil, fish and mushrooms after
1411 household cooking. *Food Chem* 2018; 254: 144-9. <https://doi.org/10.1016/j.foodchem.2018.01.182>.
- 1412 [65] Rivera JD, Bachman Se Fau - Hubbert ME, Hubbert Me Fau - Branine ME, Branine Me Fau - Horst RL,
1413 Horst RI Fau - Williams SN, Williams Sn Fau - Galyean ML, et al. Short communication: serum and
1414 tissue concentrations of vitamin D metabolites in beef heifers after buccal dosing of 25-
1415 hydroxyvitamin D3. *J Dairy Sci* 2005; 88: 1364-9.
- 1416 [66] Zhang F, Nunes M, Segmuller B, Dunphy R, Hesse RH, Setty SK. Degradation chemistry of a Vitamin D
1417 analogue (ecalcidene) investigated by HPLC-MS, HPLC-NMR and chemical derivatization. *J. Pharm.*
1418 *Biomed. Anal.* 2006; 40: 850-63. <https://doi.org/10.1016/j.jpba.2005.07.052>.
- 1419 [67] Mahmoodani F, Perera CO, Fedrizzi B, Abernethy G, Chen H. Degradation studies of cholecalciferol
1420 (vitamin D3) using HPLC-DAD, UHPLC-MS/MS and chemical derivatization. *Food Chem* 2017; 219: 373-
1421 81. [10.1016/j.foodchem.2016.09.146](https://doi.org/10.1016/j.foodchem.2016.09.146).
- 1422 [68] Walther B, Karl Jp Fau - Booth SL, Booth Sl Fau - Boyaval P, Boyaval P. Menaquinones, bacteria, and the
1423 food supply: the relevance of dairy and fermented food products to vitamin K requirements. *Adv.*
1424 *Nutr.* 2013; 4: 463-73.
- 1425 [69] Elder SJ, Haytowitz Db Fau - Howe J, Howe J Fau - Peterson JW, Peterson Jw Fau - Booth SL, Booth SL.
1426 Vitamin k contents of meat, dairy, and fast food in the u.s. *Diet. J. Agri. Food Chem.* 2006; 54: 463-7.
- 1427 [70] Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Effect of food
1428 matrix on circulating vitamin K concentrations. *Haemostasis* 2000; 30: 298-307.

- 1429 [71] Kamao M, Suhara Y, Tsugawa N, Uwano M, Yamaguchi N, Uenishi K, et al. Vitamin K content of foods
1430 and dietary vitamin K intake in Japanese young women. *J Nutr Sci Vitaminol (Tokyo)* 2007; 53: 464-70.
- 1431 [72] Ferland G, Sadowski JA. Vitamin K1 (phylloquinone) content of edible oils: effects of heating and light
1432 exposure. *J. Agric. Food Chem.* 1992; 40: 1869-73. <https://doi.org/10.1021/jf00022a028>.
- 1433 [73] Kalač P. The effects of silage feeding on some sensory and health attributes of cow's milk: A review.
1434 *Food Chem* 2011; 125: 307-17. <https://doi.org/10.1016/j.foodchem.2010.08.077>.
- 1435 [74] Mora O, Romano JI Fau - Gonzalez E, Gonzalez E Fau - Ruiz F, Ruiz F Fau - Shimada A, Shimada A. Low
1436 cleavage activity of 15,15'-dioxygenase to convert beta-carotene to retinal in cattle compared with
1437 goats, is associated with the yellow pigmentation of adipose tissue. *Int. J. Vitam. Nutr. Res.* 2000; 70:
1438 199-205.
- 1439 [75] Khachik F, Spangler CJ, Smith Jr JC, Canfield LM, Steck A, Pfander H. Identification, quantification, and
1440 relative concentrations of carotenoids and their metabolites in human milk and serum. *Anal Chem*
1441 1997; 69: 1873-81.
- 1442 [76] Nguyen ML, Schwartz SJ. Lycopene stability during food processing. *Exp. Biol. Med. (Maywood)* 1998;
1443 218: 101-5.
- 1444 [77] Lessin WJ, Catigani GL, Schwartz SJ. Quantification of cis-trans Isomers of Provitamin A Carotenoids in
1445 Fresh and Processed Fruits and Vegetables. *J. Agric. Food Chem.* 1997; 45: 3728-32.
1446 <https://doi.org/10.1021/jf960803z>.
- 1447 [78] Delchier N, Reich M, Renard CMGC. Impact of cooking methods on folates, ascorbic acid and lutein in
1448 green beans (*Phaseolus vulgaris*) and spinach (*Spinacea oleracea*). *LWT-Food Sci Technol* 2012; 49:
1449 197-201. <https://doi.org/10.1016/j.lwt.2012.06.017>.
- 1450 [79] Bureau S, Mouhoubi S, Touloumet L, Garcia C, Moreau F, Bédouet V, et al. Are folates, carotenoids and
1451 vitamin C affected by cooking? Four domestic procedures are compared on a large diversity of frozen
1452 vegetables. *LWT-Food Sci Technol* 2015; 64: 735-41. <https://doi.org/10.1016/j.lwt.2015.06.016>.

- 1453 [80] Fleshman MK, Lester GE, Riedl KM, Kopec RE, Narayanasamy S, Curley Jr RW, et al. Carotene and novel
1454 apocarotenoid concentrations in orange-fleshed Cucumis melo melons: determinations of β -carotene
1455 bioaccessibility and bioavailability. *J. Agri. Food Chem.* 2011; 59: 4448-54.
- 1456 [81] Kopec RE, Riedl KM, Harrison EH, Curley RW, Jr., Hruszkewycz DP, Clinton SK, et al. Identification and
1457 quantification of apo-lycopenals in fruits, vegetables, and human plasma. *J. Agric. Food Chem.* 2010;
1458 58: 3290-6. <https://doi.org/10.1021/jf100415z>.
- 1459 [82] Kopec RE, Schwartz SJ, Carotenoid Cleavage Dioxygenase and Presence of Apo-Carotenoids in Biological
1460 Matrices, Carotenoid Cleavage Products, American Chemical Society 2013, pp. 31-41.
- 1461 [83] Rodrigo MJ, Alquézar B, Alós E, Medina V, Carmona L, Bruno M, et al. A novel carotenoid cleavage
1462 activity involved in the biosynthesis of Citrus fruit-specific apocarotenoid pigments. *J. Exp. Botany*
1463 2013; 64: 4461-78.
- 1464 [84] Wang JY, Lin PY, Al-Babili S. On the biosynthesis and evolution of apocarotenoid plant growth
1465 regulators. *Semin. Cell Dev. Biol.* 2021; 109: 3-11.
- 1466 [85] Shamarao N, Chethankumar M. Antiobesity drug-likeness properties and pancreatic lipase inhibition of a
1467 novel low molecular weight lutein oxidized product, LOP6. *Food Funct* 2022.
1468 <https://doi.org/10.1039/d1fo04064b>.
- 1469 [86] Soupas L, Huikko L, Lampi A-M, Piironen V. Oxidative stability of phytosterols in some food applications.
1470 *Eu. Food Res. Tech.* 2005; 222: 266. <https://doi.org/10.1007/s00217-005-0031-0>.
- 1471 [87] Ryan E, McCarthy FO, Maguire AR, O'Brien NM. Phytosterol Oxidation Products: Their Formation,
1472 Occurrence, and Biological Effects. *Food Rev. Int.* 2009; 25: 157-74.
1473 <https://doi.org/10.1080/87559120802682797>.
- 1474 [88] Scholz B, Guth S, Engel KH, Steinberg P. Phytosterol oxidation products in enriched foods: Occurrence,
1475 exposure, and biological effects. *Mol. Nutr. Food Res.* 2015; 59: 1339-52.
- 1476 [89] González-Larena M, García-Llatas G, Vidal MC, Sánchez-Siles LM, Barberá R, Lagarda MJ. Stability of
1477 plant sterols in ingredients used in functional foods. *J. Agric. Food Chem.* 2011; 59: 3624-31.

- 1478 [90] McDonald K, Langenbahn HJ, Miller JD, McMullin DR. Phytosterol oxidation products from coffee
1479 silverskin. *J. Food Chem.* 2022; 87: 728-37.
- 1480 [91] Menéndez-Carreño M, Ansorena D, Astiasarán I. Stability of sterols in phytosterol-enriched milk under
1481 different heating conditions. *J. Agri. Food Chem.* 2008; 12: 9997-10002.
- 1482 [92] Botelho PB, Galasso M, Dias V, Mandrioli M, Lobato LP, Rodriguez-Estrada MT, et al. Oxidative stability
1483 of functional phytosterol-enriched dark chocolate. *LWT-Food Sci Technol* 2014; 55: 444-51.
1484 <https://doi.org/10.1016/j.lwt.2013.09.002>.
- 1485 [93] Scholz B, Menzel N, Lander V, Engel K-H. Heating Two Types of Enriched Margarine: Complementary
1486 Analysis of Phytosteryl/Phytostanyl Fatty Acid Esters and Phytosterol/Phytostanol Oxidation Products.
1487 *J. Agric. Food Chem.* 2016; 64: 2699-708. <https://doi.org/10.1021/acs.jafc.6b00617>.
- 1488 [94] Soupas L, Huikko L, Lampi A-m, Piironen V. Pan-frying may induce phytosterol oxidation. *Food Chem*
1489 2007; 101: 286-97. <https://doi.org/10.1016/j.foodchem.2006.01.035>.
- 1490 [95] Cooperstone JL, Francis DM, Schwartz SJ. Thermal processing differentially affects lycopene and other
1491 carotenoids in cis-lycopene containing, tangerine tomatoes. *Food Chem* 2016; 210: 466-72.
1492 <https://doi.org/10.1016/j.foodchem.2016.04.078>.
- 1493 [96] Amerongen AV, Veerman EC. Saliva--the defender of the oral cavity. *Oral Dis* 2002; 8: 12-22.
1494 <https://doi.org/10.1034/j.1601-0825.2002.1o816.x>.
- 1495 [97] Gorelik S, Ligumsky M, Kohen R, Kanner J. A novel function of red wine polyphenols in humans:
1496 prevention of absorption of cytotoxic lipid peroxidation products. *FASEB J* 2008; 22: 41-6.
1497 <https://doi.org/10.1096/fj.07-9041com>.
- 1498 [98] Kanner J, Gorelik S, Roman S, Kohen R. Protection by polyphenols of postprandial human plasma and
1499 low-density lipoprotein modification: the stomach as a bioreactor. *J. Agric. Food Chem.* 2012; 60:
1500 8790-6. <https://doi.org/10.1021/jf300193g>.
- 1501 [99] Grisham MB, Ryan EM. Cytotoxic properties of salivary oxidants. *Am J Physiol* 1990; 258: C115-21.
1502 <https://doi.org/10.1152/ajpcell.1990.258.1.C115>.

- 1503 [100] Nagler RM, Klein I, Zarzhevsky N, Drigues N, Reznick AZ. Characterization of the differentiated
1504 antioxidant profile of human saliva. *Free Radic. Biol. Med.* 2002; 32: 268-77.
1505 [https://doig.org/10.1016/s0891-5849\(01\)00806-1](https://doig.org/10.1016/s0891-5849(01)00806-1).
- 1506 [101] Ginsburg I, Kohen R, Koren E. Saliva: a 'solubilizer' of lipophilic antioxidant polyphenols. *Oral Dis* 2013;
1507 19: 321-2. <https://doig.org/10.1111/odi.12038>.
- 1508 [102] Bennick A. Interaction of plant polyphenols with salivary proteins. *Crit. Rev. Oral Biol. Med.* 2002; 13:
1509 184-96. <https://doig.org/10.1177/154411130201300208>.
- 1510 [103] Gorelik S, Kohen R, Ligumsky M, Kanner J. Saliva plays a dual role in oxidation process in stomach
1511 medium. *Arch. Biochem. Biophys.* 2007; 458: 236-43. <https://doig.org/10.1016/j.abb.2006.12.006>.
- 1512 [104] Peri L, Pietraforte D, Scorza G, Napolitano A, Fogliano V, Minetti M. Apples increase nitric oxide
1513 production by human saliva at the acidic pH of the stomach: a new biological function for polyphenols
1514 with a catechol group? *Free Radic. Biol. Med.* 2005; 39: 668-81.
1515 <https://doig.org/10.1016/j.freeradbiomed.2005.04.021>.
- 1516 [105] Somaratne G, Ye A, Nau F, Ferrua MJ, Dupont D, Paul Singh R, et al. Role of biochemical and
1517 mechanical disintegration on beta-carotene release from steamed and fried sweet potatoes during in
1518 vitro gastric digestion. *Food Res. Int.* 2020; 136: 109481.
1519 <https://doig.org/10.1016/j.foodres.2020.109481>.
- 1520 [106] Tyssandier V, Reboul E, Dumas JF, Bouteloup-Demange C, Armand M, Marcand J, et al. Processing of
1521 vegetable-born carotenoids in the human stomach and duodenum. *Am J Physiol Gastrointest Liver*
1522 *Physiol* 2003; 284: G913-23.
- 1523 [107] Gorelik S, Lapidot T, Shaham I, Granit R, Ligumsky M, Kohen R, et al. Lipid peroxidation and coupled
1524 vitamin oxidation in simulated and human gastric fluid inhibited by dietary polyphenols: health
1525 implications. *J. Agric. Food Chem.* 2005; 53: 3397-402. <https://doig.org/10.1021/jf040401o>.
- 1526 [108] Kopec RE, Caris-Veyrat C, Nowicki M, Bernard JP, Morange S, Chitchumroonchokchai C, et al. The Effect
1527 of an Iron Supplement on Lycopene Metabolism and Absorption During Digestion in Healthy Humans.
1528 *Mol Nutr Food Res* 2019; 63: e1900644. <https://doig.org/10.1002/mnfr.201900644>.

- 1529 [109] Sy C, Dangles O, Borel P, Caris-Veyrat C. Iron-induced oxidation of (all-E)-beta-carotene under model
1530 gastric conditions: kinetics, products, and mechanism. *Free Radic Biol Med* 2013; 63C: 195-206.
- 1531 [110] Hirota S, Takahama U. Starch Can Inhibit Nitrite-Dependent Oxidation of Crocin in Gastric Lumen
1532 Increasing Bioavailability of Carotenoids. *Food Sci. Tech. Res.* 2013; 19: 1121-6.
1533 <https://doig.org/10.3136/fstr.19.1121>.
- 1534 [111] Kopec RE, Caris-Veyrat C, Nowicki M, Gleize B, Carail M, Borel P. Production of asymmetric oxidative
1535 metabolites of [13C]-beta-carotene during digestion in the gastrointestinal lumen of healthy men. *Am*
1536 *J Clin Nutr* 2018; 108: 803-13. <https://doig.org/10.1093/ajcn/nqy183>.
- 1537 [112] Kopec RE, Gleize B, Borel P, Desmarchelier C, Caris-Veyrat C. Are lutein, lycopene, and beta-carotene
1538 lost through the digestive process? *Food Funct* 2017; 8: 1494-503. 10.1039/c7fo00021a.
- 1539 [113] Chernukhina LA, Blazhevich MA, Pinskaia IE, Donchenko DV. Retinol-binding glycolipoproteins in
1540 secretions of the intermediate zone of the chicken glandular stomach. *Ukr. Biokhim. Zh.* 1989; 61: 36-
1541 42.
- 1542 [114] Palmero P, Panozzo A, Colle I, Chigwedere C, Hendrickx M, Van Loey A. Role of structural barriers for
1543 carotenoid bioaccessibility upon high pressure homogenization. *Food Chem* 2016; 199: 423-32.
1544 <https://doig.org/10.1016/j.foodchem.2015.12.062>.
- 1545 [115] Palmero P, Lemmens L, Ribas-Agusti A, Sosa C, Met K, Umutoni JD, et al. Novel targeted approach to
1546 better understand how natural structural barriers govern carotenoid in vitro bioaccessibility in
1547 vegetable-based systems. *Food Chem* 2013; 141: 2036-43.
1548 <https://doig.org/10.1016/j.foodchem.2013.05.064>.
- 1549 [116] Verriussen TA, Vanierschot M, Ongena SI, Cardinaels R, Van Den Bulck E, Van Loey AM, et al. Role of
1550 mechanical forces in the stomach phase on the in vitro bioaccessibility of B-carotene. *Commun Agric*
1551 *Appl Biol Sci* 2014; 79: 3-8.
- 1552 [117] Rich GT, Faulks RM, Wickham MS, Fillery-Travis A. Solubilization of carotenoids from carrot juice and
1553 spinach in lipid phases: II. Modeling the duodenal environment. *Lipids* 2003; 38: 947-56.

- 1554 [118] Goupy P, Genot C, Hammaz F, Halimi C, Caris-Veyrat C, Borel P. Mechanisms Governing the Transfer of
1555 Pure and Plant Matrix Carotenoids Toward Emulsified Triglycerides. *Mol Nutr Food Res* 2020; 64:
1556 e1900911. <https://doi.org/10.1002/mnfr.201900911>.
- 1557 [119] Yuan X, Xiao J, Liu X, McClements DJ, Cao Y, Xiao H. The gastrointestinal behavior of emulsifiers used to
1558 formulate excipient emulsions impact the bioavailability of beta-carotene from spinach. *Food Chem*
1559 2019; 278: 811-9. <https://doi.org/10.1016/j.foodchem.2018.11.135>.
- 1560 [120] Park S, Mun S, Kim Y-R. Emulsifier Dependent in vitro Digestion and Bioaccessibility of β -Carotene
1561 Loaded in Oil-in-Water Emulsions. *Food Biophysics* 2018; 13: 147-54.
1562 <https://doi.org/10.1007/s11483-018-9520-0>.
- 1563 [121] Liu Y, Lei F, Yuan F, Gao Y. Effects of milk proteins on release properties and particle morphology of
1564 beta-carotene emulsions during in vitro digestion. *Food Funct* 2014; 5: 2940-7.
1565 <https://doi.org/10.1039/c4fo00585f>.
- 1566 [122] Zhang ZW, Patchett SE, Perrett D, Domizio P, Farthing MJ. Gastric alpha-tocopherol and beta-carotene
1567 concentrations in association with Helicobacter pylori infection. *Eur. J. Gastroenterol. Hepatol.* 2000;
1568 12: 497-503. <https://doi.org/10.1097/00042737-200012050-00004>.
- 1569 [123] Tang GW, Serfaty-Lacrosniere C, Camilo ME, Russell RM. Gastric acidity influences the blood response
1570 to a beta-carotene dose in humans. *Am J Clin Nutr* 1996; 64: 622-6.
- 1571 [124] Borel P, Armand M, Ythier P, Dutot G, Melin C, Senft M, et al. Hydrolysis of emulsions with different
1572 triglycerides and droplet sizes by gastric lipase in vitro - Effect on pancreatic lipase activity. *J Nutr*
1573 *Biochem* 1994; 5: 124-33.
- 1574 [125] Borel P, Armand M, Senft M, Andre M, Lafont H, Lairon D. Gastric lipase: evidence of an adaptive
1575 response to dietary fat in the rabbit. *Gastroenterology* 1991; 100: 1582-9.
- 1576 [126] Amara S, Bourlieu C, Humbert L, Rainteau D, Carrière F. Variations in gastrointestinal lipases, pH and
1577 bile acid levels with food intake, age and diseases: Possible impact on oral lipid-based drug delivery
1578 systems. *Adv Drug Del Rev* 2019; 142: 3-15. <https://doi.org/10.1016/j.addr.2019.03.005>.

- 1579 [127] Cardinault N, Tyssandier V, Grolier P, Winklhofer-Roob BM, Ribalta J, Bouteloup-Demange C, et al.
1580 Comparison of the postprandial chylomicron carotenoid responses in young and older subjects. *Eur J*
1581 *Nutr* 2003; 42: 315-23.
- 1582 [128] Cardinault N, Gorrard JM, Tyssandier V, Grolier P, Rock E, Borel P. Short-term supplementation with
1583 lutein affects biomarkers of lutein status similarly in young and elderly subjects. *Exp Gerontol* 2003;
1584 38: 573-82.
- 1585 [129] Winklhofer-Roob BM, Roob JM, Maritschnegg M, Sprinz G, Hiller D, Marktfelder E, et al. Does aging
1586 affect the response of vitamin E status to vitamin E depletion and supplementation? *Ann N Y Acad Sci*
1587 2004; 1031: 381-4.
- 1588 [130] Petry FC, Mercadante AZ. Addition of either gastric lipase or cholesterol esterase to improve both
1589 beta-cryptoxanthin ester hydrolysis and micellarization during in vitro digestion of fruit pulps. *Food*
1590 *Res Int* 2020; 137: 109691. <https://doi.org/10.1016/j.foodres.2020.109691>.
- 1591 [131] Iddir M, Degerli C, Dingo G, Desmarchelier C, Schlee T, Borel P, et al. Whey protein isolate modulates
1592 beta-carotene bioaccessibility depending on gastro-intestinal digestion conditions. *Food Chem* 2019;
1593 291: 157-66. <https://doi.org/10.1016/j.foodchem.2019.04.003>.
- 1594 [132] Colle IJP, Lemmens L, Knockaert G, Van Loey A, Hendrickx M. Carotene Degradation and Isomerization
1595 during Thermal Processing: A Review on the Kinetic Aspects. *Cri. Rev. Food Sci. Nutr.* 2016; 56: 1844-
1596 55. <https://doi.org/10.1080/10408398.2013.790779>.
- 1597 [133] Re R, Fraser PD, Long M, Bramley PM, Rice-Evans C. Isomerization of lycopene in the gastric milieu.
1598 *Biochem. Biophys. Res. Commun.* 2001; 281: 576-81.
- 1599 [134] Moraru C, Lee TC. Kinetic studies of lycopene isomerization in a tributyrin model system at gastric pH. *J*
1600 *Agric Food Chem* 2005; 53: 8997-9004. <https://doi.org/10.1021/jf051672h>.
- 1601 [135] Tyssandier V, Choubert G, Grolier P, Borel P. Carotenoids, mostly the xanthophylls, exchange between
1602 plasma lipoproteins. *Int J Vitam Nutr Res* 2002; 72: 300-8.
- 1603 [136] Bilusic T, Blazevic I, Dropulic AM, Markic J, Bratanic A, Kokeza A. Gastrointestinal stability of
1604 carotenoids from raw and freeze-dried vegetables. *Ital J Food Sci* 2019; 31: 172-83.

- 1605 [137] Courraud J, Berger J, Cristol JP, Avallone S. Stability and bioaccessibility of different forms of
1606 carotenoids and vitamin A during in vitro digestion. Food Chem 2013; 136: 871-7.
1607 <https://doi.org/10.1016/j.foodchem.2012.08.076>.
- 1608 [138] Nimalaratne C, Savard P, Gauthier SF, Schieber A, Wu J. Bioaccessibility and digestive stability of
1609 carotenoids in cooked eggs studied using a dynamic in vitro gastrointestinal model. J Agric Food Chem
1610 2015; 63: 2956-62. <https://doi.org/10.1021/jf505615w>.
- 1611 [139] Blanquet-Diot S, Soufi M, Rambeau M, Rock E, Alric M. Digestive stability of xanthophylls exceeds that
1612 of carotenes as studied in a dynamic in vitro gastrointestinal system. J Nutr 2009; 139: 876-83.
1613 <https://doi.org/10.3945/jn.108.103655>.
- 1614 [140] Carpenter CE, Clark E. Evaluation of Methods Used in Meat Iron Analysis and Iron Content of Raw and
1615 Cooked Meats. J. Agri. Food Chem. 1995; 43: 1824-7. <https://doi.org/10.1021/jf00055a014>.
- 1616 [141] Barreto-Lins MH, Campos FA, Azevedo MC, Flores H. A re-examination of the stability of retinol in
1617 blood and serum, and effects of a standardized meal. Clin Chem 1988; 34: 2308-10.
- 1618 [142] Nourooz-Zadeh J, Tajaddini-Sarmadi J, Wolff SP. Measurement of Hydroperoxides in Edible Oils Using
1619 the Ferrous Oxidation in Xylenol Orange Assay. J. Agric. Food Chem. 1995; 43: 17-21.
1620 <https://doi.org/10.1021/jf00049a005>.
- 1621 [143] Crotova J, Rustad T. A new fluorimetric method for simultaneous determination of lipid and protein
1622 hydroperoxides in muscle foods with the use of diphenyl-1-pyrenylphosphine (DPPP). LWT-Food Sci
1623 Technol 2020; 128: 109467. <https://doi.org/10.1016/j.lwt.2020.109467>.
- 1624 [144] Cheng Z, Li Y. What Is Responsible for the Initiating Chemistry of Iron-Mediated Lipid Peroxidation: An
1625 Update. Chem Rev 2007; 107: 748-66. <https://doi.org/10.1021/cr040077w>.
- 1626 [145] Vallier MJ, Le Bourvellec C, Dangles O. Iron-induced peroxidation of trilinolein nano-emulsions under
1627 model gastric conditions and its inhibition by dietary phenolic antioxidants. Food Funct 2020; 11:
1628 9144-56. <https://doi.org/10.1039/d0fo01767a>.

- 1629 [146] Sy C, Caris-Veyrat C, Dufour C, Boutaleb M, Borel P, Dangles O. Inhibition of iron-induced lipid
1630 peroxidation by newly identified bacterial carotenoids in model gastric conditions: comparison with
1631 common carotenoids. *Food Funct* 2013; 4: 698-712.
- 1632 [147] Goupy P, Reynaud E, Dangles O, Caris-Veyrat C. Antioxidant activity of (all-E)-lycopene and synthetic
1633 apo-lycopenoids in a chemical model of oxidative stress in the gastro-intestinal tract. *New J Chem*
1634 2012; 36: 575-87. <https://doi.org/10.1039/C1NJ20437H>.
- 1635 [148] Kanner J, Lapidot T. The stomach as a bioreactor: dietary lipid peroxidation in the gastric fluid and the
1636 effects of plant-derived antioxidants. *Free Radic Biol Med* 2001; 31: 1388-95.
1637 [https://doi.org/10.1016/s0891-5849\(01\)00718-3](https://doi.org/10.1016/s0891-5849(01)00718-3).
- 1638 [149] Lorrain B, Dangles O, Genot C, Dufour C. Chemical modeling of heme-induced lipid oxidation in gastric
1639 conditions and inhibition by dietary polyphenols. *J Agric Food Chem* 2010; 58: 676-83.
- 1640 [150] Lorrain B, Dangles O, Loonis M, Armand M, Dufour C. Dietary iron-initiated lipid oxidation and its
1641 inhibition by polyphenols in gastric conditions. *J Agric Food Chem* 2012; 60: 9074-81.
- 1642 [151] Rabkin B, Tirosh O, Kanner J. Reactivity of Vitamin E as an Antioxidant in Red Meat and the Stomach
1643 Medium. *J Agric Food Chem* 2022; 70: 12172-9. [10.1021/acs.jafc.2c03674](https://doi.org/10.1021/acs.jafc.2c03674).
- 1644 [152] Gobert M, Rémond D, Loonis M, Buffière C, Santé-Lhoutellier V, Dufour C. Fruits, vegetables and their
1645 polyphenols protect dietary lipids from oxidation during gastric digestion. *Food funct* 2014; 5: 2166-
1646 74.
- 1647 [153] Zhang Y, Smuts JP, Dodbiba E, Rangarajan R, Lang JC, Armstrong DW. Degradation study of carnosic
1648 acid, carnosol, rosmarinic acid, and rosemary extract (*Rosmarinus officinalis* L.) assessed using HPLC. *J*
1649 *Agric Food Chem* 2012; 12: 9305-14.
- 1650 [154] Jordán MJ, Castillo J, Bañón S, Martínez-Conesa C, Sotomayor JA. Relevance of the carnosic
1651 acid/carnosol ratio for the level of rosemary diterpene transfer and for improving lamb meat
1652 antioxidant status. *Food Chem.* 2014; 151: 212-8.

- 1653 [155] Lukić I, Krapac M, Horvat I, Godena S, Kosić U, Brkić Bubola K. Three-factor approach for balancing the
1654 concentrations of phenols and volatiles in virgin olive oil from a late-ripening olive cultivar. *LWT-Food*
1655 *Sci Technol* 2018; 87: 194-202. <https://doi.org/10.1016/j.lwt.2017.08.082>.
- 1656 [156] Veneziani G, Esposto S, Minnocci A, Taticchi A, Urbani S, Selvaggini R, et al. Compositional differences
1657 between veiled and filtered virgin olive oils during a simulated shelf life. *LWT-Food Sci Technol* 2018;
1658 94. <https://doi.org/10.1016/j.lwt.2018.04.049>.
- 1659 [157] Achat S, Rakotomanomana N, Madani K, Dangles O. Antioxidant activity of olive phenols and other
1660 dietary phenols in model gastric conditions: Scavenging of the free radical DPPH and inhibition of the
1661 haem-induced peroxidation of linoleic acid. *Food Chem.* 2016; 213: 135-42.
- 1662 [158] Roche M, Dufour C, Mora N, Dangles O. Antioxidant activity of olive phenols: mechanistic investigation
1663 and characterization of oxidation products by mass spectrometry. *Org Biomol Chem* 2005; 3: 423-30.
1664 <https://doi.org/10.1039/B416101G>.
- 1665 [159] Yeum KJ, Leekim YC, Yoon S, Lee KY, Park IS, Lee KS, et al. Similar metabolites formed from beta-
1666 carotene by human gastric mucosal homogenates, lipoxygenase, or linoleic acid hydroperoxide. *Arch.*
1667 *Biochem. Biophys.* 1995; 321: 167-74.
- 1668 [160] Paiva S, Yeum KJ, Lee KS, Park IS, Lee-Kim YC, Russell RM. Endogenous carotenoid concentrations in
1669 cancerous and non-cancerous tissues of gastric cancer patients in Korea. *Asia Pac J Clin Nutr* 1999; 8:
1670 160-6. <https://doi.org/10.1046/j.1440-6047.1999.00087.x>.
- 1671 [161] Oueslati K, de La Pomelie D, Sante-Lhoutellier V, Gatellier P. Impact of the Fenton process in meat
1672 digestion as assessed using an in vitro gastro-intestinal model. *Food Chem* 2016; 209: 43-9.
1673 <https://doi.org/10.1016/j.foodchem.2016.04.041>.
- 1674 [162] Gueraud F, Tache S, Steghens JP, Milkovic L, Borovic-Sunjic S, Zarkovic N, et al. Dietary polyunsaturated
1675 fatty acids and heme iron induce oxidative stress biomarkers and a cancer promoting environment in
1676 the colon of rats. *Free Radic Biol Med* 2015; 83: 192-200.
1677 <https://doi.org/10.1016/j.freeradbiomed.2015.02.023>.

- 1678 [163] Hirota S, Takahama U. Reactions of polyphenols in masticated apple fruit with nitrite under stomach
1679 simulating conditions: Formation of nitroso compounds and thiocyanate conjugates. *Food Res Int*
1680 2015; 75: 20-6. <https://doi.org/10.1016/j.foodres.2015.05.018>.
- 1681 [164] Xie Z, Li X, Tang R, Wang G, Lu Y, Li X, et al. Reactions of polyphenols in pomegranate peel with nitrite
1682 under simulated stomach conditions. *Food Sci Nutr* 2019; 7: 3103-9.
1683 <https://doi.org/10.1002/fsn3.1173>.
- 1684 [165] Buller ID, Patel DM, Weyer PJ, Prizment A, Jones RR, Ward MH. Ingestion of Nitrate and Nitrite and Risk
1685 of Stomach and Other Digestive System Cancers in the Iowa Women's Health Study. *Int J Environ Res*
1686 *Public Health* 2021; 18: 6822. <https://doi.org/10.3390/ijerph18136822>.
- 1687 [166] Velmurugan B, Bhuvanewari V, Burra UK, Nagini S. Prevention of N-methyl-N'-nitro-N-
1688 nitrosoguanidine and saturated sodium chloride-induced gastric carcinogenesis in Wistar rats by
1689 lycopene. *Eur J Cancer Prev* 2002; 11: 19-26. <https://doi.org/10.1097/00008469-200202000-00004>.
- 1690 [167] Matsumoto M, Yokoyama H, Suzuki H, Shiraishi-Yokoyama H, Hibi T. Retinoic acid formation from
1691 retinol in the human gastric mucosa: role of class IV alcohol dehydrogenase and its relevance to
1692 morphological changes. *Am J Physiol Gastrointest Liver Physiol* 2005; 289: G429-33.
1693 <https://doi.org/10.1152/ajpgi.00502.2004>.
- 1694 [168] Karkeni E, Bonnet L, Astier J, Couturier C, Dalifard J, Tourniaire F, et al. All-trans-retinoic acid represses
1695 chemokine expression in adipocytes and adipose tissue by inhibiting NF-kappaB signaling. *J Nutr*
1696 *Biochem* 2017; 42: 101-7. <https://doi.org/10.1016/j.jnutbio.2017.01.004>.
- 1697 [169] Linnewiel-Hermoni K, Motro Y, Miller Y, Levy J, Sharoni Y. Carotenoid derivatives inhibit nuclear factor
1698 kappa B activity in bone and cancer cells by targeting key thiol groups. *Free Radic Biol Med* 2014; 75:
1699 105-20. <https://doi.org/10.1016/j.freeradbiomed.2014.07.024>.
- 1700 [170] Linnewiel K, Ernst H, Caris-Veyrat C, Ben-Dor A, Kampf A, Salman H, et al. Structure activity relationship
1701 of carotenoid derivatives in activation of the electrophile/antioxidant response element transcription
1702 system. *Free Radic Biol Med* 2009; 47: 659-67.

- 1703 [171] Zheng L, Kelly CJ, Colgan SP. Physiologic hypoxia and oxygen homeostasis in the healthy intestine. A
1704 Review in the Theme: Cellular Responses to Hypoxia. *Am J Physiol Cell Physiol* 2015; 309: C350-60.
1705 <https://doi.org/10.1152/ajpcell.00191.2015>.
- 1706 [172] Tyssandier V, Cardinault N, Caris-Veyrat C, Amiot MJ, Grolier P, Bouteloup C, et al. Vegetable-borne
1707 lutein, lycopene, and beta-carotene compete for incorporation into chylomicrons, with no adverse
1708 effect on the medium- term (3-wk) plasma status of carotenoids in humans. *Am J Clin Nutr* 2002; 75:
1709 526-34.
- 1710 [173] Armand M, Borel P, Pasquier B, Dubois C, Senft M, Andre M, et al. Physicochemical characteristics of
1711 emulsions during fat digestion in human stomach and duodenum. *Am J Physiol* 1996; 271: G172-G83.
- 1712 [174] Stiggers JE, Hernell O, Stafford RJ, Carey MC. Physical-chemical behavior of dietary and biliary lipids
1713 during intestinal digestion and absorption. 1. Phase behavior and aggregation states of model lipid
1714 systems patterned after aqueous duodenal contents of healthy adult human beings. *Biochemistry*
1715 1990; 29: 2028-40.
- 1716 [175] Hernell O, Stiggers JE, Carey MC. Physical-chemical behavior of dietary and biliary lipids during
1717 intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during
1718 duodenal fat digestion in healthy adult human beings. *Biochemistry* 1990; 29: 2041-56.
- 1719 [176] Yamashita K, Takeda N, Ikeda S. Effects of various tocopherol-containing diets on tocopherol secretion
1720 into bile. *Lipids* 2000; 35: 163-70.
- 1721 [177] Mustacich DJ, Shields J, Horton RA, Brown MK, Reed DJ. Biliary secretion of alpha-tocopherol and the
1722 role of the mdr2 P-glycoprotein in rats and mice. *Arch Biochem Biophys* 1998; 350: 183-92.
- 1723 [178] Leo MA, Ahmed S, Aleynik SI, Siegel JH, Kasmin F, Lieber CS. Carotenoids and tocopherols in various
1724 hepatobiliary conditions. *J Hepatol* 1995; 23: 550-6.
- 1725 [179] Desmarchelier C, Tourniaire F, Preveraud DP, Samson-Kremser C, Crenon I, Rosilio V, et al. The
1726 distribution and relative hydrolysis of tocopheryl acetate in the different matrices coexisting in the
1727 lumen of the small intestine during digestion could explain its low bioavailability. *Mol Nutr Food Res*
1728 2013; 57: 1237-45. <https://doi.org/10.1002/mnfr.201200720>.

- 1729 [180] Palmero P, Panozzo A, Simatupang D, Hendrickx M, Van Loey A. Lycopene and beta-carotene transfer
1730 to oil and micellar phases during in vitro digestion of tomato and red carrot based-fractions. Food Res.
1731 Int. 2014; 64: 831-8. <https://doi.org/10.1016/j.foodres.2014.08.022>.
- 1732 [181] Mensi A, Borel P, Goncalves A, Nowicki M, Gleize B, Roi S, et al. beta-lactoglobulin as a vector for beta-
1733 carotene food fortification. J Agric Food Chem 2014; 62: 5916-24. <https://doi.org/10.1021/jf501683s>.
- 1734 [182] Borel P, Pasquier B, Armand M, Tyssandier V, Grolier P, Alexandre-Gouabau MC, et al. Processing of
1735 vitamin A and E in the human gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 2001; 280:
1736 G95-G103.
- 1737 [183] Borel P, Grolier P, Armand M, Partier A, Lafont H, Lairon D, et al. Carotenoids in biological emulsions:
1738 solubility, surface-to-core distribution, and release from lipid droplets. J Lipid Res 1996; 37: 250-61.
- 1739 [184] Desmarchelier C, Margier M, Preveraud DP, Nowicki M, Rosilio V, Borel P, et al. Comparison of the
1740 Micellar Incorporation and the Intestinal Cell Uptake of Cholecalciferol, 25-Hydroxycholecalciferol and
1741 1-alpha-Hydroxycholecalciferol. Nutrients 2017; 9. <https://doi.org/10.3390/nu9101152>.
- 1742 [185] Tyssandier V, Lyan B, Borel P. Main factors governing the transfer of carotenoids from emulsion lipid
1743 droplets to micelles. Biochim Biophys Acta 2001; 1533: 285-92.
- 1744 [186] Chitchumroonchokchai C, Failla ML. Hydrolysis of zeaxanthin esters by carboxyl ester lipase during
1745 digestion facilitates micellarization and uptake of the xanthophyll by Caco-2 human intestinal cells. J
1746 Nutr 2006; 136: 588-94.
- 1747 [187] Breithaupt DE, Bamedi A, Wirt U. Carotenol fatty acid esters: easy substrates for digestive enzymes?
1748 Comp Biochem Physiol B Biochem Mol Biol 2002; 132: 721-8.
- 1749 [188] Reboul E, Berton A, Moussa M, Kreuzer C, Crenon I, Borel P. Pancreatic lipase and pancreatic lipase-
1750 related protein 2, but not pancreatic lipase-related protein 1, hydrolyze retinyl palmitate in
1751 physiological conditions. Biochim Biophys Acta 2006; 1761: 4-10.
- 1752 [189] Eroglu A, Hruszkewycz DP, dela Sena C, Narayanasamy S, Riedl KM, Kopec RE, et al. Naturally Occurring
1753 Eccentric Cleavage Products of Provitamin A β -Carotene Function as Antagonists of Retinoic Acid
1754 Receptors*. J Biol Chem 2012; 287: 15886-95. <https://doi.org/10.1074/jbc.M111.325142>.

- 1755 [190] Cichon MJ, Moran NE, Riedl KM, Schwartz SJ, Clinton SK. Identification of an Epoxide Metabolite of
1756 Lycopene in Human Plasma Using ¹³C-Labeling and QTOF-MS. *Metabolites* 2018; 8.
1757 <https://doi.org/10.3390/metabo8010024>.
- 1758 [191] Margier M, Le May C, Antoine T, Halimi C, Nowicki M, Lespine A, et al. P-glycoprotein (ABCB1) is
1759 involved in vitamin K efflux. *Food Chem* 2021; 343: 128510.
1760 <https://doi.org/10.1016/j.foodchem.2020.128510>.
- 1761 [192] Mapelli-Brahm P, Margier M, Desmarchelier C, Halimi C, Nowicki M, Borel P, et al. Comparison of the
1762 bioavailability and intestinal absorption sites of phytoene, phytofluene, lycopene and beta-carotene.
1763 *Food Chem* 2019; 300: 125232. <https://doi.org/10.1016/j.foodchem.2019.125232>.
- 1764 [193] Goncalves A, Margier M, Roi S, Collet X, Niot I, Goupy P, et al. Intestinal scavenger receptors are
1765 involved in vitamin K1 absorption. *J Biol Chem* 2014. <https://doi.org/10.1074/jbc.M114.587659>.
- 1766 [194] Goncalves A, Roi S, Nowicki M, Niot I, Reboul E. Cluster-determinant 36 (CD36) impacts on vitamin E
1767 postprandial response. *Mol Nutr Food Res* 2014. <https://doi.org/10.1002/mnfr.201400339>.
- 1768 [195] Olivier M, Bott GR, Frisdal E, Nowick M, Plengpanich W, Desmarchelier C, et al. ABCG1 is involved in
1769 vitamin E efflux. *Biochim Biophys Acta* 2014; 1841: 1741-51.
1770 <https://doi.org/10.1016/j.bbalip.2014.10.003>.
- 1771 [196] Zachman RD, Olson JA. Formation and Enterohepatic Circulation of Water-Soluble Metabolites of
1772 Retinol(Vitamin A)in the Rat. *Nature* 1964; 201: 1222-3.
- 1773 [197] Zachman RD, Dunagin PE, Jr., Olson JA. Formation and enterohepatic circulation of metabolites of
1774 retinol and retinoic acid in bile duct-cannulated rats. *J Lipid Res* 1966; 7: 3-9.
- 1775 [198] Dunagin PE, Zachman RD, Olson JA. The Identification of Metabolites of Retinal and Retinoic Acid in Rat
1776 Bile. *Biochim. Biophys. Acta* 1966; 124: 71-85.
- 1777 [199] Dunagin PE, Meadows EH, Olson JA. Retinoyl Beta-Glucuronic Acid:A Major Metabolite of Vitamin A in
1778 Rat Bile. *Science* 1964; 148: 86-7.
- 1779 [200] Skare KL, DeLuca HF. Biliary metabolites of all-trans-retinoic acid in the rat. *Arch Biochem Biophys*
1780 1983; 224: 13-8. [https://doi.org/10.1016/0003-9861\(83\)90185-6](https://doi.org/10.1016/0003-9861(83)90185-6).

- 1781 [201] Arnaud SB, Goldsmith RS, Lambert PW, Go VL. 25-Hydroxyvitamin D3: evidence of an enterohepatic
1782 circulation in man. *Proc Soc Exp Biol Med* 1975; 149: 570-2. [https://doi.org/10.3181/00379727-149-](https://doi.org/10.3181/00379727-149-38853)
1783 [38853](https://doi.org/10.3181/00379727-149-38853).
- 1784 [202] Lee-Kim YC, Meydani M, Kassarian Z, Blumberg JB, Russell RM. Enterohepatic circulation of newly
1785 administered alpha-tocopherol in the rat. *Int J Vitam Nutr Res* 1988; 58: 284-91.
- 1786 [203] Bardowell SA, Duan F, Manor D, Swanson JE, Parker RS. Disruption of Mouse Cytochrome P450 4f14
1787 (Cyp4f14 Gene) Causes Severe Perturbations in Vitamin E Metabolism*. *J Biol Chem* 2012; 287: 26077-
1788 86. <https://doi.org/10.1074/jbc.M112.373597>.
- 1789 [204] Zhao Y, Lee MJ, Cheung C, Ju JH, Chen YK, Liu B, et al. Analysis of multiple metabolites of tocopherols
1790 and tocotrienols in mice and humans. *J Agric Food Chem* 2010; 58: 4844-52.
1791 <https://doi.org/10.1021/jf904464u>.
- 1792 [205] Avioli LV, Lee SW, McDonald JE, Lund J, DeLuca HF. Metabolism of vitamin D3-3H in human subjects:
1793 distribution in blood, bile, feces, and urine. *J Clin Invest* 1967; 46: 983-92.
1794 <https://doi.org/10.1172/JCI105605>.
- 1795 [206] Ledger JE, Watson GJ, Ainley CC, Compston JE. Biliary excretion of radioactivity after intravenous
1796 administration of 3H-1,25-dihydroxyvitamin D3 in man. *Gut* 1985; 26: 1240-5.
1797 <https://doi.org/10.1136/gut.26.11.1240>.
- 1798 [207] Clements MR, Chalmers TM, Fraser DR. Enterohepatic circulation of vitamin D: a reappraisal of the
1799 hypothesis. *Lancet* 1984; 1: 1376-9. [https://doi.org/10.1016/s0140-6736\(84\)91874-9](https://doi.org/10.1016/s0140-6736(84)91874-9).
- 1800 [208] Gao C, Liao MZ, Han LW, Thummel KE, Mao Q. Hepatic Transport of 25-Hydroxyvitamin D3 Conjugates:
1801 A Mechanism of 25-Hydroxyvitamin D3 Delivery to the Intestinal Tract. *Drug Metab Dispos* 2018; 46:
1802 581-91. <https://doi.org/10.1124/dmd.117.078881>.
- 1803 [209] Traber MG, Leonard SW, Ebeuwa I, Violet PC, Wang Y, Niyiyati M, et al. Vitamin E absorption and
1804 kinetics in healthy women, as modulated by food and by fat, studied using 2 deuterium-labeled alpha-
1805 tocopherols in a 3-phase crossover design. *Am J Clin Nutr* 2019; 110: 1148-67.
1806 <https://doi.org/10.1093/ajcn/nqz172>.

- 1807 [210] Traber MG, Leonard SW, Ebeuwa I, Violet PC, Niyiyati M, Padayatty S, et al. Vitamin E catabolism in
1808 women, as modulated by food and by fat, studied using 2 deuterium-labeled alpha-tocopherols in a 3-
1809 phase, nonrandomized crossover study. *Am J Clin Nutr* 2020; 113: 92-103.
1810 <https://doi.org/10.1093/ajcn/nqaa298>.
- 1811 [211] Hosomi A, Arita M, Sato Y, Kiyose C, Ueda T, Igarashi O, et al. Affinity for alpha-tocopherol transfer
1812 protein as a determinant of the biological activities of vitamin E analogs. *FEBS Lett* 1997; 409: 105-8 AF
1813 H AraiUniv TokyoFac Pharmaceut SciDept Hlth ChemBunkyo KuHongo 7-3-1Tokyo 13, Japan.
- 1814 [212] Konishi T, Baba S, Sone H. Whole-body autoradiographic study of vitamin K distribution in rat. *Chem*
1815 *Pharm Bull (Tokyo)* 1973; 21: 220-4. <https://doi.org/10.1248/cpb.21.220>.
- 1816 [213] Hirota Y, Tsugawa N, Nakagawa K, Suhara Y, Tanaka K, Uchino Y, et al. Menadione (vitamin K3) is a
1817 catabolic product of oral phylloquinone (vitamin K1) in the intestine and a circulating precursor of
1818 tissue menaquinone-4 (vitamin K2) in rats. *J Biol Chem* 2013; 288: 33071-80.
1819 <https://doi.org/10.1074/jbc.M113.477356>.
- 1820 [214] Shearer MJ, Mallinson CN, Webster GR, Barkhan P. Clearance from plasma and excretion in urine,
1821 faeces and bile of an intravenous dose of tritiated vitamin K 1 in man. *Br J Haematol* 1972; 22: 579-88.
1822 <https://doi.org/10.1111/j.1365-2141.1972.tb05704.x>.
- 1823 [215] Ostlund RE, McGill JB, Zeng CM, Covey DF, Stearns J, Stenson WF, et al. Gastrointestinal absorption and
1824 plasma kinetics of soy delta(5)- phytosterols and phytostanols in humans. *Am. J. Physiol. Endocrinol.*
1825 *Metab.* 2002; 282: E911-6. <https://doi.org/10.1152/ajpendo.00328.2001>.
- 1826 [216] Baumgartner S, Mensink RP, Konings M, Schott HF, Friedrichs S, Husche C, et al. Postprandial plasma
1827 oxyphytosterol concentrations after consumption of plant sterol or stanol enriched mixed meals in
1828 healthy subjects. *Steroids* 2015; 99: 281-6. <https://doi.org/10.1016/j.steroids.2015.01.017>.
- 1829 [217] Zhong S, Bird A, Kopec RE. The Metabolism and Potential Bioactivity of Chlorophyll and Metallo-
1830 chlorophyll Derivatives in the Gastrointestinal Tract. *Mol. Nutr. Food Res.* 2021; 65: 2000761.
1831 <https://doi.org/10.1002/mnfr.202000761>.

- 1832 [218] Lindqvist A, He YG, Andersson S. Cell type-specific expression of beta-carotene 9',10'-monooxygenase
1833 in human tissues. *J Histochem Cytochem* 2005; 53: 1403-12.
1834 <https://doi.org/10.1369/jhc.5A6705.2005>.
- 1835 [219] Goncalves A, Roi S, Nowicki M, Dhaussy A, Huertas A, Amiot MJ, et al. Fat-soluble vitamin intestinal
1836 absorption: absorption sites in the intestine and interactions for absorption. *Food Chem* 2015; 172:
1837 155-60. <https://doi.org/10.1016/j.foodchem.2014.09.021>.
- 1838 [220] Belyaeva OV, Korkina OV, Stetsenko AV, Kim T, Nelson PS, Kedishvili NY. Biochemical Properties of
1839 Purified Human Retinol Dehydrogenase 12 (RDH12): Catalytic Efficiency toward Retinoids and C9
1840 Aldehydes and Effects of Cellular Retinol-Binding Protein Type I (CRBPI) and Cellular Retinaldehyde-
1841 Binding Protein (CRALBP) on the Oxidation and Reduction of Retinoids. *Biochemistry* 2005; 44: 7035-
1842 47. <https://doi.org/10.1021/bi050226k>.
- 1843 [221] Lampen A, Meyer S, Arnhold T, Nau H. Metabolism of vitamin A and its active metabolite all-trans-
1844 retinoic acid in small intestinal enterocytes. *J Pharmacol Exp Ther* 2000; 295: 979-85.
- 1845 [222] Erkelens MN, Mebius RE. Retinoic Acid and Immune Homeostasis: A Balancing Act. *Trends Immunol*
1846 2017; 38: 168-80. <https://doi.org/10.1016/j.it.2016.12.006>.
- 1847 [223] Mora JR, Iwata M, Eksteen B, Song S-Y, Junt T, Senman B, et al. Generation of Gut-Homing IgA-
1848 Secreting B Cells by Intestinal Dendritic Cells. *Science* 2006; 314: 1157-60.
1849 <https://doi.org/10.1126/science.1132742>.
- 1850 [224] Eksteen B, Mora JR, Haughton EL, Henderson NC, Lee-Turner L, Villablanca EJ, et al. Gut Homing
1851 Receptors on CD8 T Cells Are Retinoic Acid Dependent and Not Maintained by Liver Dendritic or
1852 Stellate Cells. *Gastroenterology* 2009; 137: 320-9. <https://doi.org/10.1053/j.gastro.2009.02.046>.
- 1853 [225] Suzuki T. Regulation of the intestinal barrier by nutrients: The role of tight junctions. *Anim Sci J* 2020;
1854 91: e13357. <https://doi.org/10.1111/asj.13357>.
- 1855 [226] Wang JL, Swartz-Basile DA, Rubin DC, Levin MS. Retinoic Acid Stimulates Early Cellular Proliferation in
1856 the Adapting Remnant Rat Small Intestine after Partial Resection. *J. Nutr.* 1997; 127: 1297-303.
1857 <https://doi.org/10.1093/jn/127.7.1297>.

- 1858 [227] Zhu J, DeLuca HF. Vitamin D 25-hydroxylase – Four decades of searching, are we there yet? Arch.
1859 Biochem. Biophys. 2012; 523: 30-6. <https://doi.org/10.1016/j.abb.2012.01.013>.
- 1860 [228] Jenkinson C. The vitamin D metabolome: An update on analysis and function. Cell Biochem. Funct.
1861 2019; 37: 408-23. <https://doi.org/10.1002/cbf.3421>.
- 1862 [229] Theodoropoulos C, Demers C, Delvin E, Ménard D, Gascon-Barré M. Calcitriol regulates the expression
1863 of the genes encoding the three key vitamin D3 hydroxylases and the drug-metabolizing enzyme
1864 CYP3A4 in the human fetal intestine. Clin Endocrinol 2003; 58: 489-99. [https://doi.org/10.1046/j.1365-
1865 2265.2003.01743.x](https://doi.org/10.1046/j.1365-2265.2003.01743.x).
- 1866 [230] Wang Z, Schuetz EG, Xu Y, Thummel KE. Interplay between vitamin D and the drug metabolizing
1867 enzyme CYP3A4. J Ster Biochem 2013; 136: 54-8. <https://doi.org/10.1016/j.jsbmb.2012.09.012>.
- 1868 [231] Zhou C, Tabb MM, Sadatrafiei A, Grun F, Blumberg B. Tocotrienols activate the steroid and xenobiotic
1869 receptor, SXR, and selectively regulate expression of its target genes. Drug Metab Dispos 2004; 32:
1870 1075-82. 10.1124/dmd.104.000299.
- 1871 [232] Schmolz L, Birringer M, Lorkowski S, Wallert M. Complexity of vitamin E metabolism. World J Biol Chem
1872 2016; 7: 14-43. <https://doi.org/10.4331/wjbc.v7.i1.14>.
- 1873 [233] Grangeon A, Clermont V, Barama A, Gaudette F, Turgeon J, Michaud V. Determination of CYP450
1874 Expression Levels in the Human Small Intestine by Mass Spectrometry-Based Targeted Proteomics. Int
1875 J Mol Sci 2021; 22: 12791.
- 1876 [234] Abe C, Uchida T, Ohta M, Ichikawa T, Yamashita K, Ikeda S. Cytochrome P450-dependent metabolism
1877 of vitamin E isoforms is a critical determinant of their tissue concentrations in rats. Lipids 2007; 42:
1878 637-45. <https://doi.org/10.1007/s11745-007-3064-2>.
- 1879 [235] Sontag TJ, Parker RS. Cytochrome P450 ω -Hydroxylase Pathway of Tocopherol Catabolism: novel
1880 mechanism of regulation of vitamin e status*. J Biol Chem 2002; 277: 25290-6.
1881 <https://doi.org/10.1074/jbc.M201466200>.

- 1882 [236] Edson KZ, Prasad B, Unadkat JD, Suhara Y, Okano T, Guengerich FP, et al. Cytochrome P450-Dependent
1883 Catabolism of Vitamin K: ω -Hydroxylation Catalyzed by Human CYP4F2 and CYP4F11. *Biochemistry*
1884 2013; 52: 8276-85. <https://doi.org/10.1021/bi401208m>.
- 1885 [237] Okano T, Shimomura Y, Yamane M, Suhara Y, Kamao M, Sugiura M, et al. Conversion of phylloquinone
1886 (Vitamin K1) into menaquinone-4 (Vitamin K2) in mice: two possible routes for menaquinone-4
1887 accumulation in cerebra of mice. *J Biol Chem* 2008; 283: 11270-9.
1888 <https://doi.org/10.1074/jbc.M702971200>.
- 1889 [238] Mladěnka P, Macáková K, Kujovská Krčmová L, Javorská L, Mrštná K, Carazo A, et al. Vitamin K -
1890 sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity. *Nutr Rev*
1891 2021; 80: 677-98. <https://doi.org/10.1093/nutrit/nuab061>.
- 1892 [239] Nakagawa K, Sawada N, Hirota Y, Uchino Y, Suhara Y, Hasegawa T, et al. Vitamin K2 biosynthetic
1893 enzyme, UBIAD1 is essential for embryonic development of mice. *PLoS ONE* 2014; 9: e104078.
1894 <https://doi.org/10.1371/journal.pone.0104078>.
- 1895 [240] Graebin CS, The Pharmacological Activities of Glycyrrhizic Acid (“Glycyrrhizin”) and Glycyrrhetic
1896 Acid, in: J-M Mérillon, KG Ramawat (Eds.), *Sweeteners: Pharmacology, Biotechnology, and*
1897 *Applications*, Springer International Publishing, Cham, 2018, pp. 245-61.
- 1898 [241] Vijayakumar TM, Kumar RM, Agrawal A, Dubey GP, Ilango K. Comparative inhibitory potential of
1899 selected dietary bioactive polyphenols, phytosterols on CYP3A4 and CYP2D6 with fluorometric high-
1900 throughput screening. *J Food Sci Technol* 2015; 52: 4537-43. [https://doi.org/10.1007/s13197-014-](https://doi.org/10.1007/s13197-014-1472-x)
1901 [1472-x](https://doi.org/10.1007/s13197-014-1472-x).
- 1902 [242] Magliocco G, Desmeules J, Matthey A, Quirós-Guerrero LM, Bararpour N, Joye T, et al. Metabolomics
1903 reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity. *Br J*
1904 *Pharmacol* 2021; 178: 4708-25. <https://doi.org/10.1111/bph.15651>.
- 1905 [243] Lifsey HC, Kaur R, Thompson BH, Bennett L, Temel RE, Graf GA. Stigmasterol stimulates transintestinal
1906 cholesterol excretion independent of liver X receptor activation in the small intestine. *J. Nutr.*
1907 *Biochem.* 2020; 76: 108263. <https://doi.org/10.1016/j.jnutbio.2019.108263>.

- 1908 [244] Masson CJ, Plat J, Mensink RP, Namiot A, Kisielewski W, Namiot Z, et al. Fatty Acid- and Cholesterol
1909 Transporter Protein Expression along the Human Intestinal Tract. PLoS ONE 2010; 5: e10380.
1910 <https://doi.org/10.1371/journal.pone.0010380>.
- 1911 [245] Levy E, Ménard D, Suc I, Delvin E, Marcil Vr, Brissette L, et al. Ontogeny, immunolocalisation,
1912 distribution and function of SR-BI in the human intestine. J Cell Sci 2004; 117: 327-37.
1913 <https://doi.org/10.1242/jcs.00856>.
- 1914 [246] Cantorna MT, Snyder L, Arora J. Vitamin A and vitamin D regulate the microbial complexity, barrier
1915 function, and the mucosal immune responses to ensure intestinal homeostasis. Crit Rev Biochem Mol
1916 Biol 2019; 54: 184-92. <https://doi.org/10.1080/10409238.2019.1611734>.
- 1917 [247] Ertesvåg A, Naderi S, Blomhoff HK. Regulation of B cell proliferation and differentiation by retinoic acid.
1918 Semin Immunol 2009; 21: 36-41. <https://doi.org/10.1016/j.smim.2008.06.005>.
- 1919 [248] Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol Prevents and
1920 Ameliorates Symptoms of Experimental Murine Inflammatory Bowel Disease. J Nutr 2000; 130: 2648-
1921 52. <https://doi.org/10.1093/jn/130.11.2648>.
- 1922 [249] Bruce D, Yu S, Ooi JH, Cantorna MT. Converging pathways lead to overproduction of IL-17 in the
1923 absence of vitamin D signaling. Int Immunol 2011; 23: 519-28.
1924 <https://doi.org/10.1093/intimm/dxr045>.
- 1925 [250] Zmora N, Suez J, Elinav E. You are what you eat: diet, health and the gut microbiota. Nat Rev
1926 Gastroenterol Hepatol 2019; 16: 35-56. <https://doi.org/10.1038/s41575-018-0061-2>.
- 1927 [251] Mandal S, Godfrey KM, McDonald D, Treuren WV, Bjørnholt JV, Midtvedt T, et al. Fat and vitamin
1928 intakes during pregnancy have stronger relations with a pro-inflammatory maternal microbiota than
1929 does carbohydrate intake. Microbiome 2016; 4: 55. <https://doi.org/10.1186/s40168-016-0200-3>.
- 1930 [252] Ellis JL, Karl JP, Oliverio AM, Fu X, Soares JW, Wolfe BE, et al. Dietary vitamin K is remodeled by gut
1931 microbiota and influences community composition. Gut Microbes 2021; 13: 1-16.
1932 <https://doi.org/10.1080/19490976.2021.1887721>.

- 1933 [253] Dingeo G, Brito A, Samouda H, Iddir M, La Frano MR, Bohn T. Phytochemicals as modifiers of gut
1934 microbial communities. *Food Funct* 2020; 11: 8444-71. <https://doi.org/10.1039/D0FO01483D>.
- 1935 [254] Navarro del Hierro J, Herrera T, Fornari T, Reglero G, Martin D. The gastrointestinal behavior of
1936 saponins and its significance for their bioavailability and bioactivities. *J Funct Foods* 2018; 40: 484-97.
1937 <https://doi.org/10.1016/j.jff.2017.11.032>.
- 1938 [255] Salehi B, Quispe C, Sharifi-Rad J, Cruz-Martins N, Nigam M, Mishra AP, et al. Phytosterols: From
1939 Preclinical Evidence to Potential Clinical Applications. *Front Pharmacol* 2021; 11: 599959.
1940 <https://doi.org/10.3389/fphar.2020.599959>.
- 1941 [256] Aldini R, Micucci M, Cevenini M, Fato R, Bergamini C, Nanni C, et al. Antiinflammatory Effect of
1942 Phytosterols in Experimental Murine Colitis Model: Prevention, Induction, Remission Study. *PLoS ONE*
1943 2014; 9: e108112. <https://doi.org/10.1371/journal.pone.0108112>.
- 1944 [257] Taylor PR, Qiao Y-L, Abnet CC, Dawsey SM, Yang CS, Gunter EW, et al. Prospective Study of Serum
1945 Vitamin E Levels and Esophageal and Gastric Cancers. *J Nat Cancer Inst* 2003; 95: 1414-6.
1946 <https://doi.org/10.1093/jnci/djg044>.
- 1947 [258] Abnet CC, Qiao Y-L, Dawsey SM, Buckman DW, Yang CS, Blot WJ, et al. Prospective study of serum
1948 retinol, β -carotene, β -cryptoxanthin, and lutein/zeaxanthin and esophageal and gastric cancers in
1949 China. *Cancer Causes Control* 2003; 14: 645-55. <https://doi.org/10.1023/A:1025619608851>.
- 1950 [259] Abnet CC, Chen Y, Chow W-H, Gao Y-T, Helzlsouer KJ, Le Marchand L, et al. Circulating 25-
1951 Hydroxyvitamin D and Risk of Esophageal and Gastric Cancer: Cohort Consortium Vitamin D Pooling
1952 Project of Rarer Cancers. *Am J Epidemiol* 2010; 172: 94-106. <https://doi.org/10.1093/aje/kwq121>.
- 1953 [260] Li P, Zhang H, Chen J, Shi Y, Cai J, Yang J, et al. Association between dietary antioxidant vitamins
1954 intake/blood level and risk of gastric cancer. *Int J Cancer* 2014; 135: 1444-53.
1955 <https://doi.org/10.1002/ijc.28777>.
- 1956 [261] Abnet CC, Corley DA, Freedman ND, Kamangar F. Diet and upper gastrointestinal malignancies.
1957 *Gastroenterology* 2015; 148: 1234-43.e4. <https://doi.org/10.1053/j.gastro.2015.02.007>.

- 1958 [262] Brawner KM, Morrow CD, Smith PD. Gastric Microbiome and Gastric Cancer. *Cancer J* 2014; 20: 211-6.
1959 <https://doi.org/10.1097/ppo.000000000000043>.
- 1960 [263] Assis D. Chronic Complications of Cholestasis. *Clin Liver Dis* 2018; 22: 533-44.
1961 <https://doi.org/10.1016/j.cld.2018.03.014>.
- 1962 [264] Floreani A, Baragiotta A, Martines D, Naccarato R, D'Odorico A. Plasma antioxidant levels in chronic
1963 cholestatic liver diseases. *Aliment Pharmacol Ther* 2000; 14: 353-8. [https://doi.org/10.1046/j.1365-
1964 2036.2000.00729.x](https://doi.org/10.1046/j.1365-2036.2000.00729.x).
- 1965 [265] Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary
1966 cirrhosis. *Am J Gastroenterol* 2001; 96: 2745-50. <https://doi.org/10.1111/j.1572-0241.2001.04134.x>.
- 1967 [266] Clugston RD. Carotenoids and fatty liver disease: Current knowledge and research gaps. *Biochim*
1968 *Biophys Acta* 2020; 1865: 158597. <https://doi.org/10.1016/j.bbalip.2019.158597>.
- 1969 [267] Barchetta I, Cimini FA, Cavallo MG. Vitamin D Supplementation and Non-Alcoholic Fatty Liver Disease:
1970 Present and Future. *Nutrients* 2017; 9: 1015.
- 1971 [268] Amanullah I, Khan YH, Anwar I, Gulzar A, Mallhi TH, Raja AA. Effect of vitamin E in non-alcoholic fatty
1972 liver disease: a systematic review and meta-analysis of randomised controlled trials. *Postgrad Med J*
1973 2019; 95: 601. <https://doi.org/10.1136/postgradmedj-2018-136364>.
- 1974 [269] Ballestri S, Capitelli M, Fontana MC, Arioli D, Romagnoli E, Graziosi C, et al. Direct Oral Anticoagulants
1975 in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A
1976 Narrative Review. *Adv Ther* 2020; 37: 1910-32. <https://doi.org/10.1007/s12325-020-01307-z>.
- 1977 [270] Gottlieb A, Canbay A. Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD)
1978 Progression. *Cells* 2019; 8: 1358.
- 1979 [271] Ferdouse A, Agrawal RR, Gao MA, Jiang H, Blaner WS, Clugston RD. Alcohol induced hepatic retinoid
1980 depletion is associated with the induction of multiple retinoid catabolizing cytochrome P450 enzymes.
1981 *PLoS ONE* 2022; 17: e0261675. <https://doi.org/10.1371/journal.pone.0261675>.
- 1982 [272] Torquato P, Bartolini D, Giusepponi D, Piroddi M, Sebastiani B, Saluti G, et al. Increased plasma levels
1983 of the lipoperoxyl radical-derived vitamin E metabolite α -tocopheryl quinone are an early indicator of

- 1984 lipotoxicity in fatty liver subjects. *Free Radic. Biol. Med.* 2019; 131: 115-25.
- 1985 <https://doi.org/10.1016/j.freeradbiomed.2018.11.036>.
- 1986 [273] Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver
1987 disease: A spectrum of clinical and pathological severity. *Gastroenterology* 1999; 116: 1413-9.
1988 [https://doi.org/10.1016/S0016-5085\(99\)70506-8](https://doi.org/10.1016/S0016-5085(99)70506-8).
- 1989 [274] Teriaky A, Mosli M, Chandok N, Al-Judaibi B, Marotta P, Qumosani K. Prevalence of fat-soluble vitamin
1990 (A, D, and E) and zinc deficiency in patients with cirrhosis being assessed for liver transplantation. *Acta*
1991 *Gastroenterol Belg* 2017; 80: 237-41.
- 1992 [275] Venu M, Martin E, Saeian K, Gawrieh S. High prevalence of vitamin A deficiency and vitamin D
1993 deficiency in patients evaluated for liver transplantation. *Liver Transpl* 2013; 19: 627-33.
1994 <https://doi.org/10.1002/lt.23646>.
- 1995 [276] Abbott-Johnson W, Kerlin P, Clague A, Johnson H, Cuneo R. Relationships between blood levels of fat
1996 soluble vitamins and disease etiology and severity in adults awaiting liver transplantation. *J.*
1997 *Gastroenterol. Hepatol.* 2011; 26: 1402-10. <https://doi.org/10.1111/j.1440-1746.2011.06746.x>.
- 1998 [277] Veraldi S, Pietrobattista A, Liccardo D, Basso MS, Mosca A, Alterio T, et al. Fat soluble vitamins
1999 deficiency in pediatric chronic liver disease: The impact of liver transplantation. *Dig Liver Dis* 2020; 52:
2000 308-13. <https://doi.org/10.1016/j.dld.2019.10.005>.
- 2001 [278] Martínez-Moneo E, Stigliano S, Hedström A, Kaczka A, Malvik M, Waldthaler A, et al. Deficiency of fat-
2002 soluble vitamins in chronic pancreatitis: A systematic review and meta-analysis. *Pancreatology* 2016;
2003 16: 988-94. <https://doi.org/10.1016/j.pan.2016.09.008>.
- 2004 [279] Quilliot D, Forbes A, Dubois F, Gueant JL, Ziegler O. Carotenoid deficiency in chronic pancreatitis: the
2005 effect of an increase in tomato consumption. *Eur J Clin Nutr* 2011; 65: 262-8.
2006 <https://doi.org/10.1038/ejcn.2010.232>.
- 2007 [280] Adam MG, Beyer G, Christiansen N, Kamlage B, Pilarsky C, Distler M, et al. Identification and validation
2008 of a multivariable prediction model based on blood plasma and serum metabolomics for the

- 2009 distinction of chronic pancreatitis subjects from non-pancreas disease control subjects. *Gut* 2021; 70:
2010 2150. <https://doi.org/10.1136/gutjnl-2020-320723>.
- 2011 [281] Nelson A, Myers K, Shwachman-Diamond Syndrome, in: MP Adam, HH Ardinger, RA Pagon, SE Wallace,
2012 LJH Bean, KW Gripp, GM Mirzaa, A Amemiya (Eds.), *GeneReviews*(®), University of Washington,
2013 Seattle, Seattle (WA), 1993.
- 2014 [282] Pichler J, Meyer R, Köglmeier J, Ancliff P, Shah N. Nutritional Status in Children With Shwachman-
2015 Diamond Syndrome. *Pancreas* 2015; 44: 590-5.
- 2016 [283] Tokgöz Y, Terlemez S, Karul A. Fat soluble vitamin levels in children with newly diagnosed celiac
2017 disease, a case control study. *BMC Pediatr* 2018; 18: 130. <https://doi.org/10.1186/s12887-018-1107-x>.
- 2018 [284] Imam MH, Ghazzawi Y, Murray JA, Absah I. Is It Necessary to Assess for Fat-Soluble Vitamin
2019 Deficiencies in Pediatric Patients With Newly Diagnosed Celiac Disease? *JPGN* 2014; 59: 225-8.
- 2020 [285] Mager DR, Qiao J, Turner J. Vitamin D and K status influences bone mineral density and bone accrual in
2021 children and adolescents with celiac disease. *Eur J Clin Nutr* 2012; 66: 488-95.
2022 <https://doi.org/10.1038/ejcn.2011.176>.
- 2023 [286] Hozyasz KK, Chelchowska M, Laskowska-Klita T. Vitamin E levels in patients with celiac disease. *Med*
2024 *Wieku Rozwoj* 2003; 7: 593-604.
- 2025 [287] Sabharwal S. Gastrointestinal Manifestations of Cystic Fibrosis. *Gastroenterol. Hepatol. (N Y)* 2016; 12:
2026 43-7.
- 2027 [288] Gabel ME, Galante GJ, Freedman SD. Gastrointestinal and Hepatobiliary Disease in Cystic Fibrosis.
2028 *Semin. Respir. Crit. Care Med.* 2019; 40: 825-41. <https://doi.org/10.1055/s-0039-1697591>.
- 2029 [289] Drzymała-Czyż S, Krzyżanowska-Jankowska P, Dziedzic K, Lisowska A, Kurek S, Goździk-Spychalska J, et
2030 al. Severe Genotype, Pancreatic Insufficiency and Low Dose of Pancreatic Enzymes Associate with
2031 Abnormal Serum Sterol Profile in Cystic Fibrosis. *Biomolecules* 2021; 11: 313.
2032 <https://doi.org/10.3390/biom11020313>.

- 2033 [290] Lagrange-Puget M, Durieu I, Ecochard R, Abbas-Chorfa F, Draï J, Steghens J-P, et al. Longitudinal study
2034 of oxidative status in 312 cystic fibrosis patients in stable state and during bronchial exacerbation.
2035 *Pediatr Pulmonol* 2004; 38: 43-9. <https://doi.org/10.1002/ppul.20041>.
- 2036 [291] Lamprecht G, Bodammer P. Nutritional strategies to enhance adaptation in intestinal failure. *Curr Opin*
2037 *Organ Transplant* 2016; 21: 140-6. <https://doi.org/10.1097/mot.000000000000289>.
- 2038 [292] Gupte GL, Beath SV. Update on intestinal rehabilitation after intestinal transplantation. *Curr Opin*
2039 *Organ Transplant* 2009; 14: 267-73.
- 2040 [293] Allan PJ, Lal S. Metabolic bone diseases in intestinal failure. *J Hum Nutr Diet* 2020; 33: 423-30.
2041 <https://doi.org/10.1111/jhn.12726>.
- 2042 [294] Goulet O, Lambe C. Intravenous lipid emulsions in pediatric patients with intestinal failure. *Curr Opin*
2043 *Organ Transplant* 2017; 22: 142-8. <https://doi.org/10.1097/mot.000000000000396>.
- 2044 [295] Bredefeld C, Hussain MM, Aversa M, Black DD, Brin MF, Burnett JR, et al. Guidance for the diagnosis
2045 and treatment of hypolipidemia disorders. *J Clin Lipidol* 2022. 10.1016/j.jacl.2022.08.009.
- 2046 [296] Fabisiak N, Fabisiak A, Watala C, Fichna J. Fat-soluble Vitamin Deficiencies and Inflammatory Bowel
2047 Disease: Systematic Review and Meta-Analysis. *J Clin Gastroenterol* 2017; 51: 878-89.
- 2048 [297] Ghishan FK, Kiela PR. Vitamins and Minerals in Inflammatory Bowel Disease. *Gastroenterol Clin North*
2049 *Am* 2017; 46: 797-808. <https://doi.org/10.1016/j.gtc.2017.08.011>.
- 2050 [298] da Cruz SP, Matos A, Pereira S, Saboya C, da Cruz SP, Ramalho A. Roux-en-Y Gastric Bypass Aggravates
2051 Vitamin A Deficiency in the Mother-Child Group. *Obes Surg* 2018; 28: 114-21.
2052 <https://doi.org/10.1007/s11695-017-2791-6>.
- 2053 [299] Smelt HJM, Pouwels S, Smulders JF. The Influence of Different Cholecalciferol Supplementation
2054 Regimes on 25(OH) Cholecalciferol, Calcium and Parathyroid Hormone after Bariatric Surgery.
2055 *Medicina (Kaunas)* 2019; 55: 252. <https://doi.org/10.3390/medicina55060252>.
- 2056 [300] Sherf-Dagan S, Goldenshluger A, Azran C, Sakran N, Sinai T, Ben-Porat T. Vitamin K-what is known
2057 regarding bariatric surgery patients: a systematic review. *Surg Obes Relat Dis* 2019; 15: 1402-13.
2058 <https://doi.org/10.1016/j.soard.2019.05.031>.

- 2059 [301] Sherf-Dagan S, Buch A, Ben-Porat T, Sakran N, Sinai T. Vitamin E status among bariatric surgery
2060 patients: a systematic review. *Surg Obes Relat Dis* 2021; 17: 816-30.
2061 <https://doi.org/10.1016/j.soard.2020.10.029>.
- 2062 [302] Granado-Lorencio F, Herrero-Barbudo C, Olmedilla-Alonso B, Blanco-Navarro I, Pérez-Sacristán B.
2063 Hypocarotenemia after bariatric surgery: a preliminary study. *Obes Surg* 2009; 19: 879-82.
2064 <https://doi.org/10.1007/s11695-008-9476-0>.
- 2065 [303] Granado-Lorencio F, Simal-Antón A, Blanco-Navarro I, González-Dominguez T, Pérez-Sacristán B.
2066 Depletion of Serum Carotenoid and Other Fat-Soluble Vitamin Concentrations following Obesity
2067 Surgery. *Obes Surg* 2011; 21: 1605-11. <https://doi.org/10.1007/s11695-011-0413-2>.
- 2068 [304] Eriksen JN, Prahm AP, Falk MK, Arrigoni E, Jeppesen PB, Larsen M, et al. Serum carotenoids and
2069 macular pigment optical density in patients with intestinal resections and healthy subjects: an
2070 exploratory study. *J Nutr Sci* 2018; 7: e8. <https://doi.org/10.1017/jns.2017.71>.
- 2071 [305] Sharma S, Murthy SI, Bhate M, Rathi V. Xerophthalmia due to vitamin A deficiency following Frey's
2072 procedure for chronic calcific pancreatitis. *BMJ Case Rep* 2021; 14: e242710.
2073 <https://doi.org/10.1136/bcr-2021-242710>.
- 2074 [306] Meyer MS, Amerilio N, Alon R, Edelstein S, Shibolet S. Fecal loss of cholecalciferol in gastrectomized
2075 rats. *Digestion* 1984; 30: 200-3. <https://doi.org/10.1159/000199108>.
- 2076 [307] Csendes A, Smok G, Burdiles P, Antezana C, Espíndola M, Espíndola L, et al. [Intestinal malabsorption in
2077 patients treated with total gastrectomy]. *Rev Med Chil* 1993; 121: 1416-21.
- 2078 [308] Rino Y, Oshima T, Yoshikawa T. Changes in fat-soluble vitamin levels after gastrectomy for gastric
2079 cancer. *Surg Today* 2017; 47: 145-50. <https://doi.org/10.1007/s00595-016-1341-5>.
- 2080 [309] Armbrecht U, Lundell L, Lindstedt G, Stockbruegger RW. Causes of malabsorption after total
2081 gastrectomy with Roux-en-Y reconstruction. *Acta Chir Scand* 1988; 154: 37-41.
- 2082 [310] Leth RD, Abrahamsson H, Kilander A, Lundell LR. Malabsorption of fat after partial gastric resection. A
2083 study of pathophysiologic mechanisms. *Eur J Surg* 1991; 157: 205-8.

- 2084 [311] Perin J, Prokopowicz G, Furtado M, Papas K, Steele KE. A Randomized Trial of a Novel Chewable
2085 Multivitamin and Mineral Supplement Following Roux-en-Y Gastric Bypass. *Obes Surg* 2018; 28: 2406-
2086 20. <https://doi.org/10.1007/s11695-018-3177-0>.
- 2087 [312] Tozzo C, Moreira EAM, de Freitas MB, da Silva AF, Portari GV, Wilhelm Filho D. Effect of RYGB on
2088 Oxidative Stress in Adults: a 6-Year Follow-up Study. *Obes Surg* 2020; 30: 3301-8.
2089 <https://doi.org/10.1007/s11695-020-04561-w>.
- 2090 [313] Aarts E, van Groningen L, Horst R, Telting D, van Sorge A, Janssen I, et al. Vitamin D absorption:
2091 consequences of gastric bypass surgery. *Eur J Endocrinol* 2011; 164: 827-32.
2092 <https://doi.org/10.1530/eje-10-1126>.
- 2093 [314] Sampaio P, Waitzberg DL, Machado NM, de Miranda Torrinhos RSM, Fonseca DC, Ferreira BAM, et al.
2094 Gastrointestinal genetic reprogramming of vitamin A metabolic pathways in response of Roux-en-Y
2095 gastric bypass. *Int J Vitam Nutr Res* 2022. 10.1024/0300-9831/a000767.
- 2096 [315] Lepus CA, Samela K, Emerick KM, Mokha JS. Vitamin D status in children with intestinal failure who
2097 have achieved enteral autonomy. *Nutr Clin Pract* 2021; 36: 1284-9.
2098 <https://doi.org/10.1002/ncp.10685>.
- 2099 [316] Takase S, Goda T, Shinohara H. Adaptive changes of intestinal cellular retinol-binding protein, type II
2100 following jejunum-bypass operation in the rat. *Biochim. Biophys. Acta* 1993; 1156: 223-31.
2101 [https://doi.org/10.1016/0304-4165\(93\)90140-4](https://doi.org/10.1016/0304-4165(93)90140-4).
- 2102 [317] Hebiguchi T, Mezaki Y, Morii M, Watanabe R, Yoshikawa K, Miura M, et al. Massive bowel resection
2103 upregulates the intestinal mRNA expression levels of cellular retinol-binding protein II and
2104 apolipoprotein A-IV and alters the intestinal vitamin A status in rats. *Int J Mol Med* 2015; 35: 724-30.
2105 <https://doi.org/10.3892/ijmm.2015.2066>.
- 2106 [318] Cooper DA, Webb DR, Peters JC. Evaluation of the potential for olestra to affect the availability of
2107 dietary phytochemicals. *J Nutr* 1997; 127: S1699-S709.

- 2108 [319] Suarez J, Rock C, Hoh E, LaCroix A, Quintana E. A dietary intervention with nuts or olestra to enhance
2109 the excretion of persistent organic pollutants in healthy adults: The NO-POPs Trial. *Environ Epidemiol*
2110 2019; 3. <https://doi.org/10.1097/01.EE9.0000610300.56349.5a>.
- 2111 [320] Jackson RW. The Effect of Mineral Oil Administration Upon the Nutritional Economy of Fatsoluble
2112 Vitamins: I. Studies with the Vitamin A of Butter Fat. *J Nutr* 1931; 4: 171-84.
2113 <https://doi.org/10.1093/jn/4.2.171>.
- 2114 [321] Gal-Ezer S, Shaoul R. The safety of mineral oil in the treatment of constipation--a lesson from
2115 prolonged overdose. *Clin Pediatr (Phila)* 2006; 45: 856-8. <https://doi.org/10.1177/0009922806295285>.
- 2116 [322] Clark JH, Russell GJ, Fitzgerald JF, Nagamori KE. Serum beta-carotene, retinol, and alpha-tocopherol
2117 levels during mineral oil therapy for constipation. *Am J Dis Child* 1987; 141: 1210-2.
2118 <https://doi.org/10.1001/archpedi.1987.04460110080028>.
- 2119 [323] Tan Y, Liu J, Zhou H, Muriel Mundo J, McClements DJ. Impact of an indigestible oil phase (mineral oil)
2120 on the bioaccessibility of vitamin D3 encapsulated in whey protein-stabilized nanoemulsions. *Food Res*
2121 *Int* 2019; 120: 264-74. <https://doi.org/10.1016/j.foodres.2019.02.031>.
- 2122 [324] Kose M, Emet S, Akpınar TS, İlhan M, Gök AFK, Dadashov M, et al. An Unexpected Result of Obesity
2123 Treatment: Orlistat-Related Acute Pancreatitis. *Case Rep Gastroenterol* 2015; 9: 152-5.
- 2124 [325] Kopec RE, Cooperstone JL, Schweiggert RM, Young GS, Harrison EH, Francis DM, et al. Avocado
2125 consumption enhances human postprandial provitamin A absorption and conversion from a novel
2126 high-beta-carotene tomato sauce and from carrots. *J Nutr* 2014; 144: 1158-66.
2127 <https://doi.org/10.3945/jn.113.187674>.
- 2128 [326] Cheng T, Zhao Y, Li X, Lin F, Xu Y, Zhang X, et al. Computation of Octanol–Water Partition Coefficients
2129 by Guiding an Additive Model with Knowledge. *J Chem Inf Model* 2007; 47: 2140-8.
2130 <https://doi.org/10.1021/ci700257y>.
- 2131 [327] Sy C, Dangles O, Borel P, Caris-Veyrat C. Stability of bacterial carotenoids in the presence of iron in a
2132 model of the gastric compartment - comparison with dietary reference carotenoids. *Arch Biochem*
2133 *Biophys* 2015; 572: 89-100. <https://doi.org/10.1016/j.abb.2014.12.030>.

- 2134 [328] Efsa Panel on Dietetic Products N, Allergies. Scientific Opinion on the substantiation of health claims
2135 related to polyphenols in olive and protection of LDL particles from oxidative damage (ID 1333, 1638,
2136 1639, 1696, 2865), maintenance of normal blood HDL cholesterol concentrations (ID 1639),
2137 maintenance of normal blood pressure (ID 3781), “anti-inflammatory properties” (ID 1882),
2138 “contributes to the upper respiratory tract health” (ID 3468), “can help to maintain a normal function
2139 of gastrointestinal tract” (3779), and “contributes to body defences against external agents” (ID 3467)
2140 pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011; 9: 2033.
2141 <https://doi.org/10.2903/j.efsa.2011.2033>.
- 2142 [329] Traber MG, Head B. Vitamin E: How much is enough, too much and why! Free Radic. Biol. Med. 2021;
2143 177: 212-25. <https://doi.org/10.1016/j.freeradbiomed.2021.10.028>.
- 2144 [330] Vervoort LM, Ronden JE, Thijssen HH. The potent antioxidant activity of the vitamin K cycle in
2145 microsomal lipid peroxidation. Biochem Pharmacol 1997; 54: 871-6. [https://doi.org/10.1016/s0006-](https://doi.org/10.1016/s0006-2952(97)00254-2)
2146 [2952\(97\)00254-2](https://doi.org/10.1016/s0006-2952(97)00254-2).
- 2147 [331] Mukai K, Itoh S, Morimoto H. Stopped-flow kinetic study of vitamin E regeneration reaction with
2148 biological hydroquinones (reduced forms of ubiquinone, vitamin K, and tocopherolquinone) in
2149 solution. J Biol Chem 1992; 267: 22277-81.
- 2150 [332] Li J, Lin JC, Wang H, Peterson JW, Furie BC, Furie B, et al. Novel role of vitamin k in preventing oxidative
2151 injury to developing oligodendrocytes and neurons. J Neurosci 2003; 23: 5816-26.
2152 <https://doi.org/10.1523/jneurosci.23-13-05816.2003>.
- 2153 [333] Thomas SR, Stocker R. Molecular action of vitamin E in lipoprotein oxidation: implications for
2154 atherosclerosis. Free Radic Biol Med 2000; 28: 1795-805. 10.1016/s0891-5849(00)00236-7.
- 2155 [334] Webster RD. Electrochemical and Spectroscopic Characterization of Oxidized Intermediate Forms of
2156 Vitamin E. Molecules 2022; 27. 10.3390/molecules27196194.
- 2157 [335] Sy C, Dangles O, Borel P, Caris-Veyrat C. Interactions between Carotenoids from Marine Bacteria and
2158 Other Micronutrients: Impact on Stability and Antioxidant Activity. Mar Drugs 2015; 13: 7020-39.
2159 <https://doi.org/10.3390/md13117020>.

